Improvements in or relating to diagnostic/therapeutic agents

专利摘要:
PURPOSE: Diagnostic and/or therapeutically active agents, more particularly to diagnostic and/or therapeutically active agents incorporating moieties which interact with or have affinity for sites and/or structures within the body so that diagnostic imaging and/or therapy of particular locations within the body may be enhanced. CONSTITUTION: A targetable diagnostic and/or therapeutically active agent comprises a suspension in an aqueous carrier liquid of a reporter comprising gas-filled microbubbles stabilized by monolayers of film-forming surfactant, the agent additionally comprises at least one vector.
公开号:KR20000052829A
申请号:KR1019990703658
申请日:1997-10-28
公开日:2000-08-25
发明作者:요 클라베네스；폴 롱베트；안데르스 회그세트；헬게 톨레샤우그；안네 네베스타트；할디스 헬레부스트；라르스 호프；알란 쿠트베르트슨；다그핀 뢰프하우그；마그네 솔바켄
申请人:조오지 디빈센조, 토브 아스 헬지, 에바 요한손；니코메드 이메이징 에이에스；
IPC主号:

专利说明:

Diagnostics / therapies or related improvements {Improvements in or Relating to Diagnostic / Therapeutic Agents}
[1] The present invention relates to diagnostic and / or therapeutically active agents, and more particularly to diagnostic and / or therapeutically active agents in admixture with residues that interact with or have affinity with sites and / or structures in the body. Diagnostic imaging and / or treatment of can be improved. Of particular interest are diagnostic agents for using ultrasound imaging, referred to below as target ultrasound contrast agents.
[2] Ultrasound imaging is known to constitute an effective and valuable diagnostic tool, for example in the study of the vascular system, in particular cardiacography and tissue microvascular system. Various contrast agents have been proposed to increase the resulting acoustic image, including solid particles, emulsion droplets, gas bubbles and suspensions of encapsulated gas or liquid. In general, low-density contrast agents that are easily compressible are recognized to be particularly effective in the backscattering surface of the acoustics they produce, which has given considerable interest to the manufacture of gas-containing and gas-generating systems.
[3] Gas-containing contrast agents are also known to be effective in magnetic resonance (MR) imaging, for example, as magnetizing contrast agents that act to reduce MR signal strength. Oxygen-containing contrast agents also represent useful paramagnetic MR contrast agents.
[4] It has also been observed that gases such as carbon dioxide can be used as negative oral or intravascular contrast agents in the field of X-ray imaging.
[5] Radioactive isotopes of radioactive gases, such as inert gases such as xenon, are also used for scintogram imaging, for example blood imaging.
[6] Targeted ultrasound contrast agents include (i) reporter residues that can interact with ultrasound irradiation to generate a detectable signal; (ii) one or more vectors, in particular, having affinity for a target site and / or structure in the body, for example a particular cell or region of pathology; And (iii) one or more binders linking the reporter and vector (s), consequently not directly binding them.
[7] The molecules and / or structures to which the diagnostic / therapeutic agent is intended to bind are referred to as targets below. Targets must be present and useful in this area / structure in order to obtain a specific burn or therapeutic effect in a selected area / structure in the body. Ideally, they are present only in the region of interest, but may also be present in other locations in the body that can cause posterior problems. This target can be defined as a molecular species (eg, a target molecule) or an unknown molecule or more complex structure present in the region to be imaged and / or treated, and can specifically or selectively bind to a given vector molecule. have.
[8] Such vectors are attached or bound to reporter residues to bind these residues to the regions / structures to be imaged and / or treated. The vector may specifically bind to the selected target, or may only selectively bind, again having affinity for a limited number of other molecules / structures, again causing back problems.
[9] There is a limited prior art related to target ultrasound contrast agents. Thus, for example, US-A-5531980 discloses one or more film-forming surfactants in which the reporter is at least partially present in a layered or layered form (the surfactant comprises a "living species designed for specific target purposes"). And a reporter comprising an aqueous suspension of air or gas microbubbles stabilized by one or more vectors). It is mentioned that the microbubbles are not directly encapsulated by the surfactant material, but are mixed in liquid filled liposomes that stabilize the microbubbles. Layered or layered surface-active substances such as phospholipids present in these liposomes inevitably comprise a lipophilic tail "back-to-back" and one or more lipid bilayers with hydrophilic heads both inside and outside. In form (see, eg, Schneider, M. on "Liposomes as drug carriers: 10 years of research" in Drug targeting, Nyon, Switzerland, 3-5 October 1984, Buri, P. and Gumma, A. (Ed), Elsevier, Amsterdam 1984).
[10] EP-A-0727225 describes a target ultrasound contrast agent in which the reporter comprises a compound having sufficient vapor pressure, the proportion of which is gaseous at the body temperature of the subject. This compound binds a surfactant or albumin carrier comprising a protein-, peptide- or carbohydrate-based cell adhesion molecule ligand as a vector. Reporter residues in such contrast agents correspond to the phase transfer colloidal system described in WO-A-9416739; It is currently recognized that the administration of such phase transfer colloids may grow unregulated, possibly leading to the generation of microbubbles which, for example, cause dangerous color shifts of the myocardial vascular system and the brain (eg, literature See Schwarz, Advances in Echo-Contrast [1994 (3)], pp 48-49.
[11] WO-A-9320802 suggested that tissue-specific ultrasound imaging improvements can be achieved using acoustically reflective oligolayered liposomes bound to tissue-specific ligands such as antibodies, peptides, lectins and the like. These liposomes are carefully selected to degas and do not have the favorable echo of gas-based ultrasound contrast agents. Also, for example, references to this technique in targets for fibrin, tromby and atherosclerotic regions are described in Alkanonyuksel, H. et al. Pharm. Sci. (1996) 85 (5), 486-490; J. Am. Coll. Cardiol. (1996) 27 (2) Suppl A, 298A; and Circulation, 68 Sci. Sessions, Anaheim 13-16 November 1995].
[12] In addition, there are a number of publications relating to ultrasound contrast agents referred to during reporter passage, including the possible use of monoclonal antibodies and / or substances that can be dissolved by the reticuloendothelial system as vectors that do not give important practical details. Enables burn improvement of organs such as the liver-for example, WO-A-9300933, WO-A-9401140, WO-A-9408627, WO-A-9428874, US-A-5088499, US-A-5348016 And US-A-5469854.
[13] The present invention is based on the discovery that gas filled microbubbles stabilized by a single layer of film-forming surfactant material are particularly useful reporters in targeted diagnostic and / or therapeutic agents. Thus, for example, the flexibility and deformability of such thin film monolayers substantially increases the echo of such reporters for liposome systems containing lipid bilayers or multilayers of such bilayers. This can limit the use of very low dosage reporter materials, thus achieving high ultrasonic contrast efficiency with the resulting stability benefits.
[14] Thus, according to one aspect of the present invention stabilized by a monolayer of film-forming surfactant material in a targetable diagnostic and / or therapeutically active agent, such as an aqueous carrier solution (eg, an injectable carrier solution). Ultrasound contrast agents are provided that comprise a suspension of reporters consisting of gas filled microbubbles and further comprising one or more vectors.
[15] The term “single layer” is used herein to refer to amphiphiles (lipophilic portions of amphiphiles arranged towards the gas phase and hydrophilic portions that interact with the aqueous phase) in the form of surfactant residues in a monolayer film or so-called Langmuir at the gas-liquid interface. It is used to represent a film similar to a Langmuir-Blodgett film.
[16] As shown in WO-A-9729783, it is believed that electrostatic repulsion between charged phospholipid membranes promotes stable formation and stabilization of monolayers at the microbubble-carrier interface. The flexibility and deformability of such thin films is believed to increase the reverberation of the products according to the invention described in connection with gas filled liposomes comprising one or more lipid bilayers. The amount of phospholipid used to stabilize this microbubble-containing aqueous suspension can be as small as necessary for the formation of a single monolayer of surfactant around each gas microbubble so that the resulting film-like structure is microscopic against collapse or coalescence. Stabilize the bubble. It is believed that microbubbles with liposome-type surfactant bilayers are not obtained when such low lipid concentrations are used.
[17] One advantageous embodiment of the present invention is that a limited attachment to a target is a very useful property of a diagnostic and / or therapeutically active agent, which property can be achieved using a vector that yields temporary retention over fixed attachment to the target. It is based on the further finding that it can. Thus such diagnostic and / or therapeutically active agents may be effectively present in the form of a delayed flow with the vascular endothelial, for example by transient interaction with endothelial cells, rather than being held fixed at a particular site. Thus, such diagnostic and / or therapeutically active agents may be concentrated on the vessel wall when the ultrasound contrast agent provides improved echo over the bulk of the bloodstream lacking anatomical features. Thus, these diagnostic and / or therapeutically active agents may allow for improved burns of capillary systems including microvessels, for example to facilitate differentiation between normal and improperly spread tissue in the heart and It may be useful for visualizing structures such as, Cooper cells, tromby and atherosclerotic damage or for visualization of neo-vascular and inflammatory tissue regions. The present invention is particularly suitable for burn changes occurring in normal blood vessels located in the area of tissue necrosis.
[18] In a further embodiment of the invention, one or more vectors may be attached or included in the reporter in a manner that is not readily exposed to the target or target reporter. Thus, increased tissue specificity can be achieved by additional methods for exposing the vector, such as exposing the diagnostic and / or therapeutically active agent after administration to external ultrasound to alter the diffusivity of the residue containing the vector. .
[19] Any biocompatible gas may be present in the reporter, and the term “gas” herein is intended to include any material (including mixtures) that is substantially or completely in the form of a gas (including steam) at a normal human temperature of 37 ° C. Used. Thus, this gas may be, for example, air; nitrogen; Oxygen; carbon dioxide; Hydrogen; Inert gases such as helium, argon, xenon or krypton; Sulfur fluorides such as sulfur hexafluoride, disgadisulfide or pentafluoride trifluoromethylsulfur; Selenium hexafluoride; Optionally halogenated silanes such as methylsilane or dimethylsilane; Low molecular weight hydrocarbons (for example containing up to 7 carbon atoms), for example, alkanes such as methane, ethane, propane, butane or pentane, cycloalkanes such as cyclopropane, cyclobutane or cyclopentane, ethylene, pro Alkenes such as phen, propadiene or butene, or alkynes such as acetylene or propine; Ethers such as dimethyl ether; Ketones; ester; Halogenated low molecular weight hydrocarbons (eg containing up to 7 carbon atoms); Or mixtures of any of the foregoing. Advantageously, at least some of the halogenated atoms in the halogenated gas are fluorine atoms such that the biocompatible halogenated hydrocarbon gas is, for example, bromochlorodifluoromethane, chlorodifluoromethane, dichlorodifluoromethane, bromotrifluoro Romethane, chlorotrifluoromethane, chloropentafluoroethane, dichlorotetrafluoroethane, chlorotrifluoroethylene, fluoroethylene, ethylfluoride, 1,1-difluoroethane and perfluorocarbons, eg Mixtures with other isomers such as, for example, perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane (eg, perfluoro-n-butane, optionally perfluoro-iso-butane) ), Perfluoroalkanes such as perfluoropentane, perfluorohexane and perfluoroheptane; Perfluoroalkenes such as perfluoropropene, perfluorobutene (eg, perfluorobut-2-ene) and perfluorobutadiene; Perfluoroalkynes such as perfluorobut-2-yne; And perfluorocyclobutane, perfluoromethylcyclobutane, perfluorodimethylcyclobutane, perfluorotrimethylcyclobutane, perfluorocyclopentane, perfluoromethylcyclopentane, perfluorodimethylcyclopentane, perfluoro Perfluorocycloalkanes such as rocyclohexane, perfluoromethylcyclohexane and perfluorocycloheptane. Other halogenated gases include fluorinated (eg perfluorinated) ethers such as methyl chloride, fluorinated (eg perfluorinated) ketones such as perfluoroacetone and perfluorodiethyl ether. The use of perfluorinated gases, such as sulfur hexafluoride and perfluoropropane, perfluorobutane and perfluoropentane, has been found to be highly stable in the blood flow of microbubbles containing such gases. It may be particularly advantageous at
[20] Since the film-forming surfactant monolayer in the reporter unit according to the invention can stabilize the microbubbles produced against uncontrollable growth, this gas is butane, cyclobutane, n-pentane, isopentane, neo Materials such as pentane, cyclopentane, perfluoropentane, perfluorocyclopentane, perfluorohexane or mixtures containing one or more of these gases, for example, as described in WO-A- As described in 9416739, it is liquid at the handling or processing temperature but gaseous at the body temperature.
[21] In principle, any suitable film-forming surfactant may be a non-polymeric and nonpolymerizable wall-forming surfactant material as described, for example, in WO-A-9521631; Polymeric surfactant materials as described, for example, in WO-A-9506518; And gas-containing phospholipids as described, for example, in WO-A-9211873, WO-A-9217212, WO-A-9222247, WO-A-9428780, WO-A-9503835 or WO-A-9729783. It can be used to form an encapsulation monolayer. Advantageously, 75%, preferably substantially all of the film-forming surfactants present in the diagnostic and / or therapeutic actives according to the invention are mixed in a single layer at the gas-liquid interface.
[22] Representative examples of useful phospholipids are synthetic or semisynthetic such as lecithin (ie phosphatidylcholine), for example natural lecithin such as egg yolk lecithin or soy lecithin and dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine or distearoylphosphatidylcholine lecithin; Phosphatidic acid; Phosphatidylethanolamine; Phosphatidylserine; Phosphatidylglycerol; Phosphatidlinositol; Cardiolipin; Sphingomyelin; Fluorinated homologs of any of the foregoing; Mixtures of any of the foregoing and mixtures with other lipids such as cholesterol.
[23] The use of phospholipids comprising primarily (e.g., 75% or more) of molecules that individually contain the entire net charge can be particularly advantageous when used essentially as the sole amphoteric component of the reporter, such as product stability and acoustic properties. It can provide useful advantages for parameters. While not wishing to be bound by theory, electrostatic repulsion between charged phospholipid membranes can promote the formation of a stable monolayer at the gas-liquid interface; As described above, the flexibility and deformability of such thin films is believed to increase the reverberation of reporters used according to the present invention as compared to gas filled liposomes comprising one or more lipid bilayers.
[24] In addition, the use of charged phospholipids can provide reporters with advantageous properties, for example stability, dispersibility and aggregation resistance, regardless of additives such as additional surfactants and / or viscous enhancers, thus injecting contrast agents. The number of components administered to the subject's body is kept to a minimum. Thus, for example, the charged surface of the microbubbles can minimize or prevent its agglomeration as a result of electrostatic repulsion.
[25] Preferably at least 75%, preferably substantially all of the phospholipids, used in the reporters of the diagnostic and / or therapeutically active agents of the invention are composed of molecules with full net charge under the conditions of manufacture and / or use. The charge may be positive or more preferably negative. Representative positively charged phospholipids include esters of phosphatidic acids such as dipalmitoylphosphatidic acid or distearoylphosphatidic acid and aminoalcohols such as hydroxyethylethyleneamine. Examples of negatively charged phospholipids are natural (eg, from soy or egg yolk), semisynthetic (eg, partially or fully hydrogenated) and synthetic phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, phosphatidic acid and carbox Diolipine. Fatty acyl groups of these phospholipids generally contain about 14-22 carbon atoms each, for example palmitoyl and stearoyl groups. Such lysosomal forms of charged phospholipids are also useful according to the present invention and the term “lyso” refers to phospholipids containing only one fatty acyl group and is preferably ester-linked to the 1-position carbon atom of the glyceryl moiety. . These lysoforms of charged phospholipids can advantageously be used in admixture with charged phospholipids containing two fatty acyl groups.
[26] Phospadidilserine represents a particularly preferred phospholipid of the use of diagnostic and / or therapeutically active agents according to the invention and preferably constitutes a substantial part of, for example, at least 80% of the phospholipid content, for example 85-92%. do. While we are not based on theoretical considerations, ion crosslinking between the carboxyl and amino groups of the surrounding serine residues may contribute to the stability of this reporter system. Preferred phosphatidylserine includes saturated (eg hydrogenated or synthetic) natural phosphatidylserine and synthetic distearoylphosphatidylserine, dipalmitoylphosphatidylserine and diarachidylphosphatidylserine.
[27] Other effectively useful lipids include stearic acid, palmitic acid, stearylamine, palmitylamine, cholesterol, bisalkyl glycerol, sphingoglycolipides, synthetic lipids (e.g., N, N-dimethyl-N-octadecyl-1 Phosphatidylethanolamine optionally mixed with one or more lipids such as octadecaneammonium chloride or bromide (DODAC, DODAB), and / or maleic acid bisalkylester.
[28] Further examples of lipids that can be used to prepare gas-containing contrast agents include fatty acids, stearic acid, palmitic acid, 2-n-hexadecylstearic acid, oleic acid, and other acid-containing lipid structures. Such lipid constructs can be coupled with amino acids containing one or more amino groups by amide bond formation; The resulting lipid-modified amino acid (e.g. dipalmitolysine or distearoyl-2,3-diaminopropionic acid) is attached to a functionalized spacer element having a coupling site for binding one or more vector molecules. It can be a useful precursor for.
[29] Further useful stabilizers include lipopeptides comprising a lipid attached to a suitably functionalized peptide linker moiety for coupling one or more vector molecules. Especially preferred are the inclusion of positively charged peptide linker elements that can be immobilized via electrostatic interaction with reporter microbubbles stabilized by negatively charged phospholipids or other surfactant membranes.
[30] Another embodiment of the invention includes a functionalized microbubble containing one or more reactors for nonspecific reaction with reporter molecules located on the cell surface. Microbubbles comprising thiol residues can bind to cell surface reporters, for example, via disulfide exchange reactions. The reversible nature of this reaction means that the microbubble flow can be controlled by changing the redox environment. Similarly, functionalized microbubbles with membranes comprising activated esters such as N-hydroxysuccinimide esters can be used to react with amino groups found in the multiplicity of cell surface molecules.
[31] For example, previously proposed microbubble-containing contrast agents based on phospholipids as described in WO-A-9409829 are generally powdered surfactants, such as freeze-dried preformed liposomes or freeze-dried or spray-dried The phospholipid solution is prepared by contacting air or other gas followed by an aqueous carrier and stirring to generate a microbubble suspension which must be administered immediately after preparation. However, this method must be imparted in order to generate the dispersion where substantial agitation energy is needed, and the size and size distribution of the microbubbles depend on the amount of energy used and are not really adjustable.
[32] The reporter or diagnostic / therapeutic agent according to the invention, on the other hand, can advantageously be prepared by generating a gas microbubble dispersion in a suitable surfactant (eg phospholipid) -containing aqueous medium, if desired autoclaved or sterilized in advance. And, preferably, after washing and / or sizing of the microbubbles thus formed, lyophilizing the dispersion in the presence of, for example, one or more cryoprotectants / freezing agents to produce dry products that are easily reconstituted with water / aqueous solution. To obtain a constantly reproducible microbubble dispersion. This method is described in more detail in WO-A-9729783, the contents of which are incorporated herein by reference; The ability to remove bubbles of undesired size and excess surfactant is known from prior art such as WO-A-9409829 and WO-A-9608234, wherein the bubbles are different phospholipids and viscous enhancers such as propylene glycol and glycerol. Agitation of the suspension gives a substantial advantage over the method as described in).
[33] The method described above has a very narrow size distribution, e.g., greater than 90% (e.g., at least 95%, preferably at least 98%), with microbubbles having a capacity average diameter of 1-7 μm and less than 5% ( For example, 3% or less, preferably 2% or less) microbubbles may be used to generate reporter microbubbles having a capacity average diameter of greater than 7 μm. The washing step may be used so that the reporter is substantially free of undesirable components such as substantially excess lipids or viscosity enhancers. Diagnostic / therapeutic agents containing reporters made in this manner may exhibit the following advantages over prior art contrast agent materials.
[34] Echo per dose can be greatly increased because substantially all of the surfactant material participates in the stabilization of the microbubbles as a single layer. Ultrasound testing in dogs shows that ultrasound contrast agents prepared as described above can increase in signal intensity scattered back from 15 dB myocardial layer at intravenous injection doses as low as 0.1 μl microbubble / kg body weight. Indicated.
[35] In vivo stability is improved for the same reason that such diagnostic / therapeutic agents may be administered at a dose of, for example, 1-10 μg / kg body weight, for example, as low as 0.1-10 μg / kg body weight. do. The use of such low concentrations of surfactants can be a clear advantage to minimize possible toxic side effects.
[36] The high efficiency / dose ratio is also particularly advantageous for target use, since rather small amounts of reporter accumulate at these sites when using a product comprising a vector having affinity for the site of interest. Thus, such preferred reporters according to the present invention can significantly improve contrast compared to known target traceable ultrasound contrast agents at the site of interest. This high efficiency makes it possible to effectively "see" a single microbubble using ultrasonic waves, even if the resolution is not clear in the scintillat graphic, but close to or possibly greater than the sensitivity of scintography, which is probably the most useful technique currently on target. Can be.
[37] A particular advantage of phosphatidylserine-based diagnostic / therapeutics is biocompatibility; Thus, acute toxic effects, such as changes in blood pressure or heart rate, are not observed in animal experiments in dogs administered with intravenous transfer of phosphatidylserine-based contrast agents prepared as described above at doses of 10 times the normal burn dose. Did.
[38] The use of charged phospholipids may be advantageous in that they contain functional groups such as carboxy or amino that facilitate binding to the vector by linking units if desired. It should be appreciated that other functional groups may be mixed in such a system by mixing lipids containing the desired functional groups with the film-forming surfactant prior to microbubble generation.
[39] It is generally not necessary to mix additives such as emulsifiers and / or viscous enhancers commonly used in the contrast agent formulations present in the diagnostic / therapeutic agents of the present invention. As described above, it is advantageous to keep the number of components to be administered to the subject's body to a minimum and to make the viscosity of the diagnostic / therapeutic agent as low as possible. Such preparations of diagnostic / therapeutic agents generally comprise a lyophilization step as described above, but include cryoprotectants / freeze protection agents or fillers such as alcohols (eg, aliphatic alcohols such as t-butanol); Polyols such as glycerol; Carbohydrates (eg, sugars such as sucrose, mannitol, trehalose or cyclodextrins or polysaccharides such as dextran); Or it may be advantageous to include polyglycols such as polyethylene glycol. Preference is given to the use of physiologically resistant sugars such as sucrose.
[40] The lyophilized product prepared as described above is easily reconstitutable, in particular with gentle agitation in water with minimal agitation, for example a few seconds. The size of the microbubbles so generated is always renewable and is independent of the amount of agitable energy used and actually depends on the size of the microbubbles formed in the initial microbubble dispersion; Surprisingly, this size parameter is sufficiently maintained in the frozen and reconstituted product. Thus, since the size of the microbubbles in the initial dispersion is easily adjustable by reaction parameters such as this method, it is possible to easily control the rate and duration of agitation and the final microbubble size.
[41] The lyophilized product has also been demonstrated to be stored stably for several months or more under ambient conditions. The microbubble dispersion resulting from reconstitution in water is stable for at least 8 hours, allowing considerable flexibility for the case where the dry product is reconstituted prior to injection.
[42] The high efficiency of this preferred reporter allows the use of smaller bubbles than usual while the still occurring ultrasonic contrast effect significantly exceeds the minimum detection level of current ultrasonic imaging devices. These smaller bubbles have effective advantages such as reduced aggregation of blood vessels, longer circulation times, greater ability to reach the target and less accumulation in the lung or other non-target organs, and diagnostic / therapeutic agents containing them with their use. Constitutes a further feature of the invention.
[43] It may also be possible to take advantage of the increased ultrasonic contrast effect of bubble clusters using such smaller bubbles. It is known from the theory that when bubbles agglomerate to form larger gas phases with a total volume V, the ultrasonic contrast effect of a certain number of bubbles with a total volume V in the dilute dispersion increases. Thus, small bubbles can be used that do not substantially produce ultrasound contrast until the small bubbles are clustered (which can occur in the target area in preference to non-target sites with low density of target molecules). Small bubbles can be designed to associate with, for example, intra-bubble bonds enhanced by interaction with a target to increase contrast in the target region. In-bubble crosslinking and consequent clustering can be affected if the reporter has unreacted linking moieties that can react with other bubble phase functional groups besides transporting the vector retained at a particular site.
[44] In the context of the present invention, the reporter unit is usually attached to a vector. However, in one form of the targeting process, often referred to as "pre-targeting," vectors (often monoclonal antibodies) are administered alone; The reporter is then administered and coupled to a residue capable of specifically binding the pre-targeting vector molecule (if the pre-targeting vector is an antibody, the reporter is an immunoglobulin-binding molecule such as Protein A or an anti-immunoglobulin antibody). May be coupled to). The advantage of this method is that the time to remove vector molecules that do not bind the target of the vector can be tolerated, thereby substantially reducing the back problems associated with the presence of excess reporter-vector conjugates. Pre-targeting with one particular vector can be observed in the context of the present invention and is coupled to the residue which binds to the other vector and the first vector by a reporter unit.
[45] It is also of interest in the specification of the present invention to measure the rate at which a contrast agent bound to a target is substituted or dislodged from it, for example in the measurement of blood reflux rate in a target region such as the myocardial layer. This can be accomplished in a controlled manner by the administration of additional vectors and / or other substances that can displace or deplete the contrast agent from its target.
[46] Ultrasound imaging modalities that can be used in accordance with the present invention are based on B-mode imaging (e.g., the sum or difference of the fundamental frequencies of the emitted ultrasonic pulses, their low or high harmonics or the pulses emitted and the frequencies derived from these harmonics). Using the time-varying magnitude of the generated signal envelope, two-dimensional and three-dimensional image techniques such as images from fundamental frequencies or second harmonics are preferred, color Doppler images and Doppler size images, and the last two and the foregoing Combinations of any of the forms. Surprisingly good second harmonic signal was obtained from the target monolayer-stabilized microspheres according to the present invention. Continuous images of tissue, such as the heart or kidney, can be collected with the aid of appropriate synchronization techniques (eg gating or respiratory movement of the subject) to reduce the effects of migration. Measurement of changes in resonant frequency or frequency absorption involving stationary or delayed microbubbles can also be usefully made to detect contrast agents.
[47] The present invention provides a tool for therapeutic drug delivery in cooperation with the vector-mediated direction of the product at the desired site. "Treatment" or "drug" means a therapeutic agent that has an effective effect on a particular disease in a living person or a non-human animal. Combinations of drugs and ultrasound contrast agents are described, for example, in WO-A-9428873 and WO-A-9507072, but such products lack a vector having affinity for a particular site and thus are preferred sites before or during drug release. Shows a relatively poor specific delay.
[48] The therapeutic compound used according to the invention may be encapsulated inside the microbubble or attached or mixed to the stabilizing membrane. Thus, the therapeutic compound of the present invention is linked to a part of the membrane or physically mixed into a stabilizing material, for example, via covalent or ionic bonds, and especially before the drug acts in the body when the drug has similar polarity or solubility to the membrane material. To prevent leakage from the product. Release of the drug may be initiated only by wet contact with the blood and administered or by a catalyzed dissolution process by other internal or external influences, such as the use of enzymes or ultrasound. The destruction of gas-containing microparticles using external ultrasound is known as an example in WO-A-9325241 as a phenomenon in ultrasound contrast agents; The rate of drug release can vary depending on the type of therapeutic use using a particular amount of ultrasound energy from the transducer.
[49] The therapeutic agents of the present invention can be covalently bound to the encapsulated membrane surface using, for example, suitable linking agents as described above. Thus, for example, a phospholipid or lipopeptide derivative, to which a drug is bound via a biodegradable bond or linker, may be prepared first, and then the derivative may be mixed with this material to prepare a reporter as described above.
[50] Representative therapeutic agents suitable for use in the drug delivery compositions of the present invention include any known therapeutic drug or active homologue thereof containing a thiol group capable of coupling with a thiol-containing microbubble under oxidative conditions producing a disulfide group. In combination with the vector (s) such drug / vector-modified microbubbles can accumulate in the target tissue; Administration of a reducing agent such as reduced glutathione can release the drug molecule from the target microbubbles in the vicinity of the target cell, thereby increasing the local concentration of the drug and increasing the therapeutic effect. In addition, the compositions of the present invention are first prepared without a therapeutic agent and then coupled or coated onto the microbubble immediately before use, such as by adding the therapeutic agent to a suspension of microbubbles in an aqueous medium to adhere or adhere the therapeutic agent to the microbubble. can do.
[51] Other drug delivery systems include vector-modified phospholipid membranes doped with lipopeptide structures comprising poly-L-lysine or poly-D-lysine chains along with target vectors. For application to gene therapy / antisense techniques of particular importance on reporter-mediated drug delivery, microbubble carriers are concentrated with DNA or RNA through electrostatic interaction with cationic polylysine. This method has the advantage that the vector (s) used for targeted delivery are not directly attached to the polylysine carrier residue. This polylysine chain is also more tightly anchored to the microbubble membrane by the presence of lipid chains. The use of ultrasound to increase the delivery effect is also considered useful.
[52] In addition, the free polylysine chain is first modified with drug or vector molecules and then concentrated on the opposite surface of the target microbubbles.
[53] Representative and non-limiting examples useful in accordance with the present invention include vincristine, vinblastine, vindesine, busulfan, chlorambucil, spiroplatin, cisplatin, carboplatin, methotrezeate, adriamycin, mitomycin, Bleomycin, cytosine arabinoside, arabinosyl adenine, mercaptopurine, mitotan, procarbazine, darktinomycin (antimycin D), daunorubicin, doxorubicin, hydrochloride, taxol, plicamycin, aminogluglucin Tethymides, estrasmustin, flutamide, lutrolide, megestrol acetate, tamozifene, testosterone, trilostane, amsacrine (m-AMSA), asparaginase (L-asparaginase), Blood products such as etoposide, anti-neoplastic agents such as interferon a-2a and 2b, hematoporphyrin or derivatives of the foregoing; Biological response modifiers such as muram peptides; Antifungal agents such as ketoconazole, nystatin, griseofulvin, flucitocin, myconazole or amphotericin B; Growth hormone, melanocyte stimulating hormone, estradiol, beclomethasone dipropionate, betamethasone, cortisone acetate, dexamethasone, flunisolidide, hydrocortisone, methylprednisolone, paramethaneson acetate, prednisolone, prednison, triamcinolone or pulluled Hormones such as locortisone acetate; Vitamins such as cyanocobalamine or retinoids; Enzymes such as alkaline phosphatase or manganese superoxide dismutase; Anti-allergic agents such as amelezanox; Inhibitors of tissue factors such as monoclonal antibodies and compounds that downregulate the expression of Fab fragments, synthetic peptides, non-peptides and tissue factors thereof; Platelet inhibitors such as GPIa, GPIb and GPIIb-IIIa, ADP reporter, thrombin reporter, Von Willebrand factor, prostaglandin, aspirin, ticlopidine, clopigogrel and leopro; Inhibitors of aggregate protein targets such as FIIa, FVa, FVIIa, FVIIIA, FIXa, FXa, tissue factor, heparin, hirudin, pyrullog, argatroban, DEGR-rFVIIa and Annexin V: inhibitors of fibrin formation and t- Fibrin degradation promoters such as PA, urokinase, plasmin, streptokinase, rt-plasminogen activator and r-stapillokinase; Anti-angiogenic factors such as methoxyprogesterone, pentosan polysulfate, suramin, taxol, thalidomide, angiostatin, interferon-alpha, metalloproteinase inhibitors, platelet factor 4, somatostatin, thrombospondine; Circulating drugs such as propranolol; Metabolic enhancers such as glutathione; anti-nodal agents such as p-aminosalicylic acid, isoniazid, capreomycin, sulfate, cyclocezin, etabutol, ethionamide, pyrazineamide, rifampin or streptomycin sulfate; Antiviral agents such as acylclevir, amantadine, azidomidine, ribavirin or vidarabine; Vasodilators such as diltiazem, nifedipine, verapamil, erythritol tetranitrate, isosorbide dinitrate, nitroglycerin or pentaerythritol tetranitrate; Daphsone, Chloramphenicol, Neomycin, Sephachlor, Sepaderoxyl, Sephalexin, Sepradin, Erythromycin, Clindamycin, Lincomycin, Amoxicillin, Ampicillin, Bacampicillin, Carbenicillin, Diclozacillin, Cyclacillin Antibiotics such as picclozacillin, hetacillin, methicillin, naphcillin, penicillin, polymizin or tetracycline; Anti-inflammatory agents such as diflunisal, ibuprofen, indomethacin, meclefenamate, mefenamic acid, naprogen, phenylbutazone, pyroxicam, tolmethine, aspirin or salicylate; Antiprotozoal agents such as chloroquine, metronidazole, quinine or meglumine antimonate; Antirheumatic agents such as penicylamine; Anesthetics such as paregory; Opiates such as codeine, morphine or opiates; Cardiac glycosides such as deslanside, digitoxin, digosine, digitalin or digitalis; Neuromuscular blockers such as atraccurium mesylate, galamine triethoxide, hexafluorenium bromide, metocurin iodide, pancuronium bromide, succinylcholine chloride, tubocurin chloride or becuronium bromide; Amobarbital, Amobarbital Sodium, Aprobarbital, Butabarbital Sodium, Chloral Hydrate, Etchlorbinol, Etynamate, Flulazepam Hydrochloride, Glutetimide, Metotrimethrazine Hydrochloride, Methi Sedatives such as plylon, midazolam hydrochloride, paraldehyde, pentobarbital, secobarbital sodium, debutal, temazepam or triazolam; Local anesthetics such as bupivacaine, chloroprocaine, ethidocaine, lidocaine, mepivacaine, procaine or tetracaine; Acid additions such as dropperidol, etomidate, fentanyl citrate and dropperidol, ketamine hydrochloride, methohexyl sodium or thiopental and pharmaceutically acceptable salts (eg hydrochloride or hydrobromide) Salts or basic salts such as sodium, calcium or magnesium salts) or derivatives thereof (for example acetate). Other examples of therapeutic agents include genetic material such as nucleic acids, RNA, and DNA of natural or synthetic origin, including recombinant RNA and DNA. DNA encoding specific proteins can be used to treat many different forms of disease. For example, tumor necrosis factor or interleukin-2 gene can be provided to treat advanced cancer; Thymidine kinase gene can be provided to treat ovarian cancer or brain tumor; The interleukin-2 gene can be provided to treat neuroblastoma, malignant melanoma or kidney cancer; Interleukin-4 gene may be provided to treat cancer.
[54] The lipophilic derivative of the drug linked to the microbubble membrane via hydrophobic interaction may have a therapeutic effect as part of the microbubble or after release from the microbubble, for example by the use of ultrasound. If the drug does not have desirable physical properties, lipophilic groups can be introduced to fix the drug to the membrane. Preferably, the lipophilic group should be introduced in a manner that does not affect the efficacy of the molecule in vivo or that the lipophilic group is cleaved to release the active drug. The lipophilic group can be introduced by various chemical means depending on the functional group available to the drug molecule. Covalent coupling can be accomplished using functional groups in drug molecules that can react with suitably functionalized lipophilic compounds. Examples of lipophilic moieties include branched and unbranched alkyl chains, cyclic compounds, aromatic moieties and fused aromatic and nonaromatic cyclic systems. In some cases the lipophilic moiety consists of a suitably functionalized steroid such as cholesterol or related compounds. Examples of particularly suitable functional groups for derivatization include nucleophilic groups such as amino, hydroxy and sulfhydryl groups. Suitable methods for lipophilic derivatization of any drug containing sulfhydryl groups, such as captopril, include the formation of thiol esters by direct alkylation, for example by reaction with an alkyl halide under basic conditions and with an active carboxylic acid. It may include. Representative examples of derivatization of any drug having carboxyl functionality, such as athenol or chlorambucil, include amide and ester formation by coupling, respectively, with amines and alcohols containing suitable physical properties. Preferred embodiments include cholesterol attachment to the therapeutic compound by forming a degradable ester bond.
[55] A preferred use of the present invention relates to angiogenesis in which new blood vessels are produced by branching from existing blood vessels. The primary stimulus for this method may be an inadequate supply of nutrients and oxygen to the cells of the tissue (hypoxia). These cells can respond by secreting many angiogenic factors; One example is vascular endothelial growth factor. These factors initiate the secretion of proteases that degrade proteins in the basement membrane as well as inhibitors that limit the action of these possible harmful enzymes. The combined effect of the signal from the reporter for loss of adhesion and angiogenic factors migrates, proliferates and rearranges endothelial cells and finally synthesizes a new perivascular basal membrane.
[56] A tumor must initiate angiogenesis to maintain its growth rate when it reaches a millimeter in length. This method is a promising target for therapeutic adjustment because angiogenesis involves characteristic changes in endothelial cells and their environment. Transformations involving angiogenesis are also very promising for diagnosis and a preferred embodiment is a malignant disease, but this concept also shows great promise in inflammation and various inflammation-related diseases. This factor is also involved in revascularization of the infarcted part of the myocardial layer and occurs when stenosis occurs in a short time.
[57] Many known reporters / targets involved in angiogenesis are shown in the table below. Using the targeting principles described herein, angiogenesis can be detected by most imaging modalities when used in medicaments. Contrast-enhanced ultrasound may have additional advantages, and the contrast agent is microspheres that are limited inside the blood vessels. Even if the target antigen is found in many cell types, these microspheres attach exclusively to endothelial cells.
[58] So-called prodrugs can also be used as therapeutic agents according to the invention. Thus, drugs can be induced to alter their physicochemical properties and applied for inclusion into the reporter; The drug so induced may be considered a prodrug and is generally inactive until cleavage of the inducer regenerates the active form of the drug.
[59] Targeting a gas-filled microbubble containing a prodrug-activated enzyme against a region of the pathology can be an image that targets the enzyme and visualized when the microbubble is properly targeted to the region of the pathology and at the same time disappears from the non-target region It is possible. In this way it is possible to determine a suitable time for infusion of the prodrug to an individual patient.
[60] Another alternative is to mix prodrugs, prodrug-activating enzymes and vectors in the same microbubble in a system where the prodrug is activated only after some external stimulation. Such stimulation may be, for example, a rupture of the microbubble by external ultrasound after the tumor-specific protease as described above or the desired target has been achieved.
[61] Therapeutic agents can be readily delivered according to the invention, for example, to diseases or necrotic areas in the heart, general blood vessels and other sites such as the liver, spleen, kidney and lymphatic system, body cavity or gastrointestinal system.
[62] The product according to the invention can be used for targeted therapeutic delivery in vivo or in vitro. Later in the specification such products may be useful in in vitro systems such as diagnostic kits or the characterization of different components of different diseases in blood or tissue samples. A technique similar to attaching them to in vitro polymer particles (eg, monodisperse magnetic particles) to separate certain blood components or cells from a sample is described herein for separation of gas-containing materials by suspension and repeated washing. It can be used using a low density of reporter units in the treatment of.
[63] Coupling of reporter units to a desired vector (and / or therapeutic drug) generally involves interaction with the reporter and / or one or more functional groups located on the vector and / or any inserted linker group / spacer element. It can be achieved by means of sharing or non-sharing including. Examples of chemically active functional groups that can be used for this purpose include carbohydrate groups, bisinal diols, thioethers, 2-aminoalcohols, 2-aminothiols, guanidinyls in addition to amino, hydroxyl, sulfhydryl, carboxyl and carbonyl groups , Imidazolyl and phenolic groups.
[64] Thus, covalent coupling of reporters and vectors can be done using linking agents comprising reactive moieties that can react with such functional groups. Examples of reactive moieties that can react with sulfhydryl groups show particular reactivity with sulfhydryl groups, but are described in Gurd, FRN in Methods Enzymol. (1967) 11, 532 of the form X-CH ₂ CO-, wherein X = Br, Cl or I, which may also be used to modify imidazolyl, thioether, phenol and amino groups α-haloacetyl compounds. N-maleimide derivatives are also considered selective to sulfhydryl groups, but may be further useful in coupling to amino groups under certain conditions. N-maleimide is described by Kitagawa, T. et al. in Chem. Pharm. Bull. (1981) 29, 1130, incorporated into a linking system for reporter-vector binding or as described in Kovacic, P. et al. in J. Am. Chem. Soc. (1959) 81, 1887, as polymer crosslinkers for bubble stabilization. See, eg, Traut, T. et al. in Biochemistry (1973) 12, 3266, a reagent such as 2-iminothiolane that introduces thiol groups via the conversion of amino groups to be considered sulfhydryl reagents when the linkage occurs through the formation of disulfide bridges. Can be. Thus, reagents that introduce reactive disulfide bonds into the reporter or vector may be useful because a linkage may occur due to disulfide changes between the vector and the reporter; Examples of such reagents include Elman's reagent (DTNB), 4,4'-dithiodipyridine, methyl-3-nitro-2-pyridyl disulfide and methyl-2-pyridyl disulfide (Kimura, T et al. in Analyt. Biochem. (1982) 122, 271).
[65] Examples of reactive moieties that can react with amino groups include alkylating agents and acylating agents. Examples of representative alkylating agents include:
[66] i) an α-haloacetyl compound exhibiting specificity for an amino group in the presence of a reactive thiol group, for example, see Wong, YH.H. in Biochemistry (1979) 24, 5337, in the form of X-CH ₂ CO-, wherein X = Cl, Br or I;
[67] ii) Michael-type reactions or as described in Smith, D.G. et al. in J. Am. Chem. Soc. (1960) 82, 4600 and Biochem. J. (1964) 91, 589, N-maleimide derivatives capable of reacting with amino groups via acylation by addition to cyclic carbonyl groups;
[68] iii) aryl halides such as reactive nitrohaloaromatic compounds;
[69] iv) McKenzie, J.A. et al. in J. Protein Chem. (1988) 7, 581] alkyl halides;
[70] v) aldehydes and ketones capable of forming a Schiff base with amino groups, wherein the adducts formed are generally stabilized through reduction to yield stable amines;
[71] vi) epoxide derivatives capable of reacting with amino, sulfhydryl or phenolic hydroxyl groups such as epichlorohydrin and bisoxirane;
[72] vii) chlorine-containing derivatives of s-triazine which are highly reactive against nucleophiles such as amino, sulfhydryl and hydroxy groups;
[73] viii) s-triazine compounds based aziridine capable of reacting with nucleophiles such as amino groups by ring opening (see, eg, Ross, WCJ in Adv. Cancer Res. (1954) 2, 1) ;
[74] ix) squaric acid diethyl ester (Tietze, L. F. in Chem. Ber. (1991) 124, 1215);
[75] x) α-haloalkyl ethers which are more reactive alkylating agents than ordinary alkyl halides by activation with ether oxygen atoms (Benneche, T. et al. in Eur. J. Med. Chem. (1993) 28, 463 ]).
[76] Representative amino-reactive acylating agents include:
[77] i) forming stable urea and thiourea derivatives, respectively, and described in Schick, A.F. et al. in J. Biol. Chem. (1961) 236, 2477; isocyanates and isothiocyanates, in particular aromatic derivatives, used for protein crosslinking;
[78] ii) Herzig, D.J. et al. sulfonyl chlorides described in in Biopolymers (1964) 2, 349, which may be useful for the introduction of fluorescent reporter groups into linkers;
[79] iii) acid halides;
[80] iv) active esters such as nitrophenyl esters or N-hydroxysuccinimidyl esters;
[81] v) acid anhydrides such as mixed, symmetric or N-carboxy anhydrides;
[82] vi) Bodansky, M. et al. other reagents useful for the formation of amide bonds as described in 'Principles of Peptide Synthesis' (1984) Springer-Verlag;
[83] vii) acyl azide, wherein the azide group is a hydrazide derivative preformed using sodium nitrate, as described, for example, in Wetz, K. et al. in Anal. Biochem. (1974) 58, 347. Occurs from);
[84] viii) for example, Rasmussen, J.K. azlactone attached to a polymer such as bisacrylamide as described in Reactive Polymers (1991) 16, 199; And
[85] ix) Imidoesters that form stable amidines upon reaction with amino groups (see, eg, Hunter, M. J. and Ludwig, M. L. in J. Am. Chem. Soc. (1962) 84, 3491).
[86] Carbonyl groups, such as aldehyde functional groups, can react with weak protein bases at pH at which the nucleophilic protein side chain functional groups are protonated. Weak bases include 1,2-aminothiol, which can be found in the N-terminal cysteine residue, which is described, for example, in Ratner, S. et al. in J. Am. Chem. Soc. (1937) 59, 200, optionally forming a stable 5-membered thiazolidine ring with an aldehyde group. Other weak bases such as phenyl hydrazone are described, for example, in Heitzman, H. et al. in Proc. Natl. Acad. Sci. USA (1974) 71, 3537.
[87] Aldehydes and ketones can also react with amines to form Schiff bases, and can advantageously be stabilized through reductive amination. Alkoxyamino residues can readily react with ketones and aldehydes to produce stable alkoxamines (see, eg, Webb, R. et al. In Bioconjugate Chem. (1990) 1, 96).
[88] Examples of reactive moieties that can react with carboxyl groups include diazo compounds such as diazoacetate esters and diazoacetamides, which react with high specificity to generate ester groups (eg, Herriot RM in Adv). Protein Chem. (1947) 3, 169]. Carboxylic acid modifiers such as carbodiimides that react through O-acylurea formation and amide bond formation may also be usefully employed; Linking can be facilitated through the addition of amines or results in direct vector-reporter coupling. Useful water-soluble carbodiimides include 1-cyclohexyl-3- (2-morpholinyl-4-ethyl) carbodiimide (CMC) and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDC) (See, eg, Zot, HG and Puett, D. in J. Biol. Chem. (1989) 264, 15552). Other useful carboxylic acid modifiers include isoxazolium derivatives such as Woodwards Reagent K; chloroformates such as p-nitrophenylchloroformate; Carbonyldiimidazole, such as 1,1'-carbonyldiimidazole; And N-carvalkoxydihydroquinolines such as N- (ethoxycarbonyl) -2-ethoxy-1,2-dihydroquinoline.
[89] Other useful reactive moieties are bisinal diones such as p-phenylenediglyoxal, which include guanidinyl groups (Wagner et al. In Nucleic acid Res. (1978) 5, 4065); And diazonium salts capable of undergoing an electrophilic substitution reaction (Ishizaka, K. and Ishizaka T. in J. Immunol. (1960) 85, 163). Bis-diazonium compounds are readily prepared by treating aryl diamine with sodium nitrate in acidic solution. If functional groups in the reporter and / or vector are desired, they may be converted to other functional groups, for example, prior to the reaction to impart further reactivity or selectivity. Examples of methods useful for this purpose include the conversion of amines to carboxylic acids using reagents such as dicarboxylic acid anhydrides; Conversion of amines to thiols using reagents such as N-acetylhomocysteine thiollactone, S-acetylmercaptosuccinic anhydride, 2-iminothiolane or thiol-containing succinimidyl derivatives; conversion of thiols to carboxylic acids using reagents such as α-haloacetate; Conversion of thiols to amines using reagents such as ethyleneimine or 2-broboethylamine; Carbodiimide followed by conversion of the carboxylic acid to the amine using a reagent such as diamine; And conversion of the alcohol to thiol using a reagent such as tosyl chloride, followed by transesterification with thioacetate and hydrolysis of the thiol with sodium acetate.
[90] Vector-reporter coupling can also be performed using enzymes such as zero-length linkers; Thus, for example, transglutaminase, peroxidase and xanthine oxidase can be used to prepare linked products. Reverse proteolysis can also be used for linkage through amide bond formation.
[91] Non-covalent vector-reporter coupling is, for example, between a polylysinyl-functionalized reporter and a polyglutamyl-functionalized reporter through high affinity binding interactions such as chelation or avidin / biotin bonds in the form of stable metal complexes. By electrostatic charge interaction. Polylysine coated noncovalently on the negatively charged membrane surface can also nonspecifically increase the affinity of the microbubbles to cells through charge interactions.
[92] In addition, the vector may be coupled to a known protein to bind phospholipids. In many cases other proteins are attached primarily to surfaces consisting of phospholipid head groups, while a single molecule of phospholipid can attach to proteins such as translocases and thus can be used to attach vectors to phospholipid microspheres; One example of such a protein is β2-glycoprotein I (Chonn, A., Semple, S.C. and Cullis, P.R., Journal of Biological Chemistry (1995) 270, 25845-25849). Phosphatidylserine-binding proteins are described in Igarashi, K. et al. in Journal of Biological Chemistry 270 (49), 29075-29078; Thus, the binding of this phosphatidylserine-binding protein with the vector can be used to attach the vector to phosphatidylserine-encapsulated microspheres. If the amino acid sequence of the binding protein is known, biological activity can be avoided, in which the phospholipid-binding protein is synthesized or isolated, used for binding with the vector and located anywhere in the molecule.
[93] It is also possible to obtain molecules that specifically bind to the surface (or “membrane”) of the microspheres by direct screening of a molecular library for microsphere-binding molecules. For example, phage libraries that display small proteins can be used for this selection. This selection can be made by simply mixing the microspheres with the phage display library and releasing the phage bonds to the suspended microspheres. If desired, such selection may be made in "physiological conditions" (eg, in the blood) to remove peptides that cross-react with blood components. The advantage of this type of selection process is that only the binding molecules attached to the fully suspended microspheres rise to the top so that only binding molecules that do not destabilize the microspheres should be selected. It may also be possible to introduce some kind of “stress” (eg, pressure) during the selection process to ensure that destable binding moieties are not selected. This selection can also be carried out by shearing conditions, for example by first reacting phage with microspheres and passing the microspheres through a surface coated with an anti-phage antibody under flow conditions. In this way it may be possible to select a binder that is capable of inhibiting shear conditions present in vivo. The binding moieties identified in this way can be coupled to a vector molecule consisting of general means for attaching any vector molecule to microspheres (via chemical binding or peptide synthesis, or at the DNA-level for recombinant vectors).
[94] Lipo-oligosaccharides or lipopeptide linkers containing vectors coupled or coupled to peptides, elements capable of modulating membrane insertion may also be useful. An example is described in Lynnhouts, J.M. et al. in Febs Letters (1995) 370 (3), 189-192. Bioinert molecules composed of known membrane insertion anchors / signals can be used as vectors for specific applications and examples are described in Xie, Y. and Morimoto, T. in J. Biol. Chem. (1995) 270 (20), 11985-11991, H1 hydrophobic segment from Na, K-ATPase α-subunit. This anchor group may also be fatty acid (s) or cholesterol.
[95] Coupling can also be performed using avidin or streptavidin with four high affinity binding sites for biotin. Thus, avidin can be used to bind the vector to the reporter when both the vector and the reporter are biotinylated. Such examples are described in Bayer, E.A. and Wilchek, M. in Methods Biochem. Anal. (1980) 26, 1). The method can also be extended to a process that can facilitate the linking of the reporter to the reporter, bubble association and possibly possibly increased echo. In addition, avidin or streptavidin can be attached directly to the surface of the reporter microparticles.
[96] Non-covalent coupling can also take advantage of the bifunctional nature of bispecific immunoglobulins. Such molecules can specifically bind two antibodies and link them. For example, bispecific IgG or chemically treated bispecific F (ab) ' ₂ segments can be used as the linking agent. Heterobifunctional bispecific antibodies have also been reported to link two different antigens (Bode, C. et al. In J. Biol. Chem. (1989) 264, 944 and Statrz, UD et al. in Proc. Natl. Acad. Sci. USA (1986) 83, 1453]. Similarly, any reporter and / or vector having two or more antigenic determinants (described in Chen, Aa et al. In Am. J. Pathol. (1988) 130, 216) is an antibody. It can be crosslinked by the molecule, forming a potentially increased echo of multi-bubble cross-linked assembly.
[97] The linking agent used in accordance with the present invention may generally be used to effect linkage of the reporter to a vector or reporter to a reporter with some degree of specificity and to attach one or more therapeutically active agents.
[98] In some cases it is believed to include the PEG component as a stabilizer upon direct binding to the vector (s) or reporter in the same molecule where PEG does not act as a spacer.
[99] So-called zero-length linkers which induce direct covalent bonds of two reactive chemical groups without introducing additional linking materials (eg using carbodiimide or upon enzymatically induced amide bond formation) are preferred. Cases can be used according to the invention as a therapeutic agent such as a biotin / avidin system inducing non-covalent reporter-vector linkages and as a therapeutic agent inducing hydrophobic or electrostatic interactions.
[100] However, most commonly the linking agent comprises two or more reactive moieties linked by spacer elements, as described above. The presence of such spacers allows difunctional linkers to react with specific functional groups in one molecule or two different molecules to form a bond between these two components and introduce an external linker-derived material into the reporter-vector bond. The reactive moieties in the linking agent may be identical (homofunctional reagents) or different (heterofunctional reagents or heteropolyfunctional reagents when several dissimilar reactive moieties are present) and may be molecules or molecules between any chemical species. Can cause covalent bonds.
[101] The nature of the foreign material introduced by the linking agent can have important implications for the target strength and general stability of the final product. Thus, for example, it is desirable to introduce labile bonds containing spacer arms that mix biodegradable or chemically sensitive or enzymatic cleavage sites. Such spacers may also contain polymeric components, for example, which act as surfactants and increase bubble stability. Such spacers may include reactive moieties as described above, for example, to increase surface crosslinking, or may include tracer elements such as fluorescent probes, spin labels or radioactive materials.
[102] Thus, the contrast agent according to the present invention is useful for all imaging modalities because contrast elements such as X-ray contrast agents, optical imaging probes, spin labels or radioactive units are easy to mix or adhere to the reporter units.
[103] The spacer element may generally consist of aliphatic chains that effectively separate the reactive moieties of the linker at a distance of 5 to 30 mm 3. They are also of great interest in biotechnological and biomedical applications (see, eg, Milton Harris, J. (ed) "Poly (ethylene glycol) chemistry, biotechnical and biomedical applications" Plenum Press, New York, 1992). It may comprise a macromolecular structure such as PEG received. PEG is highly hydrated with two or three water molecules soluble in most solvents, including water, and bound to each ethylene glycol segment in an aqueous environment; This has the effect of preventing the uptake of proteins on other polymers or PEG-modified surfaces. PEG is known to be non-toxic and not harmful to active proteins or cells, but covalently linked PEG is known to be non-immune and non-antigenic. In addition, PEG is easily modified and can bind to other molecules that have little effect on its chemistry. Their advantageous solubility and biological properties are evident from the many possible uses of PEG and copolymers of PEG, including block copolymers such as PEG-polyurethane and PEG-polypropylene.
[104] Suitable molecular weights for the PEG spacer used according to the invention are, for example, from 120 daltons to 20 kilodaltons.
[105] The main mechanism for uptake of particles by cells of the reticuloendothelial system (RES) is opsonism by plasma proteins in the blood; These mark the foreign particles absorbed by the RES. The biological properties of the PEG spacer elements used in accordance with the present invention can serve to increase contrast cycle time in a manner similar to that observed for PEGylated liposomes (Klibanov, AL et al. In FEBS Letters (1990) 268, 235-237 and Blume, G. and Cevc, G. in Biochim. Biophys. Acta (1990) 1029, 91-97). Increased coupling efficiency for the region of interest can also be achieved using antibodies bound to PEG spacer ends (Maruyama, K. et al. In Biochim. Biophys. Acta (1995) 1234, 74-80). And Hansen, CB et al. In Biochim. Biophys. Acta (1995) 1239, 133-144.
[106] In some cases it is believed to include the PEG component as a stabilizer upon binding directly to the reporter in the same molecule in which the vector (s) is bound or PEG does not act as a spacer.
[107] Other representative spacer elements include structural polysaccharides such as polygalacturonic acid, glycosaminoglycans, heparinoids, cellulose and marine polysaccharides such as alginates, chitosan and carrageenan; Storage polysaccharides such as starch, glycogen, dextran and aminodextran; Polyamino acids and their methyl and ethyl esters such as lysine, glutamic acid and aspartic acid alone or in copolymers; And polypeptides, oligosaccharides and oligonucleotides which may or may not bind to enzyme cleavage sites.
[108] In general, the spacer element may comprise cleavable groups such as bisinal glycol, azo, sulfone, ester, thioester or disulfide groups. Chemical formula
[109] -(Z) mYXC (R ¹ R ² ) .XY (Z) n- where X and Z are -O-, -S- and -NR- where R is hydrogen or an organic group Y is a carbonyl, thiocarbonyl, sulfonyl, phosphoryl or similar acid-forming group, respectively; m and n are each 0 or 1; R ¹ and R ² are each hydrogen, an organic group, or -XY (Z); spacers comprising a biodegradable methylene diester or diamide group of m-group or together with divalent organic groups) may be useful; For example, as described in WO-A-9217436, such groups are readily biodegradable, for example in the presence of estase in vivo, but are stable in the absence of such enzymes. Thus, they can be advantageously linked to a therapeutic agent to allow slow release of the therapeutic agent.
[110] Poly [N- (2-hydroxyethyl) methacrylamide] is a useful spacer material by low interaction with cells and tissues (Volfova, I., Rihova, B. and VR and Vetvicka, P. in J. Bioact.Comp. Polymers (1992) 7, 175-190). Experiments with similar polymers consisting primarily of closely related 2-hydroxypropyl derivatives have shown that cells are only absorbed to a lesser extent by the mononuclear phagocyte system (Goddard, P., Williamson, I., Bron, J., Hutchkinson). , LE, Nicholls, J. and Petrak, K. in J. Bioct.Compat.Polym. (1991) 6, 4-24).
[111] Other useful polymeric spacer materials include:
[112] i) copolymers of methyl methacrylate and methacrylic acid; They may be eroded (see Lee, P.I. in Pharm. Res. (1993) 10, 980), and carboxylate substituents may cause higher swelling than neutral polymers;
[113] ii) block copolymers of polymethacrylate with biodegradable polyesters (see San Roman, J. and Guillen-Garcia, P. in Biomaterials (1991) 12, 236-241);
[114] iii) polymers of cyanoacrylates, ie esters of 2-cyanoacrylic acid, which are biodegradable and have been used in the form of nanoparticles for selective drug delivery (Forestier, F., Gerrier, P., Chaumard, C., Quero, AM, Couvreur, P. and Labarre, C. in J. Antimicrob. Chemoter. (1992) 30, 173-179);
[115] iv) polyvinyl alcohols which are water soluble and generally considered biocompatible (see Langer, R. in J. Control. Release (1991) 16, 53-60);
[116] v) copolymers of vinyl methyl ether and maleic anhydride mentioned as bioeroded (Finne, U., Hannus, M. and Urtti, A. in Int. J. Pharm. (1992) 78. 237-241 ] Reference);
[117] vi) polyvinylpyrrolidone, for example, rapidly filtered by elongation with a molecular weight of less than about 25,000 (Hespe, W., Meier, AM and Blankwater, YM in Arzeim.-Forsch./Drug Res. (1977) 27, 1158-1162);
[118] vii) polymers and copolymers of short-chain aliphatic hydroxy acids such as glycolic acid, lactic acid, butyric acid, valeric acid and caproic acid (see Carli, F. in Chim. Ind. (Milan) (1993) 75, 494-9) ) And copolymers which mix aromatic hydroxy acids to increase their degradation rate (Imasaki, K., Yoshida, M., Fukuzaki, H., Asano, M., Kumakura, M.). , Mashimo, T., Yamanaka, H. and Nagai.T. In Int. J. Pharm. (1992) 81, 31-38);
[119] viii) polyesters composed of alternating units of ethylene glycol and terephthalic acid, for example Dacron ^R as non-degradable but very biocompatible;
[120] ix) for example polyurethanes (Kobayashi, H., Hyon, SH and Ikada, Y. in "Water-curable and biodegradable prepolymer" -J. Biomed. Mater. Res. (1991) 25, 1481-1494 ] Aliphatic hydroxy acid polymers when mixed with (Younes, H., Nataf, PR, Cohn, D., Appelbaum, YJ, Pizov, G. and Uretzky, G. in Biomater.Artif.Cells Artif.Organs (1988) 16, 705-719), the block copolymer comprising a biodegradable segment;
[121] x) flexible “soft” segments known to be resistant to transplanted tissue, including, for example, poly (tetramethylene glycol), poly (propylene glycol) or poly (ethylene glycol) and for example 4,4 Polyurethanes that can be mixed with aromatic “hard” segments including '-methylenebis (phenylene isocyanate) (Ratner, BD, Johnston, AB and Lenk, TJ in J. Biomed. Mater. Res: Applied Biomaterials ( 1987) 21, 59-90; Sa Da Costa, V. et al. In J. Coll.Interface Sci. (1981) 80, 445-452 and Affrossman, S. et al. In Clinical Materials (1991) 8, 25 -31);
[122] xi) hydrolyzable ester linkages (see Song, CX, Cui, XM and Schindler, A. in Med. Biol. Eng. Comput. (1993) 31, S147-150). And poly (1,4-dioxan-2-one) which may include glycolide units to improve absorbency (Bezwada, RS, Shalaby, SW and Newman, HDJ in Agricultural and synthetic polymers: Biodegradability and utilization (1990) (ed Glass, JE and Swift, G.), 167-174-ACS symposium Series, # 433, Washington DC, USA-American Chemical Society.
[123] xii) Rabbit studies (Brem, H., Kader, A., Epstein, JI, Tamargo, RJ, Domb, A., Langer, R. and Leong, KW in Sel. Cancer Ther. (1989) 5, 55 And rat studies (Tamargo, RJ, Epstein, JI, Reinhard, CS, Chasin, M. and Brem, H. in J. Biomed. Mater. Res. (1989) 23, 253-266). Polyanhydrides, such as copolymers of sebacic acid (octanedioic acid) and bis (4-carboxy-phenoxy) propane, which have been shown to be useful for controlled release of drugs in the brain without toxic effects;
[124] xiii) biodegradable polymers containing ortho-ester groups used for controlled release in vivo (see Maa, Y. F. and Heller, J. in J. Control. Release (1990) 14, 21-28); And
[125] xiv) polyphosphazenes, alternately inorganic polymers composed of phosphorus and nitrogen atoms (see Chrommen, J. H., Vandorpe, J. and Schacht, E. H. in J. Control. Release (1993) 24, 167-180).
[126] The following table lists linking agents and reagents for protein modification that may be useful for preparing the target traceable therapeutic agent according to the present invention.
[127] Heterodifunctional coupling agents
[128] ConnectionReactivity 1Reactivity 2Explanation ABHcarbohydratePhotoreactivityANB-NOS-NH ₂ PhotoreactivityAPDP (1)-SHPhotoreactivityIodide Disulfide Linkers APG-NH ₂ PhotoreactivityReacts selectively with Arg at pH 7-8 ASIB (1)-SHPhotoreactivityIodinable ASBA (1)-COOHPhotoreactivityIodinable EDC-NH ₂ -COOHZero-length coupling agent GMBS-NH ₂ -SHSulfo-GMBS-NH ₂ -SHreceptivity HSAB-NH ₂ PhotoreactivitySulfo-HSAB-NH ₂ Photoreactivityreceptivity MBS-NH ₂ -SHSulfo-MBS-NH ₂ -SHreceptivity M ₂ C ₂ Hcarbohydrate-SHMPBHcarbohydrate-SHNHS-ASA (1)-NH ₂ PhotoreactivityIodinable Sulfo-NHS-ASA (1)-NH ₂ PhotoreactivityWater Soluble, Iodideable Sulfo-NHS-LC-ASA (1)-NH ₂ PhotoreactivityWater Soluble, Iodideable PDPHcarbohydrate-SHDisulfide Linker PNP-DTP-NH ₂ PhotoreactivitySADP-NH ₂ PhotoreactivityDisulfide Linker Sulfo-SADP-NH ₂ PhotoreactivityWater Soluble Disulfide Linker SAED-NH ₂ PhotoreactivityDisulfide Linker SAND-NH ₂ PhotoreactivityWater Soluble Disulfide Linker SANPAH-NH ₂ PhotoreactivitySulfo-SANPAH-NH ₂ Photoreactivityreceptivity SASD (1)-NH ₂ PhotoreactivityWater Soluble Iodide Disulfide Linker SIAB-NH ₂ -SHSulfo-SIAB-NH ₂ -SHreceptivity SMCC-NH ₂ -SHSulfo-SMCC-NH ₂ -SHreceptivity SMPB-NH ₂ -SHSulfo-SMPB-NH ₂ -SHreceptivity SMPT-NH ₂ -SHSulfo-LC-SMPT-NH ₂ -SHreceptivity SPDP-NH ₂ -SHSulfo-SPDP-NH ₂ -SHreceptivity Sulfo-LC-SPDP-NH ₂ -SHreceptivity
[129] Sulfo-SAMCA (2)-NH ₂ PhotoreactivitySulfo-SAPB-NH ₂ Photoreactivityreceptivity (1) = iodizable; (2) = fluorescence
[130] Homo-functional coupling agent
[131] ConnectionResponsiveExplanation BS-NH ₂ BMH-SHBASED (1)PhotoreactivityIodide Disulfide Linker BSCOES-NH ₂ Sulfo-BSCOES-NH ₂ receptivity DFDNB-NH ₂ DMA-NH ₂ DMP-NH ₂ DMS-NH ₂ DPDPB-NH ₂ Disulfide linker DSG-NH ₂ DSP-NH ₂ Disulfide linker DSS-NH ₂ DST-NH ₂ Sulfo-DST-NH ₂ receptivity DTBP-NH ₂ Disulfide linker DTSSP-NH ₂ Disulfide linker EGS-NH ₂ Sulfo-EGS-NH ₂ receptivity SPBP-NH ₂
[132] Biotin
[133] Diagnosis / TreatmentResponsiveExplanation Biotin-BMCC-SHBiotin-DPPE * Preparation of Biotinylated Liposomes Biotin-LC-DPPE * Preparation of Biotinylated Liposomes Biotin-HPDP-SHDisulfide linker Biotin-hydrazidecarbohydrateBiotin-LC-HydrazidecarbohydrateIodoacetyl-LC-Biotin-NH ₂ NHS-Iminobiotin-NH ₂ Reduced affinity for avidin NHS-SS-Biotin-NH ₂ Disulfide linker Photoreactive BiotinNucleic acidSulfo-NHS-Biotin-NH ₂ receptivity Sulfo-NHS-LC-Biotin-NH ₂ DPPE = dipalmitoylphosphatidylethanolamine; LC = long chain
[134] Protein Modification Diagnostics / Therapies
[135] Diagnosis / TreatmentResponsivefunction Elman Reagent-SHQuantification / Detection / Protection DTT-S.S-restoration 2-mercaptoethanol-S.S-restoration 2-metcaptylamine-S.S-restoration Traut reagent-NH ₂ -SH introduced SATA-NH ₂ Introduced protected -SH AMCA-NHS-NH ₂ Fluorescent marker AMCA-hydrazidecarbohydrateFluorescent marker AMCA-HPDP-S.S-Fluorescent marker SBF-chloride-S.S-Fluorescence Detection of -SH N-ethylmaleimide-S.S--SH block NHS-acetate-NH ₂ -NH ₂ block and acetylation Citraconic Anhydride-NH ₂ Reversibly block and introduce negative charge DTPA-NH ₂ Introducing the chelator BNPS-ScartolTryptophanTryptophan residue cleavage Bolton-Hunter-NH ₂ Introducing iodinable groups
[136] Other useful protein modifications include partial or complete deglycosidation by nuramidase, endoglycosidase, or periodate because deglycosidation is often less absorbed by liver, spleen, macrophages, etc. Glycosidation often results in increased uptake by the liver and macrophages; Preparation of the truncated form by proteolytic cleavage includes reduced size and shorter half-life in circulation; And cationization (see, eg, Kumagi et al. In J. Biol. Chem. (1987) 262, 15214-15219; Triguero et al. In Proc. Natl. Acad. Sci. USA (1989) 86, 4761-4765; Pardridge et al. In J. Pharmacol.Exp. Therap. (1989) 251, 821-826 and Pardrige and Boado, Febs Lett. (1991) 288, 30-32.
[137] Vectors that can be usefully used in the target traceable diagnostic / therapeutic agent according to the present invention include:
[138] i) An antibody that can be used as a vector for a wide range of targets and has advantageous properties such as very high specificity, high affinity (preferably), and possibility of modification affinity as desired. Whether the antibody is bioactive or not depends on the specific vector / target combination. Both conventional and genetically treated antibodies can be used, and genetically treated antibodies allow for the accepted treatment of the antibody, for example, for specific needs regarding affinity and specificity. The use of human antibodies may be desirable to avoid possible immune responses against vector molecules. Further useful classes of antibodies are so-called bi- and multispecific antibodies that have specificity for two or more different antibodies in one antibody molecule. Such antibodies are useful for, for example, enhancing the formation of bubble clusters, and can also be used for various therapeutic purposes, for example, transport of toxic residues to a target. Various characteristics of bispecific antibodies are described in McGuinness, B.T. et al. in Nat. Biotechnol. (1996) 14, 1149-1154; by George, A.J. et al. in J. Immunol. (1994) 152, 1802-1811; by Bonardi et al. in Cancer Res. (1993) 53, 3015-3021; and by French, R. R. et al. in Cancer Res. (1991) 51, 2353-2361.
[139] ii) cell adhesion molecules, their receptors, cytokines, growth factors, peptide hormones and fragments thereof. Such vectors rely on normal biological protein-protein interactions with target molecular receptors and in many cases generate biological responses upon binding to the target and are therefore bioactive; These may be of relatively insignificant relationship with the vector targeting the proteoglycan.
[140] iii) non-peptide agonists / antagonists or inactive binders of receptors for cell adhesion molecules, cytokines, growth factors and peptide hormones. This category is not agonist or antagonist, but may include non-living vectors that may exhibit useful targets.
[141] iv) Oligonucleotides and modified oligonucleotides that bind DNA or RNA through Watson-Crick or other forms of base-pairing. Such oligonucleotides, which are generally in vivo in the extracellular space as a result of cellular damage and are generally non-living, can be useful, for example, for targeting of necrotic regions associated with many different pathological conditions. Oligonucleotides can be designed to bind to specific DNA- or RNA-binding proteins such as transcription factors that are very often highly overexpressed or activated in tumor cells or activated immune or endothelial cells. Combination libraries can be used to select oligonucleotides that specifically bind to any possible target molecule and thus can be used as target vectors.
[142] v) DNA-binding drugs may behave similarly to oligonucleotides but may exhibit biologically active and / or toxic effects when taken up by cells.
[143] vi) protease substrate / inhibitor. Proteases are associated with many pathological conditions. Many substrates / inhibitors are nonpeptidic but are often bioactive, at least for inhibitors.
[144] vii) Vector molecules can be generated from combinatorial libraries without necessarily knowing the exact molecular targets by functionally selecting molecules (in vitro, ex vivo or in vivo) that bind to the region / structure to be imaged.
[145] viii) A variety of small molecules, including known bioactive compounds for binding to various types of biological receptors. Such vectors or targets thereof can be used to generate non-living compound binding to the same target.
[146] ix) A protein or peptide that binds to a glucosamioglycan side chain, eg, a heparan sulphate comprising a larger molecule's glucosaminoglycan-binding moiety, causes a biological response upon binding to the glucosaminoglycan. Does not cause Proteoglycans are not found in red blood cells and eliminate the undesirable uptake of these cells.
[147] Other peptide vectors and lipopeptides thereof of particular interest for targeted ultrasound imaging are as follows: atherosclerotic plaque binding peptides such as YRALVDTLK, YAKFRETLEDTRDRMY and RALVDTEFKVKQEAGAK; Thrombus binding peptides such as NDGDFEEIPEEYLQ and GPRG, platelet binding peptides such as PLYKKIIKKLLES; And cholecystokinin, α-melanosite-stimulating hormone, heat stable enterotoxin 1, vasoactive enteric peptide, synthetic alpha-M2 peptide from the third heavy chain complementarity-determining region and homologs thereof for tumor application.
[148] The following table shows the various vectors that can be targeted to specific types of targets and the indicated regions used for the target traceable diagnostic and / or therapeutic agents according to the invention comprising such vectors.
[149] Protein and Peptide Vectors-Antibodies
[150] Vector formTargetDescription / Use AreaRef Antibodies (Common)CD34Common vascular diseases, normal blood vessel walls (eg myocardial layer), activated endothelial cells, immune cellsOne 〃ICAM-1〃One 〃ICAM-2〃One 〃ICAM-3〃One 〃E-selectin〃One 〃P-selectin〃One 〃PECAM〃One 〃Integrins such as VLA-1, VLA-2, VLA-3, VLA-4, VLA-5, VLA-6, β ₁ α ₇ , β ₁ α ₈ , β ₁ α _v , LFA-1, Mac -1, CD41a, etc.〃2 〃GlyCAMVascular wall in lymph nodes (highly specific for lymph nodes)3 〃MadCam 1〃3 〃FibrinTromby4 〃Tissue factorActivated endothelial, tumor5 〃MyosinNecrosis, myocardial infarction6 〃CEA (cancer antigen)tumor7 〃Mucintumor8 〃Multiple Drug Resistance Proteinstumor9 〃Prostate Specific AntibodyProstate cancer〃Cathepsin BTumors (various species of proteases often overexpress somewhat specific in various tumors-cathepsin B is such a protease)10 〃Transferrin receptorTumor, blood vessel wall11 MoAb 9.2.27 Antibodies Upregulated in Tumor Cell Growth12 〃VAP-1Adhesion molecule13 Antibodies Antibodies Antibodies Antibodies AntibodiesBand 3 protein CD34 (sialumucin) CD31 (PECAM-1) Intermediate Filament Necrotic Cells / Tissues CD44β2-Micro-globulin MHC Species 1 Integrin αvβ3Upregulated during phagocytic activity Endothelial cell Endothelial cell tumor Cells General tumors; Angiogenesisabbc
[151] references
[152] a) Heider, KH, M. Sproll, S. Susani, E. Patzelt, P. Beaumier, E. Ostermann, H. Ahorn, and GR Adolf, 1996. "Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas ". Cancer Immunology Immunotheraphy 43: 245-253.
[153] b) I. Roitt, J. Brostoff, and D. Male. 1985. Immunology, London: Gower Medical Publishing, p. 4.7
[154] c) Stromblad, S., and D. A. Cheresh. 1996. "Integrins, angiogenesis and vascular cell survival". Chemistry & Biology 3: 881-885.
[155] Protein and Peptide Vectors-Cell Adhesion Molecules, etc.
[156] Vector formTargetDescription / Use AreaRef L-selectinCD4MadCAM1GlyCam 1Common vascular diseases, normal vascular wall (eg myocardial layer), activated endothelial, lymph nodes3 Other SelectinCarbohydrate Ligands (Sialyl Lewis x) Heparan SulfateCommon vascular diseases, normal vascular wall (eg myocardial layer), activated endothelial14 RGD-peptideIntegreen〃2 PECAMPECAM, and othersEndothelial, cells in the immune system15 Integrins such as VLA-1, VLA-2, VLA-3, VLA-4, VLA-5, VLA-6, β ₁ α ₇ , β ₁ α ₈ , β ₁ α _v , LFA-1, Mac -1, CD41a, etc.Laminin, collagen, fibronectin, VCAM-1, thrombospodine, vitronectin, etc.Endothelium, blood vessel wall, etc.16 Integrin receptors such as laminin, collagen, fibronectin, VCAM-1, thrombospodine, vitronectin and the likeIntegrins such as VLA-1, VLA-2, VLA-3, VLA-4, VLA-5, VLA-6, β ₁ α ₇ , β ₁ α ₈ , β ₁ α _v , LFA-1, Mac -1, CD41a, etc.Cells, blood vessel walls, etc. in the immune system1718 Neuronal cell adhesion molecule (N-CAM) integrin αvβ3RGD-peptideProteoglycan N-CAM (homologous affinity) CD31 (PECAM-1) integrinEndothelial Cell Angiogenesis19c
[157] Vector containing cytokine / growth factor / peptide hormones and segments thereof
[158] Vector formTargetDescription / Use AreaRef Epidermal growth factorEGF-receptor or related receptortumor20 Nerve growth factorNGF-receptortumor21 SomatostatinST-receptortumor22 EndothelinEndothelin-ReceptorVessel wallInterleukin-1IL-1-receptorInflammation, different types of activated cells23 Interleukin-2IL-2-receptor〃24 Chemokines (receptors in which approximately 20 different cytokines are partially distributed)Chemokine receptors, proteoglycansInflammation25 Tumor necrosis factorTNF-receptorInflammationParathyroid hormonePTH-receptorBone diseaseBone Morphogenic ProteinBMP-receptorBone diseaseCalcitoninCT-receptorBone diseaseColony Stimulating Factors (G-CSF, GM-CSF, M-CSF, IL-3)Corresponding specific receptor, proteoglycanEndothelial26 Insulin-like growth factor IIGF-I ReceptorTumors, other growth tissuesAtria sodium diuretic factorANF-receptorKidney, blood vessel wallVasopressinVasopressin receptorKidney, blood vessel wallVEGFVEGF-receptorsEndothelial area, angiogenesisFibroblast growth factorFGF-receptor, proteoglycanEndothelium, angiogenesis27 Schwann cell growth factorProteoglycan Specific Receptors 28
[159] Various protein and peptide vectors
[160] Vector formTargetDescription / Use AreaRef StreptavidinkidneyKidney disease29 Bacterial Fibronectin-Binding ProteinsFibronectinVessel wall30 Fc-Parts of AntibodiesFc-receptorMonocyte-macrophage31 TransferrinTransferrin-receptorTumor vessel wall11 Streptokinase / Tissue Plasminogen ActivatorTrombyTrombyPlasminogen, plasminFibrinTromby, tumor32 Mast cell proteinasesProteoglycan 33 ElastaseProteoglycan 34 Lipoprotein LipaseProteoglycan 35 AgglutinaseProteoglycan 36 Extracellular Superoxide DismutaseProteoglycan 37 Heparin Joiner IIProteoglycan 38 Retinal survival factorProteoglycan Specific Receptors 39 Heparin-bound brain mitosisProteoglycan Specific Receptors 40 Apolipoproteins such as apolypoprotein BProteoglycan specific receptors (eg, LDL receptors) 41 Apolipoprotein ELDL Receptor Proteoglycans 42 Adhesion-promoting proteins such as furfurinProteoglycan 43 Viral coat proteins such as HIV, herpesProteoglycan 44 Complex of microbial adhesin, eg, “antigen 85” mycobacteriaFibronectin, collagen, fibrinogen, vitronectin, heparan sulfate 45 β-amyloid precursorProteoglycanΒ-amyloid Accumulation in Alzheimer's Disease46 Tenasin, for example tenasin CHeparan Sulfate, Integrin 47
[161] Vectors containing non-peptide agonists / antagonists or non-living binders of receptors for cytokinin / growth factor / peptide hormone / cell adhesion molecules
[162] Vector formTargetDescription / Use AreaRef Several agonists / antagonists are known for these factors acting through G-protein coupled receptors4849 Endothelial antagonistsEndothelial receptorsVessel wallDesmopressin (vasopressin homologue)Vasopressin receptorRenal vessel wallDemoxitoxin (oxytocin homologue)Oxytocin receptorReproductive system, mammary gland, brainAngiotensin II Receptor Antagonists C-11974, TCV-116Angiotensin II ReceptorVascular wallNonpeptide RGD-HomologsIntegreenCell walls in the immune system50
[163] Vectors containing antiangiogenic factors
[164] Vector formTargetDescription / Use AreaRef AngiostatinEC of tumorPlasminogen SegmentK Cartilage-induced inhibitorsEC of tumor J β-cyclodextrin tetradecasulfateTumor, inflammation C Pumagiline and HomologsTumor, inflammation E Interferon-αEC of tumor K Interferon-γEC of tumor E Interleukin-12EC of tumor E LinomideTumor, inflammation A MedroxyprogesteroneEC of tumor K Metalloproteinase inhibitorsEC of tumor K Pentosan polysulfateEC of tumor K Platelet factor 4EC of tumor M SomatostatinEC of tumor K SuraminEC of tumor K TexolEC of tumor K ThalidomideEC of tumor K ThrombospondinEC of tumor K
[165] Vector containing angiogenic factors
[166] Vector formTargetDescription / Use AreaRef Acid Fibroblast Growth FactorEC of tumor K AdenosineEC of tumor K AngiogeninEC of tumor K Angiotensin IIEC of tumor K Basement membrane componentstumorFor example, tenasin, collagen IVM Basic fibroblast growth factorEC of tumor K BradykininEC of tumor K Calcitonin gene-related peptideEC of tumor K Epidermal growth factorEC of tumor K Fibrintumor K Fibrinogentumor K HeparinEC of tumor K HistamineEC of tumor K Hyaluronic acid or its segmentEC of tumor K Interleukin-1αEC of tumor K Laminin, laminin segmentEC of tumor K NicotinamideEC of tumor K Platelet activatorEC of tumor K Platelet-induced endothelial growth factorEC of tumor K Prostaglandins E1, E2EC of tumor K SpermineEC of tumor K SpermineEC of tumor K Substance PEC of tumor K Transformation Growth Factor-αEC of tumor K Transformation Growth Factor-βEC of tumor K Tumor Necrosis Factor-αEC of tumor K Vascular Endothelial Growth Factor / Vascular Permeability FactorEC of tumor K Vitronectin A
[167] Vector molecules other than angiogenic factors recognized to have a known affinity for receptors involved in angiogenesis
[168] Vector formTargetDescription / Use AreaRef AngiopoietinTumor, inflammation B α ₂ -antiplasminTumor, inflammation Combinatorial libraries, compoundsTumor, inflammationFor example: compounds that bind to the basement membrane after degradationEndoglinTumor, inflammation D EndocrineTumor, inflammation D Endostatin [collagen segments]Tumor, inflammation M Factor VII-associated antigenTumor, inflammation D FibrinopeptidesTumor, inflammation ZC Fibroblast Growth Factor, BasicTumor, inflammation E Hepatosite growth factorTumor, inflammation I Insulin-like growth factorTumor, inflammation R InterleukinTumor, inflammationFor example: IL-8I Leukemia inhibitory factorTumor, inflammation A Metalloproteinase inhibitorsTumor, inflammationFor example, BatimastadE Monoclonal antibodiesTumor, inflammationFor example: for angiogenic factors or their receptors or components of a fibrinolytic systemPeptides such as cyclic RGD _D FVTumor, inflammation B, Q Placental growth factorTumor, inflammation J Placenta Proliperin-Related ProteinsTumor, inflammation E PlasminogenTumor, inflammation M Plasminogen activatorTumor, inflammation D Plasminogen Activator InhibitorTumor, inflammation U, V Platelet activator antagonistTumor, inflammationInhibitors of angiogenesisA Platelet-induced growth factorTumor, inflammation E PlayotropinTumor, inflammation ZA ProliperinTumor, inflammation E Proliperin Related ProteinsTumor, inflammation E SelectinTumor, inflammationFor example, E-selectinD SPARCTumor, inflammation M Snake venom (RGD-containing)Tumor, inflammation Q Tissue Inhibitors of MetalloproteinasesTumor, inflammationFor example, TIMP-2U ThrombinTumor, inflammation H Thrombin-receptor-active tetradecapeptideTumor, inflammation H Thymidine phosphorylaseTumor, inflammation D Tumor growth factorTumor, inflammation ZA
[169] Receptors / targets associated with angiogenesis
[170] Vector formTargetDescription / Use AreaRef BigglycanTumor, inflammationDermatan Sulfate ProteoglycanX CD34Tumor, inflammation L CD44Tumor, inflammation F Collagen Types I, IV, VI, VIIITumor, inflammation A DecorinTumor, inflammationDermatan Sulfate ProteoglycanY Dermatan Sulfate ProteoglycanTumor, inflammation X EndothelinTumor, inflammation G Endothelin receptorTumor, inflammation G Fibronectintumor P Flk-1 / KDR, Flt-4Tumor, inflammationVEGF receptorD FLT-1 (fms sheep tyrosine kinase)Tumor, inflammationVEGF-A receptorO Heparan SulfateTumor, inflammation P Hepatosite growth factor receptor (c-met)Tumor, inflammation I Insulin-like growth factor / mannose-6-phosphate receptorTumor, inflammation R Integrin: β ₃ and β ₅ , integrin α _V β ₃ , integrin α ₆ β ₁ , integrin α ₆ , integrin β ₁ , integrin α ₂ β ₁ , integrin α _V β ₃ , integrin α ₅ integrin α _V β ₅ , fibrin ReceptorTumor, inflammationSubunit of Laminin Receptor Fibronectin ReceptorD, P Intracellular adhesion molecules-1 and -2Tumor, inflammation P Serrated gene productTumor, inflammation T Ly-6Tumor, inflammationLymphocyte active proteinN Matrix metalloproteinaseTumor, inflammation D MHC Species IITumor, inflammation V-shaped gene productTumor, inflammation T Osteopontintumor Z PECAMTumor, inflammationAlias CD31P Plasminogen activator receptorTumor, inflammation ZC Platelet-induced growth factor receptorTumor, inflammation E Selectin: E-, P-Tumor, inflammation D Sialyl Lewis-XTumor, inflammationBlood group antibodiesM Stress Proteins: Glucose Regulated, Heat Shock Family and OthersTumor, inflammationMolecular ChaperoneCindecanTumor, inflammation T ThrombospondinTumor, inflammation M TIE receptorTumor, inflammationTyrosine kinases with Ig- and EGF positive domainsE Tissue factorTumor, inflammation Z
[171] Tissue Inhibitors of MetalloproteinasesTumor, inflammationFor example, TIMP-2U Transformed growth factor receptorTumor, inflammation E Urokinase type plasminogen activator receptorTumor, inflammation D Vascular Cellular Adhesion Molecule (VCAM)Tumor, inflammation D Vascular Endothelial Growth Factor-related ProteinTumor, inflammation Vascular Endothelial Growth Factor-A ReceptorTumor, inflammation K Von willebrand factor-associated antibodiesTumor, inflammation L
[172] Oligonucleotide vector
[173] Vector formTargetDescription / Use AreaRef Oligonucleotides complementary to genes for repeat sequences such as ribosomal RNA, Alu-sequences,DNA that can be produced by necrosisAll other diseases, including tumor myocardial infarction necrosis51 Oligonucleotides complementary to disease-specific mutations (eg, mutated oncogenes)DNA preparable by necrosis in areas of related diseasetumor51 Oligonucleotides Complementary to Infectious DNAInfectious DNAViral or bacterial infection51 Triple or quadruple-helix forming oligonucleotidesSame as above exampleSame as above example51 Oligonucleotides with recognition sequences for DNA- or RNA-binding proteinsDNA-binding proteins such as transcription factors (often overexpressed / activated in tumor or activated endothelial / immune cells)Tumor activated endothelial activated immune cells
[174] Modified nucleotide vector
[175] Vector formTargetDescription / Use AreaRef Phosphorothioate oligosOn unmodified oligosOn unmodified oligos51 2'-O-methyl substituted oligos〃〃51 Illusion oligos〃〃51 Oligos with hairpin structure to increase degradation〃〃51 Oligos with terminal phosphorothioate〃〃51 2'-fluoro oligos〃〃51 2'-amino oligos〃〃51 DNA-binding drugs bound to oligos (see, eg, below)〃Increased binding affinity compared to pure oligos52 Peptide nucleic acids (PNAs, oligonucleotides having a peptide backbone)〃Increased binding affinity and stability compared to standard oligos53
[176] Nucleoside and Nucleotide Vectors
[177] Vector formTargetDescription / Use AreaRef Adenosine or homologueAdenosine receptorsVascular wall heart54 ADP, UDP, UTP and moreVarious nucleotide receptorsMany tissues, such as the brain, spinal cord, kidneys, spleen55
[178] Receptors Including DNA-binding Drugs
[179] Vector formTargetDescription / Use AreaRef Acridine derivatives distamycin netroplopsin actinomycin D echinomycin bleomycinDNA prepared by necrosisAll other diseases related to tumors, myocardial infarction and necrosis or other methods of releasing DNA from cells
[180] Receptor containing protease substrate
[181] Vector formTargetDescription / Use AreaRef Peptide or Nonpeptidic SubstrateCathepsin BTumors, various types, for example, various variants capable of somewhat overexpressing the protease of cathepsin B10
[182] Receptors Including Protease Inhibitors
[183] Vector formTargetDescription / Use AreaRef Peptide or non-peptidic inhibitors such as N-acetyl-Leu-Leu-norrousinCathepsin BTumors, various types, for example, various variants capable of somewhat overexpressing the protease of cathepsin B10 Bestin ([(2S, 3R) -3-amino-2-hydroxy-4-phenyl-butanoyl] -L-leucine hydrochloride)AminopeptidaseTumors, for example on the cell surfacePepablock (4- (2-aminoethyl) -benzenesulfonyl fluoride hydrochloride)Serine ProteaseTumor, vascular wall, etc.Commercially available inhibitors, such as captopril enalapril ricinooprilAngiotensin converting enzymeEndothelial cellsLow Specific Nonpeptidic CompoundsCoagulation factorVascular wall injury, tumor, etc.Protease Nexin (Extracellular Protease Inhibitor)Proteoglycan 56 AntithrombinProteoglycan, aggregation factor 57
[184] Vector from Combination Library
[185] Vector formTargetDescription / Use AreaRef Antibodies with Structures Determined During DevelopmentMay be unaware in preparing the functional selection of any of the aforementioned targets-or vectors that bind to selected diseased structuresAny diseased or normal structure of interest, for example, the walls of tromby, tumor or myocardial vessels58,59,60 Peptides with Sequences Determined During Development〃〃58,59,60 Oligonucleotides with Sequences Determined During Development〃〃58, 59,60 Variations of the Oligos Above〃〃58,59,60 Other compounds with structures determined during development〃〃58,59,60
[186] Carbohydrate vector
[187] Vector formTargetDescription / Use AreaRef Neo-GlycoproteinMacrophageGeneral Activation / InflammationOligosaccharides With Terminal GalactoseAsialo-glycoprotein receptorliver61 HyaluronanAggrecan (proteoglycan) "link protein" cell-surface receptor: CD44 62 Mannose Blood brain barrier, brain tumors and other diseases causing changes in BBB63 Bacterial glycopeptides 〃64
[188] Geological vector
[189] Vector formTargetDescription / Use AreaRef GM1 gangliosideCholera bacteria in the gastrointestinal tractDiagnosis / Treatment of CholeraPlatelet activator (PAF) antagonistPAF receptorDiagnosis of inflammationProstaglandin antagonists of inflammationProstograndine receptorDiagnosis of inflammationInflammation Thromboxane AntagonistLeukotrienes receptorDiagnosis of inflammation
[190] Small molecule vector
[191] Vector formTargetDescription / Use AreaRef AdrenalineCorresponding receptor Beta blockerAdrenergic beta-receptorsMyocardial Layer for Beta-1 BlockersAlpha-BlockerAdrenergic alpha-receptorsVessel wallBenzodiazepines Serotonin-HomologSerotonin-receptor Anti-histamineHistamine-receptorsVessel wallAcetyl-choline Receptor AntagonistACh-receptor VerapamilCa ²⁺ -Channel BlockerHeart muscleNifedipineCa ²⁺ -Channel BlockerHeart muscleAmylorideNa ⁺ / H ⁺ -exchangerIt blocks this exchange in the kidney and is generally upregulated in cells stimulated by growth factors.Digitalis GlycosideNa ⁺ / K ⁺ -ATP-asesMyocardial terminal vascular system, central nervous systemThromboses / prostaglandin receptor antagonists or agonistsThromboxane / prostaglandin receptorVascular wall, endothelialGlutathioneGlutathione-receptorrucotriene-receptorLungs, brainBiotinBiotin Transport Protein on Cell Surface 65 FolateFolate Transport Protein on Cell Surfacetumor66 RiboflavinRiboflavin Transport Protein on Cell Surface 67
[192] references
[193]
[194]
[195]
[196]
[197]
[198]
[199] The following non-limiting examples illustrate the invention. As described in WO-A-9607434, confirmation of microparticle properties of the product was carried out using a microscope. Ultrasonic delivery measurements can be performed using a wideband transducer to represent a microbubble suspension exhibiting increased sound beam attenuation compared to the standard. Flow cytometry of the product can be used to confirm the attachment of macromolecules to the product. Specific to cells expressing the target using microscopy and / or flow chambers containing immobilized cells, for example by using cell colonies expressing the target construct and additional cell colonies not expressing the target. The ability of the targeted microbubble to bind can be studied in vitro. Radioactive, fluorescent or enzyme-labeled streptavidin / avidin can be used to analyze biotin adhesion.
[200] Example 1 Attachment of Poly-L-Lysine-Coated Phosphatidylserine-Encapsulated Microbubbles to Endothelial Cells
[201] Poly-L-lysine (8 mg) with a molecular weight of 115 kDa was dissolved in water (400 μl). Freshly redispersed microbubbles (40 μl) of phosphatidylserine-encapsulated perfluorobutane were incubated in water (400 μl) or poly-L-lysine solution for 15 minutes at room temperature. Zeta potential measurements confirmed that the uncoated bubbles were negatively charged while the poly-L-lysine-coated microbubbles were positively charged. Cell attachment studies using human endothelial cells grown in culture dishes were performed with the microbubbles described above and uncoated microbubbles were used as controls. Microscopes of endothelial cells after culture show a significantly increased number of poly-L-lysine-coated microbubbles attached to endothelial cells as compared to uncoated microbubbles.
[202] Example 2 Gas Filled Microbubbles Including Phosphatidylserine and RGDC-Mal-PEG _3400- DSPE
[203] a) Synthesis of Boc-NH-PEG _3400- DSPE (t-butyl carbamate poly (ethylene glycol) distearoylphosphatidyl-ethanolamine)
[204] DSPE (Distearoylphosphatidylethanolamine) (31 mg, Segena Inc.) was added to Boc-NH-PEG ₃₄₀₀ -SC (t-butyl carbamate poly (ethylene glycol)-in chloroform (2 ml). To a solution of succinimidyl carbonate) (150 mg) and triethylamine (33 μl) was added. The mixture was stirred at 41 ° C. for 10 minutes to form a clear solution. The solvent was rotary evaporated and the residue was dissolved in acetonitrile (5 ml). The dispersion thus obtained was cooled to 4 ° C. and centrifuged before the solution was separated from undissolved material and evaporated to dryness. The structure of the obtained product was confirmed by NMR.
[205] b) Synthesis of H ₂ N-PEG ₃₄₀₀ -DSPE (amino-poly (ethylene glycol) -distearoylphosphatidylethanolamine)
[206] Boc-NH-PEG ₃₄₀₀ -DSPE (167 mg) was stirred in 4 M hydrochloric acid in dioxane (5 ml) for 2.5 hours at room temperature. The solvent was removed by rotary evaporation and the residue was dissolved in chloroform (1.5 ml) and washed with water (2 x 1.5 ml). The organic phase was removed by rotary evaporation. TLC (chloroform / methanol / water 13: 5: 0.8) gave the title product with Rf = 0.6; The structure of the ninhydrin positive product was confirmed by NMR.
[207] c) Synthesis of Mal-PEG _3400- DSPE (3-maleimidopropionate-poly (ethylene glycol) distearoylphosphatidylethanolamine)
[208] A solution of N-succinimidyl-3-maleimidopropionate (5.6 mg, 0.018 mmol) in tetrahydrofuran (0.2 ml) was added to tetrahydrofuran (1 ml) and 0.1 M sodium phosphate buffer pH 7.5 (2 ml). Was added to H ₂ N-PEG ₃₄₀₀ -DSPE (65 mg, 0.012 mmol) dissolved in. The reaction mixture was heated to 30 ° C., the reaction was completed by TLC and the solvent was evaporated.
[209] d) Synthesis of RGDC-Mal-PEG ₃₄₀₀ -DSPE
[210] Mal-PEG _3400- DSPE (0.010 mmol) in 0.1 M sodium phosphate buffer with pH 7.5 was added to the peptide RGDC (0.010 mmol). The reaction mixture was heated to 37 ° C. if necessary and the reaction was completed by TLC, then the solvent was removed.
[211] e) Preparation of gas-filled microbubbles encapsulated by phosphatidylserine and RGDC-Mal-PEG _3400- DSPE
[212] A mixture of phosphatidylserine (90-99.9 mol%) and Mal-PEG ₃₄₀₀ -DSPE (10-0.1 mol%) was added to 5% propylene glycol-glycerol in water (1 ml). This dispersion was heated to 80 ° C. or less for 5 minutes and then cooled to ambient temperature. This dispersion (0.8 ml) was then transferred to a vial (1 ml) and the top space was flushed with perfluorobutane. After the vial was shaken for 45 seconds in the cap-mixer, the sample was placed on a roller table. After centrifugation the bottom layer was exchanged with 0.1 M sodium phosphate buffer with pH 7.5. Peptide RGDC dissolved in 0.1 M sodium phosphate buffer with pH 7.5 was placed in a washed microbubble placed on a roller table. The washing process was then repeated.
[213] f) Preparation of gas-filled microbubbles encapsulated by phosphatidylserine and RGDC-Mal-PEG _3400- DSPE
[214] To phosphatidylserine (5 mg) was added 5% propylene glycol-glycerol in water (1 ml). This dispersion was heated to 80 ° C. or less for 5 minutes and then cooled to ambient temperature. This dispersion (0.8 ml) was transferred to a vial (1 ml) and the top space was flushed with perfluorobutane. After the vial was shaken for 45 seconds in the cap-mixer, the sample was placed on a roller table. After centrifugation the bottom layer was exchanged with 0.1 M sodium phosphate buffer with pH 7.5. RGDC-Mal-PEG _3400- DSPE dissolved in 0.1 M sodium phosphate buffer with pH 7.5 was placed in a washed microbubble and then placed on a roller table. The washing process was repeated to mix RGDC-Mal-PEG ₃₄₀₀ -DSPE into the microbubble membrane.
[215] Example 3 Gas-filled Microbubbles Encapsulated with Phosphatidylserine, Phosphatidylcholine and Biotinamidocaproate-PEG _3400- Ala-Cholesterol
[216] a) Synthesis of Z-Ala-cholesterol (3-O- (carbenzyloxy-L-alanyl) cholesterol)
[217] Cholesterol (4 mmol), Z-alanine (5 mmol) and dimethylaminopyridine (4 mmol) were dissolved in dimethylformamide / tetrahydrofuran (20 ml + 5 ml) and dicyclohexylcarbodiimide was added. The reaction mixture was stirred at ambient temperature overnight. Dicyclohexylurea was filtered and the solvent was rotary evaporated. The residue was dissolved in chloroform, undissolved dicyclohexylurea was filtered and the solvent was rotary evaporated. The residue was placed on a silica gel column and the Z-Ala-cholesterol was eluted with toluene / petroleum ether (20: 2) followed by toluene / diethyl ether (20: 2). Fractions containing the title compound were combined and the solvent was removed by rotary evaporation. The structure of the product was confirmed by NMR.
[218] b) Synthesis of Ala-cholesterol (3-O- (L-alanyl) -cholesterol)
[219] Z-Ala-cholesterol (0.48 mmol) was placed in tetrahydrofuran (20 ml) and glacial acetic acid (3 ml) and hydrogenated for 2 hours in the presence of palladium on 5% carbon. The reaction mixture was filtered and concentrated in vacuo.
[220] c) Synthesis of Boc-NH-PEG ₃₄₀₀ -Ala-cholesterol
[221] Ala-cholesterol was added to a solution of Boc-NH-PEG ₃₄₀₀ -SC (t-butyl carbamate poly (ethylene glycol) -succinimidyl carbonate) in chloroform followed by triethylamine. The suspension was stirred at 41 ° C for 10 minutes. The crude product was purified by chromatography.
[222] d) Synthesis of H ₂ N-PEG ₃₄₀₀ -Ala-cholesterol
[223] Boc-NH-PEG _3400- Ala-cholesterol was stirred in 4 M hydrochloric acid in dioxane at ambient temperature for 2.5 hours. The solvent was removed by rotary evaporation and the residue was dissolved in chloroform and washed with water. The organic phase was dried by rotary evaporation. The crude product was purified by chromatography.
[224] e) Synthesis of Biotinamidocaproate-PEG _3400- Ala-Cholesterol
[225] A solution of biotinamidocaproate N-hydroxysuccinimide ester in tetrahydrofuran was dissolved in H ₂ N-PEG ₃₄₀₀ -Ala-cholesterol dissolved in tetrahydrofuran and 0.1 M sodium phosphate buffer (2 ml) at pH 7.5. Added. The reaction mixture was heated to 30 ° C, the reaction was completed by TLC and the solvent was evaporated.
[226] f) Process for preparing gas-filled microbubbles encapsulated with phosphatidylserine, phosphatidylcholine and biotinamidocaproate-PEG _3400- Ala-cholesterol
[227] To a mixture of phosphatidylserine and phosphatidylcholine (total 90-99.9 mol%) and biotinamidocaproate-PEG _3400- Ala-cholesterol (10-0.1 mol%) (5 ml), 5% propylene glycol-glycerol (1 ml) ) Was added. This dispersion was heated to 80 ° C. or less for 5 minutes and cooled to ambient temperature. This dispersion (0.8 ml) was then transferred to a vial (1 ml) and the top space was flushed with perfluorobutane. This vial was shaken for 45 seconds in a cap-mixer and the sample was placed on a roller table. After centrifugation, the lower layer was exchanged with water and washing was repeated.
[228] g) Other methods of preparing gas-filled microbubbles encapsulated with phosphatidylserine, phosphatidylcholine and biotinamidocaproate-PEG _3400- Ala-cholesterol
[229] To a mixture of phosphatidylserine and phosphatidylcholine (5 ml) was added 5% propylene glycol-glycerol (1 ml) in water. This dispersion was heated to 80 ° C. or less for 5 minutes and cooled to ambient temperature. This dispersion (0.8 ml) was then transferred to a vial (1 ml) and the top space was flushed with perfluorobutane. This vial was shaken for 45 seconds in a cap-mixer and the sample was placed on a roller table. After centrifugation, the lower layer was exchanged with water. Biotinamidocaproate-PEG _3400- Ala-cholesterol dissolved in water was added to the washed microbubbles and placed on a roller table for several hours. The washing process was repeated to add Biotinamidocaproate-PEG _3400- Ala-cholesterol to the microbubble membrane.
[230] Example 4 Gas-Filled Microbubbles Encapsulated with Phosphatidylserine, Phosphatidylcholine and Biotinamidocaproate-PEG _3400- Ala-Cholesterol and Drug-Cholesterol
[231] a) synthesis of drug-cholesterol
[232] Cholesterol (4 mmol), drug with acid groups and dimethylaminopyridine (4 mmol) were dissolved in dimethylformamide / tetrahydrofuran (20 ml + 5 ml) and dicyclohexylcarbodiimide was added. The reaction mixture was stirred at ambient temperature overnight. Dicyclohexylurea was filtered and the solvent was rotary evaporated. The title compound was purified by chromatography.
[233] b) Process for preparing gas filled microbubbles encapsulated with phosphatidylserine, phosphatidylcholine and biotinamidocaproate-PEG _3400- Ala-cholesterol and drug-cholesterol
[234] A mixture of phosphatidylserine, phosphatidylcholine (total 90-99.9 mol%), biotinamidocaproate-PEG _3400- Ala-cholesterol (prepared in Example 3) and drug-cholesterol (total 10-0.1 mol%) (5 ml) To 5% propylene glycol-glycerol (1 ml) in water was added. This dispersion was heated to 80 ° C. or less for 5 minutes and cooled to ambient temperature. This dispersion (0.8 ml) was then transferred to a vial (1 ml) and the top space was flushed with perfluorobutane. This vial was shaken for 45 seconds in a cap-mixer and the sample was placed on a roller table. After centrifugation, the lower layer was exchanged with water and washing was repeated.
[235] Example 5 Gas Filled Microbubbles Encapsulated with Phosphatidylserine and Thiolated-Anti-CD34-Mal-PEG _3400- DSPE
[236] a) preparation of an anti-CD34 antibody
[237] Thiolation of anti-CD34 antibodies is described by Hansen, C.B. et al. (1995) Biochem. Biophys. Acta 1239, 133-144.
[238] b) Process for preparing gas filled microbubbles encapsulated with phosphatidylserine and thiolated-anti-CD34-Mal-PEG _3400- DSPE
[239] To a mixture (5 ml) of phosphatidylserine, phosphatidylcholine (90-99.9 mol%) and Mal-PEG _3400- DSPE (10-0.1 mol%, prepared as in Example 2), 5% propylene glycol-glycerol (1 ml) was added. This dispersion was heated to 80 ° C. or less for 5 minutes and cooled to ambient temperature. This dispersion (0.8 ml) was then transferred to a vial (1 ml) and the top space was flushed with perfluorobutane. This vial was shaken for 45 seconds in a cap-mixer and the sample was placed on a roller table. After centrifugation, the lower layer is exchanged with a suitable buffer and the coupling of thiolated antibodies to microbubbles is described, for example, in Goundalkar, A., Ghose, T. and Mezei, M. in J. Pharm. Pharmacol. (1984) 36 465-66 or Hansen, CB et al. (1995) Biochem. Biophys. Acta 1239 133-144. This microbubble was then placed on a roller table for several hours and washed. Flow cytometry analysis of the resulting microbubbles (using fluorescently labeled secondary antibody) was used to confirm the attachment of the anti-CD34 antibody to the bubbles. The stability of the bubble specifically binding to CD34-expressing cells was studied microscopically using one CD34 expressing cell colony and a colony unless it expresses CD34.
[240] Example 6 Biotin Attached to a Gas-Filled Microbubble
[241] Biotin is prepared in many different ways, for example, in Corley, P. and Loughrey, H.C. in (1994) Biochim. Biophys. Acta 1195, 149-156 may be attached to the microbubble in a manner similar to that described. The resulting bubbles are analyzed by flow cytometry, for example using fluorescent streptavidin to detect the attachment of biotin to the bubbles. Alternatively, radioactive or enzyme-labeled streptavidin / avidin is used for biotin attachment assay.
[242] Example 7 Gas Filled Microbubbles Encapsulated with Distearoylphosphatidylserine and Biotin-DPPE
[243] To distearoylphosphatidylserine (DSPS) (22.6 mg) was added 4% propylene glycol-glycerol (4 ml) in water. This dispersion was heated to 80 ° C. or less for 5 minutes and cooled to ambient temperature. An aqueous dispersion of biotin-DPPE (1.5 mg) in 4% propylene glycol-glycerol (1 ml) was added and the sample was placed on a roller table for 1-2 hours. This suspension was filled into vials and the top space was flushed with perfluorobutane. The vial was shaken for 45 seconds before the sample was placed on a roller table. After centrifugation for 7 minutes, the lower layer was exchanged with water and washing was repeated twice. Normal HPLC equipped with an evaporative light scattering detector confirmed that the microbubbles contained 4 mol% biotin-DPPE. The average particle diameter of the microbubbles was 4 μm, measured with a Coulter counter. Ultrasonic transmission measurements using a 3.5 MHz wideband converter showed that particle dispersions below 2 mg / ml produced acoustic beams higher than 5 dB / cm.
[244] Example 8 Gas Filled Microbubbles Encapsulated with Biotinylated Antibody Covalently Bonded to Phosphatidylserine and Streptavidin-Succ-PEG-DSPE
[245] a) Synthesis of Succ-PEG ₃₄₀₀ -DSPE
[246] NH ₂ -PEG ₃₄₀₀ -DSPE (prepared as in Example 2) was prepared using succinic anhydride in a similar manner as described in Nayer, R. and Schroit, AJ in Biochemistry (1985) 24, 5967-71. Compounded.
[247] b) Process for preparing gas filled microbubbles encapsulated with phosphatidylserine and Succ-PEG _3400- DSPE
[248] To a mixture (5 ml) of phosphatidylserine (90-99.9 mol%) and Succ-PEG _3400- DSPE (10-0.1 mol%) was added 5% propylene glycol-glycerol (1 ml) in water. This dispersion was heated to 80 ° C. or less for 5 minutes and cooled to ambient temperature. This dispersion (0.8 ml) was then transferred to a vial (1 ml) and the top space was flushed with perfluorobutane. This vial was shaken for 45 seconds in a cap-mixer and the sample was placed on a roller table. After centrifugation, the lower layer was exchanged with water and washing was repeated. Alternatively, the microbubbles can be prepared as described in Example 2 (f).
[249] c) Coupling of streptavidin to gas filled microbubbles encapsulated with phosphatidylserine and Succ-PEG _3400- DSPE
[250] Streptavidin was covalently bound to Succ-PEG ₃₄₀₀ -DSPE in a microbubble membrane using standard water soluble carbodiimides. This sample was placed on a roller table during the reaction. After centrifugation, the lower layer was exchanged with water and washing was repeated. The functionality of the attached streptavidin was analyzed by binding to fluorescently labeled biotin, biotinylated antibody (detected with fluorescently labeled secondary antibody) or biotinylated and fluorescent- or radio-labeled oligonucleotides. Analysis was performed by fluorescence microscopy or scintillation counting.
[251] d) Method for preparing gas-filled microbubbles encapsulated with biotin non-covalently bound to phosphatidylserine and streptavidin-Succ-PEG _3400- DSPE
[252] Microbubbles from Example 8 (c) were incubated in a solution containing a biotinylated vector, such as a biotinylated antibody. Vector-coated microbubbles were washed as described above.
[253] Example 9 Gas Filled Microbubbles Encapsulated with Biotinylated Oligonucleotides Noncovalently Bonded to Phosphatidylserine and Streptavidin-Succ-PEG-DSPE
[254] a) Synthesis of Succ-PEG ₃₄₀₀ -DSPE
[255] NH ₂ -PEG ₃₄₀₀ -DSPE (prepared as in Example 2) was prepared using succinic anhydride in a similar manner as described in Nayer, R. and Schroit, AJ in Biochemistry (1985) 24, 5967-71. Compounded.
[256] b) Process for preparing gas filled microbubbles encapsulated with phosphatidylserine and Succ-PEG _3400- DSPE
[257] To a mixture (5 ml) of phosphatidylserine (90-99.9 mol%) and Succ-PEG _3400- DSPE (10-0.1 mol%) was added 5% propylene glycol-glycerol (1 ml) in water. This dispersion was heated to 80 ° C. or less for 5 minutes and cooled to ambient temperature. This dispersion (0.8 ml) was then transferred to a vial (1 ml) and the top space was flushed with perfluorobutane. This vial was shaken for 45 seconds in a cap-mixer and the sample was placed on a roller table. After centrifugation, the lower layer was exchanged with water and washing was repeated. Alternatively, the microbubbles can be prepared as described in Example 2 (f).
[258] c) Coupling of streptavidin to gas filled microbubbles encapsulated with phosphatidylserine and Succ-PEG _3400- DSPE
[259] Streptavidin was covalently bound to Succ-PEG ₃₄₀₀ -DSPE in a microbubble membrane using standard water soluble carbodiimides. This sample was placed on a roller table during the reaction. After centrifugation, the lower layer was exchanged with water and washing was repeated. The functionality of the attached streptavidin was analyzed by binding to fluorescently labeled biotin, biotinylated antibody (detected with fluorescently labeled secondary antibody) or biotinylated and fluorescent- or radio-labeled oligonucleotides. Analysis was performed by fluorescence microscopy or scintillation counting.
[260] d) Process for preparing gas-filled microbubbles encapsulated with biotinylated oligonucleotides non-covalently bound to phosphatidylserine and streptavidin-Succ-PEG _3400- DSPE
[261] Microbubbles from Example 9 (c) were incubated in a solution containing biotinylated oligonucleotides. Oligonucleotide-coated microbubbles were washed as described above. Binding of oligonucleotides to bubbles was detected using fluorescently-labeled oligonucleotides to attach to the bubbles or by hybridizing oligonucleotides attached to labeled (fluorescent or radioactive) complementary oligonucleotides. The functionality of the oligonucleotide-containing microbubbles was analyzed, for example, by hybridizing bubbles to immobilized DNA-containing sequences complementary to the attached oligonucleotides. By way of example, oligonucleotides complementary to ribosomal DNA (which has many copies per haploid genome) and oligonucleotides complementary to (eg, one copy of ras) tumor gene (eg, one haploid genome) can be used.
[262] Example 10 Gas Filled Microbubbles Encapsulated with Phosphatidylserine and Folate-PEG-DSPE
[263] a) preparation of folate-PEG-Succ-DSPE
[264] Folate-PEG-Succ-DSPE is described by Lee, R.J. and Low, P.S. in (1995) Biochimica. Biophysica. Acta 1233, 134-144.
[265] b) Process for preparing gas filled microbubbles encapsulated with phosphatidylserine and folate-PEG-Succ-DSPE
[266] To a mixture (5 ml) of phosphatidylserine (90-99.9 mol%) and folate-PEG-Succ-DSPE (10-0.1 mol%) was added 5% propylene glycol-glycerol (1 ml) in water. This dispersion was heated to 80 ° C. or less for 5 minutes and cooled to ambient temperature. This dispersion (0.8 ml) was then transferred to a vial (1 ml) and the top space was flushed with perfluorobutane. This vial was shaken for 45 seconds in a cap-mixer and the sample was placed on a roller table. After centrifugation, the lower layer was exchanged with water and washing was repeated. Alternatively, microbubbles were prepared as described in Example 2 (e) or 2 (f). Analysis of folate attachment was performed, for example, by microscopic studies of binding of folate-containing microbubbles to cells expressing different levels of the polyether receptor.
[267] Example 11 Phosphatidylserine and Thiolation-Anti-CD34-Mal-PEG _3400- DSPE, Thiolation-Anti-ICAM-1-Mal-PEG _3400- DSPE and Thiolation-Anti-E-Selectin-Mal-PEG Gas-filled microbubbles encapsulated in ₃₄₀₀ -DSPE
[268] a) Method for preparing thiolated-anti-CD34 antibody
[269] Thiolation of anti-CD34 antibodies is described by Hansen, C.B. et al. in (1995) Biochim. Biophys. Acta 1239, 133-144.
[270] b) methods of preparing thiolated-anti-ICAM-1 antibodies
[271] Thiolation of anti-ICAM-1 antibodies is described by Hansen, C.B. et al. in (1995) Biochim. Biophys. Acta 1239, 133-144.
[272] c) methods of preparing thiolated-anti-E-selectin antibodies
[273] Thiolation of anti-E-selectin antibodies is described by Hansen, C.B. et al. in (1995) Biochim. Biophys. Acta 1239, 133-144.
[274] d) phosphatidylserine and thiolated-anti-CD34-Mal-PEG _3400- DSPE, thiolated-anti-ICAM-1-Mal-PEG ₃₄₀₀ -DSPE, thiolated-anti-E-selectin-Mal-PEG ₃₄₀₀ -DSPE Of gas-filled microbubbles encapsulated with
[275] To a mixture (5 ml) of phosphatidylserine (90-99.9 mol%) and Mal-PEG _3400- DSPE (10-0.1 mol%, prepared as in Example 2) 5% propylene glycol-glycerol (1 ml) in water Was added. This dispersion was heated to 80 ° C. or less for 5 minutes and cooled to ambient temperature. This dispersion (0.8 ml) was transferred to a vial (1 ml) and the top space was flushed with perfluorobutane. This vial was shaken for 45 seconds in a cap-mixer and the sample was placed on a roller table. After centrifugation, the lower layer was exchanged with a suitable buffer and the coupling of antibodies from Examples 11 (a), 11 (b) and 11 (c) to microbubbles is described by Goundalkar, A., Ghose, T. and Mezei, M. in J. Pharm. Pharmacol. (1984) 36, 465-466 or Hansen, CB et al. in (1995) Biochim. Biophys. Acta 1239, 133-144. This microbubble was left on the roller table for several hours and washed.
[276] Example 12 Peptide FNFRLKAGOKIRFGAAAWEPPRARI Attached to Gas-Filled Microbubbles Encapsulated with Phosphhatyl Serine
[277] Peptide FNFRLKAGQKIRFGAAAWEPPRARI comprising phosphatidylserine-binding and heparin-binding sections was synthesized. This peptide was added to the phosphatidylserine-encapsulated perfluorobutane microbubbles performed and mixed thoroughly.
[278] Example 13 Fibronectin Covalently Bonded to Gas-Filled Microbubbles Encapsulated with Phosphatidylserine and Phosphatidylethanolamine
[279] a) microbubble manufacturing method
[280] DSPS (25 mg) and DSPE (5.0 mg) were weighed in clean vials and 5 ml of 1.4% propylene / glycol / 2.4% glycerol solution was added. The mixture was warmed to 80 ° C. for 5 minutes. The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. This vial was shaken for 45 seconds in a cap-mixer and the microbubbles were washed twice with distilled water and then resuspended in 0.1 M sodium borate buffer (pH 9).
[281] b) modification of fibronectin
[282] Fibronectin (1.0 mg) in 5 ml of 0.01 M Hepes buffer (pH 8) was added to 0.1 mmol crosslinker SDBP. The mixture was incubated for 2 hours on ice.
[283] c) microbubble deformation
[284] The microbubble suspension from (a) was added to the protein solution from (b) and incubation was performed on a roller table for 2 hours at room temperature. The untreated material was removed by floating the microbubbles and replaced with 0.1 M sodium borate buffer (pH 9). This process was repeated three times.
[285] d) in vitro analysis
[286] Microbubbles were subjected to the in vitro assay described in Example 21. Gradual accumulation of microbubble binding to cells was observed.
[287] Example 14 Gas-filled Microbubbles Encapsulated with Phosphatidylserine and 3β- [N- (N ', N'-dimethylaminoethane) carbamoyl] Cholesterol
[288] a) 3β- [N- (N ', N'-dimethylaminoethane) carbamoyl] cholesterol (DC-chol) (Farhood, H., Gao, X, Barsoum, J. and Huang, L., Anal. Biochem. 225, 89-93 (1995))
[289] Cholesteryl in 1,4-dioxane in a stirred solution of 2-dimethylaminoethylamine (19.40 mg, 24: 1, 0.22 mmol) and triethylamine (310 μL, 2.23 mmol) in dichloromethane (3 ml) Chloroformate (100 mg, 0.22 mmol) solution was added slowly at room temperature. After completion of the reaction the mixture was evaporated to dryness and the residue was purified by flash chromatography (CHCl ₃ / MeOH, 4: 1). A white solid was obtained in an amount of 105 mg (95%). The structure was confirmed by NMR and MALDI.
[290] b) preparation of microbubble dispersion
[291] A single layer-encapsulated microbubble containing perfluorobutane was weighed into 2 ml vials of DSPS (4.5 mg) and (DC-chol) (0.5 mg) in a mixture of 90% phosphatidylserine and 10% (DC-chol). Prepared from. 0.8 ml of propylene glycol / glycerol (4%) in water was added. The solution was heated at 80 ° C. for 5 minutes and shaken. The solution was then cooled to ambient temperature and the upper space was flushed with perfluorobutane. This vial was shaken in a cap-mixer at 4450 vibrations / min for 45 seconds and then placed on a roller table. The sample was washed by centrifugation at 2000 rpm for 5 minutes. The lower layer was removed with a syringe and distilled water was added in the same volume. The headspace was flushed back with perfluorobutane and the sample was placed on a roller table until a homogeneous appearance was obtained. The washing process was repeated again.
[292] Example 15 Gas-filled Microbubbles Encapsulated with Phosphatidylserine and WEPPRARI-PE
[293] Phosphatidylethanolamine (PE) was reacted with an equimolar amount of crosslinker N-hydroxysuccinimidyl-2,3-dibromopropionate in a 1: 1 mixture of dioxane and 0.02 M HEPES buffer (pH 8.0). Incubate on ice for 2 hours, add equimolar amount of heparin-binding peptide WEPPRARI and add 0.2 M disodium tetraborate to pH 9 and continue incubation for 2 hours at room temperature. This reaction product was purified by chromatography. Perfluorobutane containing monolayer-encapsulated microbubbles were prepared from a mixture of 80-95% phosphatidylserine (PS) and 5-20% peptide-substituted PE.
[294] Example 16 Gas Filled Microbubbles Encapsulated with Phosphatidylserine and Inactivated Human Thrombin-Succ-PEG _3400- DSPE
[295] a) inactivation of human thrombin
[296] Human thrombin was incubated for 30 min at 37 ° C. with 20% molar excess of D-Phe-L-Pro-L-Arg-chloromethyl ketone in 0.05 M HEPES buffer, pH 8.0.
[297] b) Process for preparing gas filled microbubbles encapsulated with phosphatidylserine and Succ-PEG _3400- DSPE
[298] To a mixture (5 mg) of phosphatidylserine (90-99.9 mol%) and Succ-PEG _3400- DSPE (10-0.1 mol%, prepared as in Example 9 (a)), 5% propylene glycol-glycerol in water ( 1 ml) was added. This dispersion was heated to 80 ° C. or less for 5 minutes and cooled to ambient temperature. This dispersion (0.8 ml) was transferred to a vial (1 ml) and the top space was flushed with perfluorobutane. This vial was shaken for 45 seconds in a cap-mixer and the sample was placed on a roller table. After centrifugation, the lower layer was exchanged with water and washing was repeated. Alternatively, the microbubbles can be prepared as described in Example 2 (f).
[299] c) Process for preparing gas filled microbubbles encapsulated with phosphatidylserine and inactivated human thrombin-Succ-PEG _3400- DSPE
[300] Inactivated human thrombin was covalently bound to Succ-PEG ₃₄₀₀ -DSPE in the microbubbles from Example 16 (b) by standard coupling method using water soluble carbodiimide. This sample was placed on a roller table during the reaction. After centrifugation, the lower layer was exchanged with water and washing was repeated.
[301] Example 17 Gas Filled Microbubbles with Methotrexate and Attached Prodrug-Activating Enzymes
[302] a) methotrexate attached via a peptide linker to a gas-filled microbubble
[303] Methods for attaching amino acids to anti-drug drug methotrexate (MTX) are well described in, for example, Huennekens, F.M. (1994), TIBTECH 12, 234-239 and references therein. Instead of a single amino acid, peptides can be attached to MTX using the same technique. Such peptides may constitute a linker for attachment of MTX to the surface of the microbubbles. One class of such linkers includes peptides of general structure (MTX) -F-K / R-X-R-Z-C, where X is any amino acid and Z is a hydrophobic amino acid. Particular examples of such linkers are (MTX) -F-K-L-R-L-C. The SH-group in the Cys-residue is used for attachment of the MTX-peptide to the microbubbles (for example consisting of phosphatidylserine and Mal-PEG-DSPE) using standard techniques as in Example 2, for example. Linkers of this kind are often believed to be cleaved by the enzyme cathepsin B, which is selectively overexpressed on the surface of external and tumor cells (Panchal, RG et al. (1996), Nat. Biotechnol. 14, 852-856). . Thus, possible prodrugs (MTX) -F-K / R-X-R may be selectively released in tumors. This prodrug may be further activated in the active drug MTX by the action of carboxypeptidase or endogenously present in the tumor or in a tumor targeted by, for example, a tumor-associated antibody (see below).
[304] b) prodrug-active enzyme covalently attached to the surface of the gas-filled microbubbles
[305] One example of a prodrug-active enzyme is the use of a microbubble encapsulated by a mixture of phosphatidylserine and phosphatidylethanolamine using, for example, an N-hydroxysuccinimide group containing a 3400 Da poly (ethylene glycol) chain at both ends. Carboxypeptidase A (CPA) capable of binding to the surface (Perron, MJ and Page, M., Br. J. Cancer 73, 281-287); This microbubble containing CPA can be targeted to a pathological region by mixing a suitable target vector in a CPA-containing bubble. Alternatively, CPA can be attached directly to a vector (eg, an antibody), for example, by the methods described above. In the latter case CPA-vector conjugates are described in Hansen, C.B. et al. (1995) Biochim. Biophys. Acta 1239 133-144 is attached to the microbubble surface. Examples of many possible prodrug-enzyme pairs are described in Huennekens, F.M. (1994) TIBTECH 12, 234-239.
[306] Example 18 With phosphatidylserine, thiolated-anti-CEA-Mal-PEG _3400- DSPE and anticancer prodrug 3 ', 5'-O-difamitoyl-5-fluoro-2'-deoxyuridine Encapsulated Gas Filled Microbubbles
[307] a) Method for preparing thiolated anti-CEA antibody
[308] Thiolation of anti-CEA antibodies is described by Hansen, C.B. et al. in (1995) Biochim. Biophys. Acta 1239, 133-144.
[309] b) Gas encapsulated with phosphatidylserine, thiolated-anti-CEA-Mal-PEG _3400- DSPE and anticancer prodrug 3 ', 5'-O-difamitoyl-5-fluoro-2'-deoxyuridine Method of making filled microbubbles
[310] Phosphatidylserine (90-99.9 mole%) and Mal-PEG ₃₄₀₀ -DSPE (10-0.1 mole%, prepared as in Example 2) and anticancer prodrug 3 ', 5'-O-difamitoyl-5-fluor To a mixture (5 mg) of rho-2'-deoxyuridine (Mori, A. et al. (1995) Cancer Chemother. Pharmacol. 35, 447-456) 5% propylene glycol-glycerol in water (1 ml) Was added. This dispersion was heated to 80 ° C. or less for 5 minutes and cooled to ambient temperature. This dispersion (0.8 ml) was transferred to a vial (1 ml) and the top space was flushed with perfluorobutane. This vial was shaken for 45 seconds in a cap-mixer and the sample was placed on a roller table. After centrifugation, the lower layer was exchanged with a suitable buffer and coupling of the antibody to the microbubbles is described by Goundalkar, A., Ghose, T. and Mezei, M. in J. Pharm. Pharmacol. (1984) 36, 465-466 or Hansen, CB et al. in (1995) Biochim. Biophys. Acta 1239, 133-144. This microbubble was left on the roller table for several hours and washed.
[311] Example 19 Gas Filled Microbubbles Encapsulated with Phosphatidylserine, Thiolated-Anti-CEA-Mal-PEG _3400- DSPE and Anticancer Prodrug N-Trifluoroacetyl-Adriamycin-14-Vallate
[312] a) Method for preparing thiolated anti-CEA antibody
[313] Thiolation of anti-CEA antibodies is described by Hansen, C.B. et al. in (1995) Biochim. Biophys. Acta 1239, 133-144.
[314] b) Process for preparing gas-filled microbubbles encapsulated with phosphatidylserine, thiolated-anti-CEA-Mal-PEG _3400- DSPE and anticancer prodrug N-trifluoroacetyl-adriamycin-14-valerate
[315] Phosphatidylserine (90-99.9 mol%) and Mal-PEG _3400- DSPE (10-0.1 mol%, prepared as in Example 2) and anticancer prodrug N-trifluoroacetyl- adriamycin-14-valerate ( To a mixture (5 mg) of Mori, A. et al. (1993) Pharm. Res. 10, 507-514) was added 5% propylene glycol-glycerol (1 ml) in water. This dispersion was heated to 80 ° C. or less for 5 minutes and cooled to ambient temperature. This dispersion (0.8 ml) was transferred to a vial (1 ml) and the top space was flushed with perfluorobutane. This vial was shaken for 45 seconds in a cap-mixer and the sample was placed on a roller table. After centrifugation, the lower layer was exchanged with a suitable buffer and coupling of the antibody to the microbubbles is described by Goundalkar, A., Ghose, T. and Mezei, M. in J. Pharm. Pharmacol. (1984) 36, 465-466 or Hansen, CB et al. in (1995) Biochim. Biophys. Acta 1239, 133-144. This microbubble was left on the roller table for several hours and washed.
[316] Example 20 How to Use
[317] Diagnostic / treatment agents comprising phosphatidylserine-encapsulated microbubbles with inactivated human thrombin-Succ-PEG ₃₄₀₀ -DSPE mixed in the encapsulation membrane were lyophilized from 0.01 M phosphate buffer (pH 7.4). This product was redispersed in sterile water and injected intravenously into patients with suspected venous thrombosis in the leg veins. Legs were examined by standard ultrasound techniques. Thrombosis was found by increased contrast compared to surrounding tissue.
[318] Example 21 Method and Biological Evaluation of Gas-Containing Microbubbles of DSPS 'Doped' with Lipopeptides Including Heparin Sulfate Binding Peptides (KRKR) and Fibronectin Peptides (WOPPRARI)
[319] This example relates to a method of making a targeted microbubble comprising multiple peptidic vectors arranged in a linear sequence.
[320] a) Synthesis of lipopeptides consisting of heparin sulphate binding peptide (KRKR) and fibronectin peptide (WOPPRARI)
[321]
[322] The lipopeptides were synthesized with an ABI 433A automated peptide synthesizer starting with Fmoc-Ile-Wang resin on a 0.1 mmole scale using a 1 mmole amino acid cartridge. All amino acids and palmitic acid were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours at 5% phenol containing 5% phenol, 5% EDT, 5% anisol and 5% H ₂ 0 to give 150 mg of crude product. Purification of 40 mg of crude material Purification by HPLC was performed using a gradient of 70-100% B (A = 0.1% TFA / water and B = MeOH) for at least 40 minutes at a flow rate of 9 ml / min. 16 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, where B = MeOH, A = 0.01% TFA / water: detection—UV 260 and fluorescence, Ex ₂₈₀ , Em ₃₅₀ —product residence time = 19.44 min). Further product characterization was performed using MALDI mass spectroscopy: expected M + H 2198, found 2199.
[323] b) Process for preparing gas-containing microbubbles of DSPS 'doped' with multi-specific lipopeptides consisting of heparin sulphate binding peptide (KRKR) and fibronectin peptide (WOPPRARI)
[324] Lipopeptides (0.5 mg) from DSPS (4.5 mg) and (a) were each weighed in two vials and 0.8 ml of a solution of 1.4% propylene glycol / 2.4% glycerol was added to each vial. The mixture was warmed to 80 ° C. for 5 minutes (shaking the vial while warming). This sample was cooled to room temperature and the upper space was flushed with perfluorobutane gas. The vial was shaken on a cap-mixer for 45 seconds and rolled overnight. The resulting microbubbles were washed several times with deionized water and analyzed with a Coulter counter (size 1-3 microns (87%) 3-5 microns (11.5%)) and acoustic attenuation (frequency at maximum attenuation: 3.5 MHz). This microbubble was stable at 120 mmHg. MALDI mass spectral analysis was used to confirm mixing of the lipopeptides into the DSPS microbubbles as follows: About 0.05-0.1 ml of the microbubble suspension was added to a clean vial and 0.05-0.1 ml of methanol was added. This suspension was sonicated for 30 seconds and this solution was analyzed by MALDI MS. Positive form yielded M + H at 2200 (lipopeptide expectation, 2198).
[325] c) In vitro studies of gas filled microbubbles of DSPS 'doped' with multi-specific lipopeptides consisting of heparin sulfate-binding peptide (KRKR) and fibronectin peptide (WOPPRARI): binding to endothelial cells under flow conditions
[326] Human endothelial cell line ECV 304 derived from the normal umbilical cord (ATCC CRL-1998) was replaced with RPMI 1640 supplemented with L-glutamine (200 mM), penicillin / streptomycin (10,000 U / ml and 10,000 μg) and 10% fetal bovine serum. Incubation in a 260 ml Nunc culture flask (chutney 153732) in medium. When these cells joined, they were secondarily cultured at a split ratio of 1: 5 to 1: 7. A 22 mm diameter cover glass was sterilized and cells in 0.5 ml complete medium with serum were added onto the plate and then placed on the bottom of the 12 well culture plate. When the cells reached confluence, the coverslips were placed in the flow chamber normally prepared. The flow chamber consists of grooves engraved in a glass plate on which coverslips are placed with the cells, and the cells abut the grooves to form flow channels. The prepared microbubbles prepared as in (b) were passed from a reservoir maintained at 37 ° C. and sent back to the reservoir using a peristaltic pump. Flow rates were controlled to simulate physiologically appropriate shear rates. The flow chamber was placed under the microscope and the interaction between the microbubbles and cells was directly seen. The camera mounted on the microscope was connected to a color video printer and a monitor. Gradual accumulation of microbubbles on the cell occurred at different rates depending on the flow rate. As the flow rate increased further, the cells began to separate from the coverslip but the microbubbles were still bound to the cells. Control bubbles without the vector did not adhere to endothelial cells and disappeared from the chamber under minimal flow conditions.
[327] d) in vivo experiments in dogs
[328] Case 1)
[329] 22 kg hybrid dogs were anesthetized with pentobarbital and mechanically ventilated. The chest was opened with a midline sternal incision, the anterior pericardium was removed, and a 30 mm gelled silicone rubber spacer was inserted between the heart and the P5-3 transducer of the ATL HDI-3000 ultrasound scanner. The scanner was fixed for intermittent shortening of imaging once in each end-stall by delayed EGC stimulation. The entire 2 ml volume of microbubbles from (b) was injected rapidly by intravenous injection. After 3 seconds, the imaged right ventricle was seen to contain contrasting material, and after 3 seconds, the left ventricle was also filled, and a transient attenuation shadow was observed with a faint back part of the left ventricle. In addition, when the attenuation shading subsided, it was seen that the brightness of the myocardial layer increased substantially in the heart region away from the left ventricle. After the initial injection, the ultrasound scanner was fixed at continuous, high frame rate and high output power images using known methods of breaking ultrasound contrast bubbles at the imaged tissue site. After a few seconds, the scanner was adjusted back to its initial value. After that, the myocardial layer became darker and closer to the default. By moving the imaged slice to a new position, the contrast effect appeared again, and by moving the slice back to its initial position, the tissue brightness near the default value appeared.
[330] Case 2) [Comparison]
[331] A total volume of 2 ml of microbubbles prepared in the same manner as in (b) above was injected using the same imaging method as above, except that lipopeptide was not included in the preparation. The increase in myocardial echo was much less severe and shorter in duration than observed in Case 1. At the end of the left ventricular attenuation phase, also myocardial contrast effect was almost lost, and myocardial echo increased in the posterior part of the left ventricle, as was not observed in Case 1.
[332] Example 22 Preparation of Gas-Filled Microbubbles Encapsulated with DSPS Including Thiolated Anti-CD34-MAL-PEG _2000- PE
[333] a) Method for preparing gas filled microbubbles encapsulated with DSPS and PE-PEG ₂₀₀₀ -Mal
[334] DSPS (4.5 mg, 3.9 mmol) and PE-PEG ₂₀₀₀ -Mal (0.5 mg) from Example 50 were weighed in clean vials and 1 ml of 1.4% propylene glycol / 2.4% glycerol solution was added. The mixture was heated to 80 ° C. for 5 minutes and filtered through a 4.5 micron filter. The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and the resulting bubbles were washed three times with distilled water.
[335] b) Thiolation of Anti-CD34 Antibodies
[336] 0.3 mg of anti-CD34 antibody was dissolved in 0.5 ml of phosphate buffered saline (PBS) (pH 7), 0.3 mg of Traut's reagent was added and the solution was stirred at room temperature for 1 hour. Excess reagent was separated from the modified protein on a NAP-5 column.
[337] c) binding of anti-CD34 antibodies to gas filled microbubbles encapsulated in DSPS and comprising DSPE-PEG ₂₀₀₀ -MAL
[338] 0.5 ml of the thiolated antibody preparation from (b) was added to the fraction of microbubbles from (a) and the binding reaction was placed on a roller table for 30 minutes. After centrifugation at 2000 rpm for 5 minutes, the lower layer was removed. The microbubbles were further washed three times with water.
[339] d) detection of encapsulated antibodies in microbubbles using FITC-binding secondary antibodies
[340] To the microbubble suspension from (c) was added 0.025 ml of FITC-bound goat-anti-mouse antibody. This mixture was incubated on a roller table for 30 minutes at room temperature in the dark and centrifuged for 5 minutes at 2000 rpm. Subsequently, the lower layer was removed and the microbubbles were further washed three times with water. Flow cytometry of microbubble suspension
[341] The analysis indicated that 98% of the colonies were fluorescent.
[342] Example 23 Preparation of Gas-Filled Microbubbles Encapsulated with DSPS Including Thiolated Anti-CD62-MAL-PEG _2000- PE
[343] The same method as described in Example 22 was used to prepare microbubbles comprising anti-CD62 antibodies.
[344] Example 24 Preparation of Gas-Filled Microbubbles Encapsulated with DSPS Including Thiolated Anti-ICAM-1-MAL-PEG _2000- PE
[345] The same method as described in Example 22 was used to prepare microbubbles comprising an anti-ICAM-1 antibody.
[346] Example 25 Preparation of Gas-Filled Microbubbles Encapsulated with DSPS and Thiolated Anti-CD62-Mal-PEG _2000- PE and Thiolated-Anti-ICAM-1-Mal-PEG _2000- PE
[347] This embodiment relates to the preparation of microbubbles comprising multiple antibody vectors for target ultrasound imaging.
[348] a) Method for preparing gas filled microbubbles encapsulated with DSPS and PE-PEG ₂₀₀₀ -Mal
[349] DSPS (4.5 mg) and PE-PEG ₂₀₀₀ -Mal (0.5 mg) from Example 2 (a) were weighed in clean vials and 1 ml of 1.4% propylene glycol / 2.4% glycerol solution was added. The mixture was heated to 80 ° C. for 5 minutes and filtered through a 4.5 micron filter. The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and then the bubble was washed three times with distilled water.
[350] b) Thiolation of anti-CD62 and anti-ICAM-1 antibodies
[351] Trout reagent was added to the anti-CD62 antibody and anti-ICAM-1 antibody dissolved in PBS buffer (pH 7, 0.5 ml) and the solution was stirred at room temperature for 1 hour. Excess reagent was separated from the modified protein on a NAP-5 column.
[352] c) Binding of anti-CD62 antibody and anti-ICAM-1 antibody to gas filled microbubbles encapsulated with DSPS and DSPE-PEG ₂₀₀₀ -MAL
[353] 0.5 ml of the thiolated antibody preparation from (b) was added to the fraction of microbubbles from (a) and the binding reaction was placed on a roller table for 30 minutes. After centrifugation at 2000 rpm for 5 minutes, the lower layer was removed. The microbubbles were further washed three times with water.
[354] PEG spacer lengths may vary to include longer (eg PEG ₃₄₀₀ and PEG ₅₀₀₀ ) or shorter (eg PEG ₆₀₀ or PEG ₈₀₀ ) chains. Addition of tertiary antibodies, such as thiolated-anti-CD34, is also possible.
[355] Example 26 Targeted Gas Filled Microbubbles Comprising a PSS Binding Component and a Fibrinated Peptide Containing Fibronectin Peptide Sequence FNFRLKAGOKIRFGGGGWOPPRAI and a DSPS Covalently Coated with Polylysine
[356] a) Synthesis of PS-binding / fibronectin segment fusion peptide FNFRLKAGOKIRFGGGGWOPPRAI
[357] This peptide was synthesized on an ABI 433A automated peptide synthesizer starting with Fmoc-Ile-Wang resin on a 0.1 mmole scale using a 1 mmole amino acid cartridge. All amino acids were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups in TFA containing 5% phenol, 5% EDT and 5% H ₂ O was performed for 2 hours to give crude product in 302 mg yield. 25 mg of crude material was purified over 40 minutes by purified HPLC using a gradient of 20-40% (A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile) at 9 ml / min flow rate. 10 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 20-50% B, where B = 0.1% TFA / acetonitrile, A = 0.01% TFA / water: detection-UV 214 and 260 nm—product residence time = 12.4 min). Product characterization was further performed using MALDI mass spectroscopy; M + H expected 2856, found 2866.
[358] b) Gas filled microbubble production method comprising DSPS non-covalently coated with polylysine and PS-binding / fibronectin fragment fusion peptide FNFRLKAGOKIRFGGGGWOPPRAI
[359] DSPS (5 mg) was weighed and placed in a clean vial with poly-L-lysine (0.2 mg) and peptide (0.2 mg) from (a) above. To this vial was added 1.0 ml of a 1.4% propylene glycol / 2.4% glycerol solution. This mixture was warmed to 80 ° C. for 5 minutes. The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and the resulting microbubbles were centrifuged at 1000 rpm for 3 minutes. After washing well with water, PBS and water, the final solution was tested for polylysine and peptide components using MALDI MS. No polypeptide material was observed in the final wash solution. Acetonitrile (0.5 ml) was then added and the microbubbles were broken by ultrasound. The analysis of the resulting solution for polylysine and PS-binding / fibronectin fusion peptides was then performed using MALDI MS. The results are shown below.
[360] MALDI EstimatesMALDI found Poly-L-lysine786, 914, 1042, 1170790, 919, 1048, 1177 DSPS-binding protein28562866
[361] Spacer elements included within the PS-binding / fibronectin fusion peptide (-GGG-) range can also be replaced with other spacers such as PEG ₃₄₀₀ or polyalanine (-AAA-). In addition, by using a preliminary target form, the DSPS-binding / fibronectin fragment fusion peptide is first associated with the cell via fibronectin peptide binding and is performed by binding to the PS binding peptide by administration of PS microbubbles.
[362] Example 27 Streptavidin / Biotinyl-Endothelin-1 Peptide Encapsulated with Phosphatidylserine and Biotin-PEG ₃₄₀₀ -Alanyl-Cholesterol (Biotin-D-Trp-Leu-Asp-Ile-Ile-Trp. OH) and biotinyl-fibrin-anti-polymeric peptide (Biotin-GPRPPERHOS.NH ₂ ) functionalized gas-filled microbubbles
[363] This example relates to the production of targeted ultrasonic microbubbles by using streptavidin as a linker between biotidinylated receptor (s) and vector (s).
[364] a) Synthesis of Biotin-PEG _3400- b-alanine Cholesterol
[365] Triethylamine (42 mL, 0.30 mmol) was added to a solution of cholesteryl-b-alanine hydrochloride (as described in Example 59) (15 mg, 0.03 mmol) in 3 ml of chloroform / methanol (2.6: 1). Was added. The mixture was stirred at room temperature for 10 minutes and a solution of biotin-PEG ₃₄₀₀ -NHS (100 mg, 0.03 mmol) in 1.4-dioxane (1 ml) was added dropwise. After stirring at room temperature for 3 hours, the mixture was evaporated to dryness and the residue was purified by flash chromatography to give 102 mg (89%) of white crystals. The structure was confirmed by MALDI-MS and NMR.
[366] b) Synthesis of Biotinylated Endothelin-1 Peptide (Biotin-D-Trp-Leu-Asp-Ile-Trp.OH)
[367] This peptide was synthesized in an ABI 433A automated peptide synthesizer starting with Fmoc-Trp (Boc) -Wang resin on a 0.1 mmole scale using a 1 mmole amino acid cartridge. All amino acids were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups in TFA containing 5% anisol and 5% H ₂ O was carried out to give crude product in 75 mg yield. 20 mg of crude product was purified over 40 minutes by purified HPLC using a gradient of 30-80% (A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile) at 9 mL / min flow rate. After lyophilization of the pure fractions 2 mg of pure material was obtained (analytical HPLC, gradient 30-80% B, where B = 0.1% TFA / acetonitrile, A = 0.01% TFA / water: detection-UV 214 nm-product retention Time = 12.6 minutes). Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 1077, found 1077.
[368] c) Synthesis of biotinyl-fibrin-anti-polymeric peptide (Biotin-GPRPPERHOS. NH ₂ )
[369] This peptide was synthesized and purified using a protocol similar to that described in (b) above. Pure product was characterized by HPLC and MALDI MS.
[370] d) Process for preparing multi-specific gas-filled microbubbles encapsulated with phosphatidylserine and biotin-PEG _3400- b-alanine cholesterol
[371] Biotin-PEG _3400- b-alanine cholesterol (0.5 mg) from DSPS (4.5 mg) and (a) was weighed into vials and 0.8 ml of 1.4% propylene glycol / 2.4% glycerol solution was added to the vials. The mixture was warmed to 80 ° C. for 5 minutes (shaking while warming). The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and the vial was rolled overnight. The microbubble suspension was washed several times with deionized water and analyzed by Coulter counter and acoustic attenuation.
[372] e) binding of fluorescein labeled streptavidin and biotinylated peptides from (b) and (c)
[373] To the microbubble preparation from (d) was added fluorescein-bound streptavidin (0.2 mg) dissolved in PBS (1 ml). This bubble was placed on a roller table for 3 hours at room temperature. After washing well with water and analyzing by fluorescence microscopy, the microbubbles were prepared from (b) and (c) biotinyl-endothelin-1 peptide (0.5 mg) and biotinyl-fibrin-anti-polymeric peptide (0.5 incubated for 2 hours in 1 ml of PBS containing mg). The microbubbles were washed well to remove unbound peptides.
[374] Example 28 Phosphatidylserine and Biotinyl-Endothelin-1 Peptide (Biotin-D-Trp-Leu-Asp-Ile-Trp.OH) and Biotinyl-Fibrin-Anti-Polymeric Peptide (Biotin-GPRPPERHOS Gas-filled microbubbles encapsulated with biotin-DPPE used to make streptavidin 'sandwich' with a mixture of .NH ₂ )
[375] a) method of preparing biotin-containing microbubbles
[376] To a mixture of phosphatidylserine (5 mg) and biotin-DPPE (0.6 mg) in a clean vial was added 5% propylene glycol-glycerol (1 ml) in water. This dispersion was heated to 80 ° C. for 5 minutes and cooled to ambient temperature. The top space was then flushed with perfluorobutane and the vial was shaken for 45 seconds in a cap-mixer. After centrifugation, the lower layer was removed and the microbubbles were washed well with water.
[377] b) streptavidin and biotinyl-endothelin-1 peptide (Biotin-D-Trp-Leu-Asp-Ile-Trp.OH) of gas-filled microbubbles encapsulated with phosphatidylserine and biotin-DPPE Binding of a Mixture of Otinyl-Fibrin-Anti-Polymeric Peptides (Biotin-GPRPPERHOS.NH ₂ )
[378] The procedure described in Example 27 was followed.
[379] Example 29 PFB Gas-Containing Microbubbles of DSPS Functionalized with Heparin Sulfate Binding Peptides / Fibronectin Peptides / RGD Peptides and Fluorescein
[380] a) Synthesis of lipopeptides containing RGD sequences and fluorescein receptor groups: dipalmitoyl-Lys-Lys-Lys-Lys [acetyl-Arg-Gly-Asp-Lys (fluorescein) Gly.OH
[381]
[382] Lipopeptides were synthesized as described in Example 21 (a) using commercially available amino acids and polymers. Lipopeptides were cleaved from the resin in TFA containing 5% water, 5% phenol and 5% EDT. After evaporation in vacuo, the crude product was precipitated and treated with diethyl ether. 40 mg of crude material was purified over 40 minutes by purified HPLC using a gradient of 60-100% (A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile) at 9 mL / min flow rate. 10 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 60-100% B, where B = 0.1% TFA / acetonitrile, A = 0.01% TFA / water: detection-UV 260-product residence time = 20-). 22 minutes). Product characterization was further performed using MALDI mass spectroscopy; M + H expected 1922, found 1920.
[383] b) Synthesis of lipopeptides containing heparin sulphate binding sequence and fibronectin peptide
[384] Synthesis and purification was performed as described in Example 21 (a).
[385] c) Process for preparing multi-specific gas-filled microbubbles of DSPS functionalized with heparin sulphate binding peptide, fibronectin peptide, acetyl-RGD peptide and fluorescein
[386] Lipopeptides (0.5 mg, 0.2 mmol) from DSPS (4 mg, 3.9 mmol) and (a) were weighed and placed in two vials, respectively, and 0.8 ml of 1.4% propylene glycol / 2.4% glycerol solution was added to each vial. . The mixture was warmed to 80 ° C. for 5 minutes (shaking while warming). The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and rolled overnight. The microbubbles thus obtained were washed several times with deionized water and analyzed using MALDI mass spectroscopy as described in Example 21 (b). Microbubbles were observed under a microscope and seemed to have a range of 1 to 5 microns in size. In addition, the microbubbles were fluorescent.
[387] Example 30 Gas-filled microbubbles comprising DSPS 'doped' with lipopeptides having affinity for endothelial cells and covalently modified with CD71 FITC-labeled anti-transferrin receptor antibody
[388] This embodiment relates to the preparation of multiple vector targeted ultrasound agents.
[389] a) Synthesis of endothelial cell binding lipopeptides: 2-n-hexadecylstearyl-Lys-Leu-Ala-Leu-Lys-Leu-Ala-Leu-Lys-Ala-Leu-Lys-Ala-Ala-Leu-Lys -Leu-Ala-NH ₂
[390] Lipopeptides shown below were synthesized on an ABI 433A automated peptide synthesizer starting with Rink amide resin on a 0.1 mmole scale using a 1 mmole amino acid cartridge.
[391]
[392] All amino acids and 2-n-hexadecylstearyl acid were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT and 5% H ₂ O to afford 150 mg of crude product. 40 mg of crude material was purified over 50 minutes by purified HPLC using a 90-100% gradient (A = 0.1% TFA / water and B = MeOH) at 9 mL / min flow rate. 10 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 90-100% B, where B = MeOH, A = 0.01% TFA / water: detection-UV 214 nm-product residence time = 23 min). Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 2869, found 2373.
[393] b) Process for preparing gas-filled microbubbles of DSPS 'doped' with endothelial cell binding lipopeptides and PE-PEG _2000- Mal
[394] Lipopeptide (0.5 mg) from DSPS (4.5 mg) and (a) was weighed together with PE-PEG _2000- Mal (0.5 mg) from Example 50 and placed in a clean vial, 1.4% propylene glycol / 2.4% glycerol 1 ml of solution was added. The mixture was warmed to 80 ° C. for 5 minutes and then filtered through a 4.5 micron filter. The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and the resulting microbubbles were washed three times with distilled water.
[395] c) Thiolation of FITC-labeled anti-transferrin receptor antibody
[396] FITC-labeled CD71 anti-transferrin receptor Ab (100 mg / mL in PBS, 0.7 ml) was reacted with Trout's reagent (0.9 mg) for 1 hour at room temperature. Excess reagent was separated from the modified protein on a NAP-5 column.
[397] d) Binding of thiolated FITC-labeled anti-transferrin receptor antibodies to gas-filled microbubbles containing microbubbles comprising endothelial cell-binding lipopeptides and DSPS 'doped' with DSPE-PEG _2000- Mal
[398] 0.5 ml (total 2 ml) of the protein fraction from (c) was added to the microbubbles from (b) and the binding reaction was carried out for 10 minutes on a roller table. After centrifugation at 1000 rpm for 3 minutes, the protein solution was removed and binding was repeated twice with 1 ml and 0.5 ml aliquots of the protein solution respectively. The bubble was then washed four times with distilled water and the samples analyzed by flow cytometry and microscopy in the presence of the antibody. Fluorescent colonies were observed above 92%.
[399] 1 shows a flow cytometry comparison of negative control microbubbles of DSPS (left curve) and bubbles combined with CD71 FITC-labeled anti-transferrin antibody (filled curve, right) showing 92% fluorescence of colonies.
[400] As described in Example 21 (b), introduction of lipopeptides into microbubbles was confirmed using MALDI mass spectroscopy.
[401] Example 31 Gas-Filled Microbubbles Including DSPS, Lipopeptides, and Captopril-Containing Molecules for Endothelial Cell Targets
[402] This embodiment relates to the preparation of ultrasound agents for combined target and therapeutic use.
[403] a) Synthesis of Captopril Functionalized Lipopeptides
[404]
[405] The structure was synthesized using a passive nitrogen bubbler device starting with Fmoc-protected Link Amide MBHA resin on a 0.125 mmol scale. Coupling was performed using standard TBTU / HOBt / DIEA protocol. Bromoacetic acid was coupled through the side chain of Lys as symmetric anhydride using DIC preactivation. Captopril dissolved in DMF was introduced onto the solid phase using DBU as the base. Simultaneous removal of peptides from the resin and deprotection of the side chain protecting groups were performed for 2 hours in TFA containing 5% EDT, 5% water and 5% ethyl methyl sulfide. 10 mg of crude product was obtained and purified over 60 minutes with purified HPLC using a gradient of 70-100% B (A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile) at 10 mL / min flow rate. . After lyophilization 2 mg of pure material was obtained (analytical HPLC, gradient 70-100% B, where A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile, flow rate 1 ml / min, detection—UV 214 nm Dwell time = 26 minutes). Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 1265.
[406] b) Synthesis of lipopeptides with affinity for endothelial cells: dipalmitoyl-Lys-Lys-Lys-Aca-Ile-Arg-Arg-Val-Ala-Arg-Pro-Pro-Leu-NH ₂
[407]
[408] Lipopeptides were synthesized on an ABI 433A automated peptide synthesizer starting with link amide resin on a 0.1 mmol scale using a 1 mmol amino acid cartridge. All amino acids and palmitic acid were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups in TFA containing 5% phenol, 5% EDT and 5% H ₂ O was performed for 2 hours to give crude product in 160 mg yield. A 35 mg aliquot of the crude product was purified over 40 minutes by purified HPLC using a 70-100% gradient (A = 0.1% TFA / water and B = MeOH) at 9 mL / min flow rate. 20 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, where B = MeOH, A = 0.01% TFA / water: detection UV 214 and 260 nm product residence time = 16 min). Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 2050, found 2055.
[409] c) Methods of making gas-filled microbubbles comprising DSPS, lipopeptides for target of endothelial cells and captopril-containing molecules for drug delivery
[410] DSPS (4.5 mg), product from (a) (0.5 mg) and product from (b) (0.5 mg) were weighed into vials and 1.0 ml of 1.4% propylene glycol / 2.4% glycerol solution was added to the vials. . The mixture was warmed to 80 ° C. for 5 minutes (shaking while warming). The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was first shaken in a cap-mixer for 45 seconds, rolled for 1 hour and washed well with deionized water. No starting material was observed in the final wash as evidenced by MALDI MS. As described in Example 21 (b), mixing of the products from (a) and (b) into the microbubbles was confirmed using MALDI mass spectrometry.
[411] d) in vitro studies of gas-filled microbubbles comprising DSPS, lipopeptides for targeting endothelial cells and captopril-containing molecules for therapeutic use
[412] Cell binding was examined under flow conditions using the in vitro assay described in Example 21 (c). The gradual accumulation of cellular microbubbles occurred depending on the flow rate. As the flow rate increased further, the cells began to fall off the coverslip, but the microbubbles were still bound to the cells. Control microbubbles without vector did not adhere to endothelial cells and disappeared from the chamber under minimal flow conditions.
[413] Example 32 Method of Making Gas-Filled Microbubbles Comprising DSPS Loaded with Lipopeptides Comprising Spiral Peptides and Peptide Antibiotic Polymyxin B Sulfate with Affinity to Cell Membranes
[414] This example relates to the preparation of targeted microbubbles comprising multiple peptidic vectors with combined targets and therapeutic uses.
[415] a) Synthesis of lipopeptides comprising helical peptides having affinity for cell membranes: hexadecylstearyl-Lys-Leu-Ala-Leu-Lys-Leu-Ala-Leu-Lys-Ala-Leu-Lys-Ala- Ala-Leu-Lys-Leu-Ala-NH ₂
[416] Prepared as described in Example 30 (a).
[417] b) methods of making multi-specific gas-filled microbubbles
[418] DSPS (5.0 mg), lipopeptides from (a) (0.3 mg) and products from polymyxin B sulfate (b) (0.5 mg) were weighed into clean vials and 1.4% propylene glycol / 2.4% glycerol solution 1.0 ml was added to the vial. The mixture was sonicated for 3-5 minutes, warmed to 80 ° C. for 5 minutes and then filtered through a 4.5 micron filter. The mixture was cooled to room temperature and the upper space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and the resulting microbubbles were centrifuged at 1000 rpm for 3 minutes. The microbubbles were washed with water until no polymyxin B sulphate or lipopeptides in the precipitate were detected by MALDI-MS. As a result of microscopic observation, the size distribution of the bubble colony was preferably 1-8 microns. To the washed bubble (about 0.2 ml) was added methanol (0.5 ml) and the mixture was placed in an ultrasonic bath for 2 minutes. It was found that the clear solution produced after analysis by MALDI-MS contained lipopeptides and polymyxin B sulfate (expected 1203, found 1207).
[419] Example 33 Methods of Making Gas-Filled Microbubbles Comprising DSPS 'Doped' with Lipopeptides Modified into Branched Structures Containing IL-1 Receptor-Binding Sequences and Containing Drug Methotrexate
[420] This embodiment relates to the production of targeted microbubbles comprising multiple vectors for target / therapeutic use.
[421] a) Synthesis of lipopeptides comprising interleukin-1 receptor binding peptides: dipalmitoyl-Lys-Gly-Asp-Trp-Asp-Gln-Phe-Gly-Leu-Trp-Arg-Gly-Ala-Ala.OH
[422]
[423] Lipopeptides were synthesized in an ABI 433A automated peptide synthesizer starting with Fmoc-Ala-Wang resin on a 0.1 mmole scale using a 1 mmole amino acid cartridge. All amino acids and palmitic acid were preactivated using HBTU prior to coupling. Simultaneous removal of the product from the resin and deprotection of the protecting group were carried out in TFA containing 5% water, 5% anisol, 5% phenol and 5% EDT for 2 hours to give 150 mg of crude product. 30 mg of crude material was purified over 40 minutes by purified HPLC using a 90-100% gradient (A = 0.1% TFA / water and B = MeOH) at 9 mL / min flow rate. 4 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 90-100% B, where B = MeOH, A = 0.01% TFA / water: detection-UV 214 nm-product residence time = 23 min). Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 2083, found 2088.
[424] b) Synthesis of branched methotrexate core structure containing thiol residues
[425]
[426] Methotrexate was synthesized on an ABI 433A automated peptide synthesizer starting with Fmoc-Cys (Trt) Tentagel resin on a 0.1 mmol scale. Simultaneous removal of the product from the resin and deprotection of the protecting group were carried out in TFA containing 5% EDT and 5% H ₂ O for 2 hours to give crude product at 160 mg. 30 mg of crude material was purified over 40 minutes by purified HPLC using a gradient of 10-30% B at 9 mL / min flow rate (A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile). 9 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 5-50% B, where B = 0.1% TFA / acetonitrile, A = 0.01% TFA / water: detection-UV 214 nm-product residence time = 9.5 minute). Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 1523, found 1523.
[427] c) methods of making multi-specific gas-filled microbubbles
[428] DSPS (4.5 mg), thiol-containing lipopeptides from Example 64 (a) and lipopeptides from (a) (0.2 mg) were weighed and placed in clean vials, 1.4% propylene glycol / 2.4% 1.0 ml of glycerol solution was added to the vial. The mixture was sonicated for 3-5 minutes, warmed to 80 ° C. for 5 minutes and then filtered through a 4.5 micron filter. The mixture was cooled to room temperature and the upper space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer, the resulting microbubbles were centrifuged at 1000 rpm for 3 minutes and the supernatant was discarded.
[429] d) binding of methotrexate branched structures to thiolated microbubbles
[430] The methotrexate structure from (b) (0.5 mg) was dissolved in PBS (pH 8.0). This solution was added to the thiol-containing microbubbles from (c) and disulfide bond formation was carried out for 16 hours. After washing well with PBS and water, the bubbles were analyzed using microscopy and MALDI MS.
[431] Disulfide bond linkages that link the methotrexate structure to the microbubbles can reduce the release of free drug molecules in vivo such that the microbubbles contain a drug delivery system along with tumor specific vectors. Physiologically acceptable reducing agents such as glutathione can also be used for drug release.
[432] Example 34 Preparation of Gas-Filled Microbubbles Coated with Poly-L-lysine Complexed with Fluorescein-Marked DNA Fragments from Plasmid pBR322
[433] This example relates to the manufacture of microbubbles for gene therapy / anti-sense applications. Specific targets can be obtained by further doping the microbubble membrane with vector-modified lipid constructs as described in Example 21.
[434] a) Process for preparing DSPS encapsulated gas-filled microbubbles
[435] DSPS (4.5 mg) was weighed and placed in clean vials. 1.0 ml of 1.4% propylene glycol / 2.4% glycerol solution was added to the vial and the mixture was sonicated for 2 minutes and warmed to 80 ° C. for 5 minutes. The solution was immediately warmed up and filtered through a 4 micron filter. The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer. The resulting microbubbles were then washed once with deionized water and the bottom layer was discarded. The microbubbles were then resuspended in 0.5 ml of water.
[436] b) Process for preparing poly-L-lysine / DNA complex and loading of DSPS-encapsulated microbubbles
[437] To 1 mg of poly-L-lysine (70-150 kD) in a clean vial was added 0.1 ml of fluorescein-labeled digest of plasmid pBR322 dissolved in TE buffer (10 mM Tris-HCl, pH 8). Water was added to make the solution a total of 0.6 ml and the pH adjusted to 8. The complex reaction was performed for 1 hour and 0.5 ml of polylysine-DNA solution was added to the microbubble suspension from (a). After 1 hour, the bubble was observed to fluoresce under a microscope to confirm the presence of DNA.
[438] Example 35 Method for Preparation of Gas-Filled Microbubbles Containing Branched Core Peptides Comprising Dabsylated-Atheromatic Atherosclerotic Plaque-Binding Sequences and RGDS
[439] This example relates to the preparation of microbubbles with thiol groups on the surface for modification with thiol-containing vectors for target / drug delivery and drug release.
[440] a) Synthesis of Branched Peptides Davyl-Tyr-Arg-Ala-Leu-Val-Asp-Thr-leu-Lys-Lys- (NH ₂ -Arg-Gly-Asp-Ser) -Gly-Cys.OH
[441]
[442] Peptides were synthesized in an ABI 433A automated peptide synthesizer starting with Fmoc-Cys (Trt) -Tentagel resin on a 0.1 mmole scale using a 1 mmole amino acid cartridge. All amino acids were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups in TFA containing 5% phenol, 5% EDT and 5% H ₂ O was carried out for 2 hours to give 160 mg of crude product. 30 mg of crude material was purified over 40 minutes by purified HPLC using a gradient of 10-60% B (A = 0.1% TFA / water and B = acetonitrile) at 9 mL / min flow rate. 2.5 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 10-50% B, 20 min, where B = 0.1% TFA / acetonitrile, A = 0.01% TFA / water: detection-UV 214 and 435 nm- Product residence time = 21 min). Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 2070, found 2073.
[443] b) Process for preparing thiol containing gas-filled microbubbles
[444] Prepared as described in Example 64 (a).
[445] c) Oxidative Coupling of Thiolated Microbubbles with Multi-Specific Peptides Through Disulfide Bond Formation
[446] The lower layer of microbubbles from (b) was discarded and replaced with a solution of dabsil-peptide (1 mg) from (a) in 0.7 ml of diluted ammonia solution (pH 8). To this was added 0.2 ml of a stock solution containing 6 mg of potassium ferricyanate dissolved in 2 ml of water. The vial was placed on a roller table and thiol oxidized for 2 hours. The bubbles were then washed well with water until the bottom layer was free of dabsyl-peptide, as evidenced by HPLC and MALDI MS. Detection of microbubble-bound peptides was performed by reducing disulfide bonds using the water-soluble reducing agent Tris- (2-carboxyethyl) -phosphine. After reduction, it was found that the sublayer contained free dabsil-peptide as demonstrated by HPLC and MALDI MS.
[447] Other physiologically acceptable reducing agents, such as reduced glutathione, may also be useful for initiating release.
[448] Example 36 Encapsulated with DSPS and Biotin-PEG ₃₄₀₀ -acyl-phosphatidylethanolamine and functionalized with Streptavidin, Oligonucleotide Biotin-GAAAGGTAGTGGGGTCGTGTGCCGG and Biotinylated Fibrin-Anti-Polymeric Peptides (Biotin-GPRPPERHOS.NH ₂ ) Method of Making a Gasified Filled Microbubble
[449] a) Synthesis of Biotin-PEG ₃₄₀₀ -acyl-phosphatidyl ethanolamine
[450] Dipalmitoyl forpatidilyl ethanolamine (21.00 mg, 0.03 mmol), biotin-PEG-CO ₂ -NHS (100 mg, 0.03 mmol) and triethylamine (42 μL, 0.30 in chloroform / methanol (3: 1) solution Mmol) was stirred at room temperature for 2 hours. After evaporation of the solvent under reduced pressure, the residue was subjected to flash chromatography (methylene chloride / methanol / water, 40: 8: 1). The product (112 mg, 94%) was obtained as a yellow rubber and the structure was confirmed by NMR and MALDI-MS.
[451] b) binding of fluorescein-linked streptavidin to gas-filled microbubbles
[452] Gas-filled microbubbles were prepared by mixing DSPS and biotin-PEG ₃₄₀₀ -acyl-phosphatidyl ethanolamine as described in the examples above. The microbubble suspension was divided into 0.2 ml aliquots and fluorescein-linked streptavidin was added as shown in the table below. This sample was incubated at ambient temperature for 15 or 30 minutes on a roller table before removing excess protein by washing with PBS. This sample was analyzed by flow cytometry and coulter counter. The results are summarized in the table below.
[453] <Result>
[454] Fraction numberAdded Streptavidin (mg / 200: 1 Sammet)Incubation Time (Ambient Temperature)% Fluorescent particlesParticle Median Diameter (microns) One0 2.0- 2030 minutes-12 (foam) 30.2 (3 x 10 ^-9 mmol)30 minutes7.83.9 42 (3 x 10 ^-8 mmol)30 minutes26.24.2 510 (1.5 x 10 ^-7 mmol)15 mins30.5na 620 (3 x 10 ^-7 mmol)30 minutes97.95.2 740 (6 x 10 ^-7 mmol)15 mins96.75.1 8 DSPS contrast20 (3 x 10 ^-7 mmol)15 mins0.63.7
[455] c) binding of streptavidin-coated microbubbles with oligonucleotides biotin-GAAAGGTAGTGGGGTCGTGTGCCGG and biotinylated fibrin-anti-polymeric peptide biotin-GPRPPERHOS
[456] The particles of aliquot No. 6 were centrifuged and the supernatant was replaced with 1 ml of PBS buffer at pH 7.5 containing 0.2 mg of biotin-GAAAGGTAGTGGGGTCGTGTGCCGG and 0.2 mg of biotin-GPRPPERHQS (as in Examples 27 (b) and (c)). Produce). After incubation for 24 hours, the particles were washed well with PBS and water.
[457] This method can be used to bind other biotinylated vectors or therapeutic agents to streptavidin- or avidin-coated microbubbles.
[458] Example 37 Preparation of Microbubbles Encapsulated with DSPS and Functionalized with Thrombus-Targeted Lipopeptides and Thrombolytic Enzyme Tissue Plasminogen Activators
[459] This example relates to the preparation of thrombus target ultrasound contrast agents containing therapeutic thrombolytics.
[460] a) of lipopeptides having affinity for thrombi (dipalmitoyl-Lys-As-Asp-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln. NH ₂ ) synthesis
[461]
[462] The lipopeptides were synthesized in an ABI 433A automated peptide synthesizer starting with link amide resin on a 0.1 mmole scale using a 1 mmole amino acid cartridge. All amino acids were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups in TFA containing 5% phenol, 5% EDT, 5% anisol and 5% H ₂ O was performed for 2 hours to give 80 mg of crude product. Purification HPLC purified 20 mg of crude material. After lyophilization 6 mg of pure material was obtained. The product was characterized using MALDI mass spectroscopy and analytical HPLC.
[463] b) modification of tissue plasminogen activator with sulfo-SMPB
[464] A 0.1 ml solution of ammonium carbonate buffer containing 0.1 mg of t-PA was prepared to add 0.2 mL by adding water. To this solution was added 0.4 mg of sulfo-SMPB dissolved in 0.05 ml of DMSO. The protein solution was left at room temperature for 45 minutes and then purified on a Superdex 200 column. The product was eluted with PBS to collect modified protein fractions.
[465] c) Preparation of microbubbles encapsulated with DSPS / thrombo-binding lipopeptides and thiol-containing lipopeptides and binding of modified tissue plasminogen activators
[466] DSPS (5.0 mg) was weighed to place lipopeptides (0.5 mg) from (a) and thiol-containing lipopeptides (0.5 mg) from Example 64 (a) into clean vials, 1.4% propylene glycol / 2.4% 1.0 ml of glycerol solution was added and the mixture was sonicated for 2 minutes and then warmed to 80 ° C. for 5 minutes. Immediately after warming the solution, the solution was filtered through a 4 micron filter. The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and the resulting microbubbles were washed twice with deionized water. The lower layer was discarded and replaced with a 1 ml aliquot of the protein solution from (b). The binding reaction was carried out for 1 hour. After centrifugation of the microbubbles, the lower layer was exchanged with 1 mL of another protein solution. The incubation step was repeated until all protein solution was exhausted. The microbubbles were then washed well with water and analyzed with a Coulter counter. Microbubbles were tested by the flow chamber analysis described in Example 21 (c). Protein-modified microbubbles have been found to bind in greater numbers than those containing either lipopeptides / DSPS or DSPS itself.
[467] Target / treatment / ultrasonic activity of these microbubbles is evaluated in models of thrombus generation in vitro and in vivo.
[468] Example 38 Preparation of a Gas-Filled Microbubble Comprising DSPS Loaded with Lipopeptides Comprising Spiral Peptides Having Affinity to Cell Membranes
[469] This example relates to the preparation of a targeted microbubble comprising a target peptidic vector of cell membrane constructs.
[470] a) Synthesis of lipopeptides comprising helical peptides having affinity for cell membranes
[471]
[472] The lipopeptides were synthesized on an ABI 433A automated peptide synthesizer starting with link amide resin on a 0.2 mmole scale using a 1 mmole amino acid cartridge. All amino acids and 2-n-hexadecylstearic acid were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% H ₂ O to afford 520 mg of crude product. 30 mg of crude material was purified over 40 minutes by purified HPLC using a gradient of 90-100% B (A = 0.1% TFA / water and B = MeOH) at 9 mL / min flow rate. 10 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 90-100% B, 20 min, where B = MeOH, A = 0.01% TFA / water: detection-UV 214 nm-product residence time = 23 min) . Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 2369, found 2375.
[473] b) method of making gas-filled microbubbles
[474] DSPS (4.5 mg) and lipopeptide (0.5 mg) from Example (a) were weighed into clean vials and 1.0 ml of 1.4% propylene glycol / 2.4% glycerol solution was added to the vials. The mixture was sonicated for 3-5 minutes and warmed to 80 ° C. for 5 minutes and then filtered through a 4.5 mm filter. The mixture was cooled to room temperature and the upper space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and the resulting microbubbles were centrifuged at 1000 rpm for 3 minutes. The microbubbles were then washed with water until no lipopeptides were detected by MALDI-MS. Coulter counter, acoustic attenuation and pressure stability tests were performed. To the aliquot of the washed bubble (about 0.2 ml) was added methanol (0.5 ml) and the mixture was placed in an ultrasonic bath for 2 minutes. The clear solution produced upon analysis by MALDI-MS was found to contain lipopeptides.
[475] c) in vitro and in vivo testing
[476] This microbubble had similar properties in vitro and in vivo as found in the microbubbles prepared in Example 21.
[477] Example 39 Gas-Filled Microbubbles Encapsulated with Phosphatidylserine and Biotylated Lipopeptides
[478] a) Synthesis of lipopeptide dipalmitoyl-lysinyl-tryptophanyl-lysinyl-lysinyl-lysinyl (biotinyl) -glycine
[479] The lipopeptides were synthesized in an ABI 433A automated peptide synthesizer starting with Fmoc-Gly-Wang resin on a 0.1 mmole scale using a 1 mmole amino acid cartridge. All amino acids and palmitic acid were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% phenol, 5% EDT, 5% anisol and 5% H ₂ O to afford 150 mg of crude product. 40 mg of crude material was purified over 40 minutes by purified HPLC using a gradient of 70-100% B (A = 0.1% TFA / water and B = MeOH) at 9 mL / min flow rate. 14 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, where B = MeOH, A = 0.01% TFA / water: detection-UV 260 and fluorescence, Ex280, Em350-product residence time = 22 minute). Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 1478, found 1471.
[480] b) Process for preparing gas-filled microbubbles 'doped' with biotinylated lipopeptide sequence from (a)
[481] DSPS (4.5 mg) and lipopeptides (0.5 mg) from Example (a) were weighed into two vials each and 0.8 ml of 1.4% propylene glycol / 2.4% glycerol solution was added to each vial. The mixture was warmed to 80 ° C. for 5 minutes (shaking the vial while warming). The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and rolled overnight. The resulting microbubbles were washed several times with deionized water and analyzed by Coulter counter and acoustic attenuation. MALDI mass spectrometric analysis was used to confirm the mixing of the lipopeptides of the DSPS microbubbles as follows: About 50-100 ml of the microbubbles were transferred to clean vials and 50-100 ml of water was added. This mixture was sonicated for 30 seconds and dropped onto a clean target disc (1 ml + 0.5 ml ACH matrix). Positive mode was obtained at M + H 1474, and lipopeptide estimate was 1478.
[482] Example 40 Preparation of Multi-Specific Gas-Filled Microbubbles Including DSPS Loaded with Lipopeptides Including Non-Liver Interleukin-1 Receptor-Binding Peptides
[483] This example relates to the preparation of a targeted microbubble comprising an in vivo peptidic vector for a target at an IL-1 receptor that does not induce signal transduction or prevent IL-1 binding.
[484] a) Synthesis of lipopeptides comprising non-living interleukin-1 receptor-binding peptides
[485]
[486] Lipopeptides were synthesized in an ABI 433A automated peptide synthesizer starting with Fmoc-Ala-Wang resin on a 0.1 mmole scale using a 1 mmole amino acid cartridge. All amino acids and palmitic acid were preactivated using HBTU prior to coupling. Simultaneous removal of lipopeptides from the resin and side chain protecting groups in TFA containing 5% water, 5% anisol, 5% phenol and 5% EDT for 2 hours yielded 150 mg of crude product. 30 mg of crude material was purified over 40 minutes by purified HPLC using a 90-100% gradient (A = 0.1% TFA / water and B = MeOH) at 9 mL / min flow rate. 4 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 90-100% B, 20 min, where B = MeOH, A = 0.01% TFA / water: detection-UV 214 nm-product residence time = 23 min) . Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 2083, found 2088.
[487] b) method of making gas-filled microbubbles
[488] DSPS (4.5 mg) and lipopeptide (0.5 mg) from Example (a) were weighed into clean vials and 1.0 ml of 1.4% propylene glycol / 2.4% glycerol solution was added to the vials. This mixture was sonicated for 3-5 minutes, warmed to 80 ° C. for 5 minutes and then filtered through a 4.5 micron filter. The mixture was cooled to room temperature and the upper space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and the resulting microbubbles were centrifuged at 1000 rpm for 3 minutes. The microbubbles were then washed with water until no lipopeptides were detected by MALDI-MS. To the washed bubble (about 0.2 ml) was added methanol (0.5 ml) and the mixture was placed in an ultrasonic bath for 2 minutes. The clear solution produced upon analysis by MALDI-MS was found to contain lipopeptides (expected 2083, found 2088).
[489] Example 41 Preparation of Perfluoropropane-Filled Microbubbles Including DSPC, DSPS, and Endothelial Cell-Binding Lipopeptides for Target Ultrasound Imaging
[490] 0.5 mg of the lipopeptide from Example 31 (b) was added to 0.8 ml of a solution containing DSPC: DSPS (3: 1) (5 mg / ml) in propylene glycol / glycerol (4% in water). The mixture was warmed to 80 ° C for 5 minutes and shaken. This solution was then cooled to ambient temperature and the upper space was flushed with perfluoropropane. The vial was shaken for 45 seconds in a cap-mixer and placed on a roller table for 5 minutes. The sample was centrifuged at 2000 rpm for 3 minutes and the lower layer was removed and replaced with distilled water. The upper space was flushed back with perfluoropropane and placed on a roller table until the sample was homogeneous. The washing process was repeated. The resulting ultrasound contrast was characterized by Coulter counter analysis, acoustic attenuation measurement and resistance to external pressure. This microbubble was tested in an in vitro assay as described in Example 21. Gradual accumulation of microbubble binding to cells was observed.
[491] Example 42 Preparation of Hexafluoride-Containing Microbubbles Including DSPC, DSPS, and Endothelial Cell-Binding Lipopeptides for Target Ultrasound Imaging
[492] 0.5 mg of the lipopeptide from Example 31 (b) was added to 0.8 ml of a solution containing DSPC: DSPS (3: 1) (5 mg / ml) in propylene glycol / glycerol (4% in water). The mixture was warmed to 80 ° C for 5 minutes and shaken. The solution was then cooled to ambient temperature and the top space was flushed with sulfur hexafluoride gas. The vial was shaken for 45 seconds in a cap-mixer and placed on a roller table for 5 minutes. The sample was centrifuged at 2000 rpm for 5 minutes, the lower layer was removed and replaced with distilled water. The top space was flushed again with sulfur hexafluoride and placed on a roller table until the sample was homogeneous. The washing process was repeated.
[493] The resulting ultrasound contrast was characterized by Coulter counter analysis, acoustic attenuation measurement and resistance to external pressure.
[494] Example 43 Preparation of Gas-Filled Microbubbles Comprising DSPG and Targeted Cell-Lifting Lipopeptides for Target Ultrasound Imaging
[495] To 0.8 ml of a solution containing DSPG (5 mg / ml) in propylene glycol / glycerol (4% in water) 0.5 mg of the lipopeptide from Example 31 (b) was added. The mixture was warmed to 80 ° C for 5 minutes and shaken. This solution was then cooled to ambient temperature and the upper space was flushed with perfluorobutane. The vial was shaken for 45 seconds in a cap-mixer and placed on a roller table for 5 minutes. The sample was centrifuged at 2000 rpm for 5 minutes, the lower layer was removed and replaced with distilled water. The upper space was flushed again with perfluorobutane and placed on a roller table until the sample was homogeneous. The washing process was repeated. The resulting ultrasound contrast was characterized by Coulter counter analysis, acoustic attenuation measurement and resistance to external pressure. This microbubble was tested in an in vitro assay as described in Example 21. Gradual accumulation of microbubble binding to cells was observed.
[496] Example 44 Preparation of Perfluoropropane-Filled Microbubbles Including DSPG for Target Ultrasound Imaging and Endothelial Cell-Binding Lipopeptides
[497] To 0.8 ml of a solution containing DSPG (5 mg / ml) in propylene glycol / glycerol (4% in water) 0.5 mg of the lipopeptide from Example 31 (b) was added. The mixture was warmed to 80 ° C for 5 minutes and shaken. This solution was then cooled to ambient temperature and the upper space was flushed with perfluoropropane. The vial was shaken for 45 seconds in a cap-mixer and placed on a roller table for 5 minutes. The sample was centrifuged at 2000 rpm for 5 minutes, the lower layer was removed and replaced with distilled water. The upper space was flushed back with perfluoropropane and placed on a roller table until the sample was homogeneous. The washing process was repeated. The resulting ultrasound contrast was characterized by Coulter counter analysis, acoustic attenuation measurement and resistance to external pressure. This microbubble was tested in an in vitro assay as described in Example 21. Gradual accumulation of microbubble binding to cells was observed.
[498] Example 45 A method for preparing a hexafluoride-containing microbubble comprising DSPG for target ultrasound imaging and endothelial cell-binding lipopeptides
[499] To 0.8 ml of a solution containing DSPG (5 mg / ml) in propylene glycol / glycerol (4% in water) 0.5 mg of the lipopeptide from Example 31 (b) was added. The mixture was warmed to 80 ° C for 5 minutes and shaken. The solution was then cooled to ambient temperature and the top space was flushed with sulfur hexafluoride gas. The vial was shaken for 45 seconds in a cap-mixer and placed on a roller table for 5 minutes. The sample was centrifuged at 2000 rpm for 5 minutes, the lower layer was removed and replaced with distilled water. The top space was flushed again with sulfur hexafluoride and placed on a roller table until the sample was homogeneous. The washing process was repeated. The resulting ultrasound contrast was characterized by Coulter counter analysis, acoustic attenuation measurement and resistance to external pressure.
[500] Example 46 Targeted Gas-Filled Microbubbles Including DSPS Covalently Coated with Polylysine
[501] DSPS (5 mg) was weighed with poly-L-lysine (0.2 mg) in a clean vial. To this vial was added 1.0 ml of a 1.4% propylene glycol / 2.4% glycerol solution. This mixture was warmed to 80 ° C. for 5 minutes. The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and the resulting microbubbles were centrifuged at 1000 rpm for 3 minutes. Wash well with water, PBS and water and the final solution was checked for polylysine content using MALDI MS. No polypeptide material was observed in the final wash solution. Acetonitrile (0.5 ml) was then added and the microbubbles were sonicated until all the bubbles broke. Polylysine analysis of the resulting solution was performed again using MALDI MS. The results are shown below:
[502] MALDI EstimatesMALDI found Poly-L-lysine786, 914, 1042, 1170790, 919, 1048, 1177
[503] Example 47 Preparation of Functionalized Gas-Filled Microbubbles for Target Ultrasound Imaging
[504] This example mainly relates to the preparation of microbubbles with reactive groups on the surface for non-specific targets using disulfide exchange reactions to bind to the multiplicity of cellular targets.
[505] a) synthesis of thiol-functionalized lipid molecules
[506]
[507] The lipid structure was synthesized on an ABI 433A automated peptide synthesizer starting with Fmoc-Cys (Trt) -Wang resin on a 0.25 mmol scale using a 1 mmol amino acid cartridge. All amino acids and palmitic acid were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT and 5% H ₂ O to afford 250 mg of crude product. 40 mg of crude material was purified over 50 minutes by purified HPLC using a gradient of 90-100% B (A = 0.1% TFA / water and B = MeOH) at 9 mL / min flow rate. 24 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, where B = 0.1% TFA / acetonitrile, A = 0.01% TFA / water: detection-UV 214 nm-product residence time = 22 minute). Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 1096, found 1099.
[508] b) Process for preparing gas-filled microbubbles comprising DSPS 'doped' with thiol-containing lipid constructs
[509] Lipid constructs (0.5 mg, 0.4 mmol) from DSPS (4.5 mg) and (a) were weighed into clean vials and 0.8 ml of a 1.4% propylene glycol / 2.4% glycerol solution in water was added. The mixture was warmed to 80 ° C. for 5 minutes (shaking the vial while warming) and filtered through a 40 mm filter while still hot. The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and then placed on a roller table overnight. The resulting microbubbles were washed several times with deionized water and analyzed for thiol group mixing using Elman reagent.
[510] Example 48 Preparation of Gas-Filled Microbubbles Including DSPS Doped with Thrombus-Binding Lipopeptides
[511] a) of lipopeptides having affinity for thrombi (dipalmitoyl-Lys-As-Asp-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln. NH ₂ ) synthesis
[512]
[513] The lipopeptides were synthesized in an ABI 433A automated peptide synthesizer starting with link amide resin on a 0.1 mmole scale using a 1 mmole amino acid cartridge. All amino acids and palmitic acid were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups in TFA containing 5% phenol, 5% EDT, 5% anisol and 5% H ₂ O was performed for 2 hours to give 80 mg of crude product. Purification HPLC purified 20 mg of crude material. After lyophilization 6 mg of pure material was obtained. The product was characterized using MALDI mass spectroscopy and analytical HPLC.
[514] b) methods of making thrombus-targeted ultrasonic microbubbles
[515] Lipopeptide (1.0 mg) from DSPS (4.5 mg) and (a) was weighed into the vial and 0.8 ml of 1.4% propylene glycol / 2.4% glycerol solution was added. The mixture was warmed to 80 ° C. for 5 minutes and filtered through a 4 micron filter. Cool to room temperature and flush the upper space with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and the resulting microbubbles were washed well with deionized water. This microbubble was characterized by microscopy and coulter counter analysis. MALDI-MS was used to confirm the presence of lipopeptides as described in the examples above.
[516] Example 49 Preparation of Transferrin-Coated Gas-Filled Microbubbles for Target Ultrasound Imaging
[517] a) synthesis of thiol-functionalized lipid molecules
[518]
[519] The lipid structure was synthesized on an ABI 433A automated peptide synthesizer starting with Fmoc-Cys (Trt) -Wang resin on a 0.25 mmol scale using a 1 mmol amino acid cartridge. All amino acids and palmitic acid were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT and 5% H ₂ O to afford 250 mg of crude product. 40 mg of crude material was purified over 50 minutes by purified HPLC using a gradient of 90-100% B (A = 0.1% TFA / water and B = MeOH) at 9 mL / min flow rate. 24 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, where B = 0.1% TFA / acetonitrile, A = 0.01% TFA / water: detection-UV 214 nm-product residence time = 22 minute). Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 1096, found 1099.
[520] b) Process for preparing gas-filled microbubbles comprising DSPS 'doped' with thiol-containing lipid constructs
[521] Lipid constructs from DSPS (4.5 mg) and (a) (0.5 mg, 0.4 mmol) were weighed into clean vials and 0.8 ml of 1.4% propylene glycol / 2.4% glycerol solution was added. The mixture was warmed to 80 ° C. for 5 minutes (shaking the vial while warming) and filtered through a 40 mm filter while still hot. The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and then placed on a roller table overnight. The resulting microbubbles were washed several times with deionized water and analyzed for thiol group mixing using Elman reagent.
[522] c) modification of transferrin to fluorescein-NHS and sulfo-SMPB
[523] To 4 mg of transferrin (Holo, Human) in PBS (1 ml) was added 0.5 ml of a DMSO solution containing 1 mg of sulfo-SMPB and 0.5 mg of fluorescein-NHS. The mixture was stirred at room temperature for 45 minutes and passed through a Sephadex 200 column using PBS as eluent. Protein fractions were collected and stored at 4 ° C. before use.
[524] d) microbubbles combined with transferrin
[525] To the thiol-containing microbubble from (b) was added 1 ml of the modified transferrin protein solution from (c). After adjusting the pH of the solution to 9, the binding reaction was carried out at room temperature for 2 hours. Microbubbles were washed well with deionized water and analyzed by Coulter counter (97% between 1 and 5 mm) and fluorescence microscopy (highly fluorescent microbubbles).
[526] Example 50 Gas-filled Microbubbles Including DSPS Mixed with PE-PEG _2000- Mal bound to Thiolated Trypsin Fluorescein
[527] a) Synthesis of Boc-NH-PEG _2000- DSPE (t-butyl carbamate poly (ethylene glycol) distearoylphosphatidyl-ethanolamine)
[528] DSPE (31 mg) was added to a solution of Boc-NH-PEG ₂₀₀₀ -SC (150 mg) in chloroform (2 ml) and triethylamine (33 μl) was added. The mixture was stirred at 41 ° C. for 10 minutes until the starting material dissolved. The solvent was rotary evaporated and the residue dissolved in acetonitrile (5 ml). The resulting dispersion was cooled to 4 ° C. and centrifuged, then the solution was filtered and evaporated to dryness. The structure of the obtained product was confirmed by NMR.
[529] b) Synthesis of H ₂ N-PEG ₂₀₀₀ -DSPE (Amino-poly (ethylene glycol) -distearoylphosphatidylethanolamine)
[530] Boc-NH-PEG ₂₀₀₀ -DSPE (167 mg) was stirred in 4 M hydrochloric acid in dioxane (5 ml) for 2.5 hours at ambient temperature. The solvent was removed by rotary evaporation and the residue was dissolved in chloroform (1.5 ml) and washed with water (2 x 1.5 ml). The organic phase was evaporated in vacuo. TLC analysis (chloroform / methanol / water 13: 5: 0.8) analyzed single ninhydrin positive drop, Rf = 0.6; The structure was confirmed by NMR.
[531] c) Synthesis of Mal-PEG _2000- DSPE (3-maleimidopropionate poly (ethylene glycol) distearoylphosphatidyl-ethanolamine)
[532] A solution of N-succinimidyl-3-maleimidopropionate (5.6 mg, 0.018 mmol) in tetrahydrofuran (0.2 ml) was added to tetrahydrofuran (1 ml) and 0.1 M sodium phosphate buffer (pH 7.5, 2 ml). ) Was added to H ₂ N-PEG ₂₀₀₀ -DSPE (65 mg, 0.012 mmol). The mixture was warmed to 30 ° C and the reaction was complete by TLC and then the solvent was removed in vacuo. The title material was purified on flash silica column using 80:20 chloroform: methanol as eluent. The structure of the pure product was confirmed by NMR and mass spectroscopy.
[533] d) Process for preparing gas-filled microbubbles of DSPS 'doped' with PE-PEG _2000- Mal
[534] DSPS (4.5 mg) and PE-PEG _2000- Mal (0.5 mg) from (c) above were weighed into clean vials and 1 ml of 1.4% propylene glycol / 2.4% glycerol solution was added. The mixture was warmed to 80 ° C. for 5 minutes and filtered through a 4.5 mm filter. The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and the resulting microbubbles were washed three times with distilled water.
[535] e) process for preparing fluorescein-labeled trypsin
[536] To 5 mg trypsin in PBS (1 ml) was added 0.2 ml of a DMSO solution containing 1 mg of Fluorescein-NHS. The mixture was stirred for 45 minutes at room temperature. The Sephadex 200 column was then charged with the modified protein mixture and the product eluted using PBS at a flow rate of 1 ml / min. Protein fractions (5 ml) were collected and stored at 4 ° C.
[537] f) methods of preparing thiolated, fluorescein-labeled trypsin
[538] To the protein fraction from (e) 1 mg of the traut reagent was added and the mixture was stirred for an additional hour at room temperature. Then 4 ml of the trout-modified product was charged to a Sephadex 200 column and the product was eluted with PBS. The protein fractions containing the maximum fluorescence intensity were collected in a total volume of 6 ml.
[539] g) Binding of microbubbles with thiolated, fluorescein-labeled trypsin
[540] Microbubbles from (d) were incubated on a roller table in 1 ml of the protein solution from (f) above. Binding was performed for 10 minutes at pH 7.3-7.8 before centrifugation and sublimate removal. This process was repeated three more times and the bubbles were washed four times with water to remove unbound protein.
[541] D. Bubbles contained active enzymes as demonstrated by cleavage of Arg-pNA derivatives in PBS.
[542] Analysis of bubbles by E. Coulter counter and measurement of echo was performed.
[543] The bubble was pressure stable.
[544] FEK-022--015 Total concentration0.83 Diameter 1-3 mm40 Diameter 3-5 mm28 5-7 mm in diameter13 Frequency of Maximum Attenuation3.3 2. Attenuation at Mhz4.9 Attenuation at 3.5 Mhz7.8 Attenuation at 5.0 Mhz7.2
[545] FIG. 2 shows flow cytometry data showing comparison with negative control bubbles (left curve). FIG. 98% of the bubbles were counted by fluorescence.
[546] Example 51 Gas-Filled Microbubbles Including DSPS and Capryl-Containing Molecules for Diagnostic and Therapeutic Uses
[547] a) Synthesis of Captopril Functionalized Lipopeptides
[548]
[549] The construct was synthesized by a manual 'bubble' method starting with Fmoc-protected link amide MBHA resin on a 0.125 mmol scale. Coupling was performed using standard TBTU / HOBt / DIEA protocols. Bromoacetic acid was coupled through the side chain of Lys as symmetric anhydride using DIC preactivity. Captopril dissolved in DMF was introduced into the solid phase using DBU as the base. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT, 5% H ₂ O and 5% ethyl methyl sulfide. 10 mg of crude was purified over 60 minutes by preparative HPLC using a gradient of 70-100% B at 10 mL / min flow rate (A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile). After lyophilization 2 mg of pure material was obtained (analytical HPLC, gradient 70-100% B, 20 min, where A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile, flow rate 1 ml / min, detection— UV 214 nm-product residence time 26 minutes). Further characterization was performed using MALDI mass spectroscopy to yield M + H estimate 1265.
[550] b) Process for preparing gas-filled microbubbles comprising DSPS and captopril containing compounds
[551] 1.0 ml of 1.4% propylene glycol / 2.4% glycerol solution was added to a mixture of DSPS (4.5 mg) and product from (a) (0.5 mg) in a vial. The mixture was sonicated for 5 minutes and warmed to 80 ° C. for 5 minutes (shaking the vial while warming). The vial was then cooled and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and the resulting microbubbles were washed well with deionized water. No compound from (a) was detected in the final wash solution using MALDI mass spectroscopy. The mixing of the captopril-containing lipopeptides into the microbubbles was confirmed by MALDI-MS as follows: About 50 μl of microbubbles were transferred to a clean vial containing about 100 μl of 90% methanol. This mixture was sonicated for 30 seconds and analyzed by MALDI mass spectrometry to yield an M + H peak corresponding to the lipopeptides from (a).
[552] Example 52 Gas-Filled Microbubbles Including Vectors Having Affinity for DSPS and Adrenergic Receptors for Diagnostic and Therapeutic Uses
[553] a) Synthesis of Protected Athenol Derivatives Suitable for Solid Phase Coupling
[554] i) Synthesis of Methyl 4-[(2,3-epoxy) propoxy] -phenylacetate
[555] A mixture of methyl 4-hydroxyphenylacetate (4.98 g, 0.030 mol), epichlorohydrin (23.5 ml, 0.30 mol) and pyridine (121 μl, 1.5 mmol) was stirred at 85 ° C. for 2 hours. The reaction mixture was cooled and excess epichlorohydrin was evaporated (rotary evaporation). The residue was dissolved in ethyl acetate, washed with brine and dried (sodium sulfate). This solution was filtered and concentrated. The concentrated residue was chromatographed (silica, hexanes / ethyl acetate 7: 3) to give 2.25 g (34%) of a colorless oil. ¹ H (300 MHz) and ¹³ C NMR (75 MHz) spectra were shown according to the structure.
[556] ii) Synthesis of methyl 4- [2-hydroxy-3-[(1-methylethyl) -amino] propoxy] phenyl acetate
[557] A mixture of methyl 4-[(2,3-epoxy) propoxy] phenylacetate (2.00 g, 9.00 mmol), isopropylamine (23 ml, 0.27 mol) and water (1.35 ml, 74.7 mmol) was stirred overnight at room temperature It was. The reaction mixture was concentrated (rotary evaporation) and the oily residue was dissolved in chloroform and dried (sodium sulfate). Filtration and concentration yielded a quantitative yield of a yellow oil which was used without further purification in the next step. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[558] iii) Synthesis of 4- [2-hydroxy-3-[(1-methylethyl) -amino] propoxy] phenylacetic acid hydrochloride
[559] A solution of methyl 4- [2-hydroxy-3-[(1-methylethyl) -amino] propoxy] phenylacetate (563 mg, 2.00 mmol) in 6M hydrochloric acid (15 ml) was heated at 100 ° C. for 4 hours. It was. The reaction mixture was concentrated (rotary evaporation) and the residue was dissolved in water and lyophilized. Depending on the structure, ¹ H and ¹³ C NMR spectra were produced, and MALDI mass spectroscopy yielded M + H at 268 as expected.
[560] iv) Synthesis of N-Boc-4- [2-hydroxy-3-[(1-methylethyl) -amino] propoxy] phenylacetic acid
[561] A solution of 4- [2-hydroxy-3-[(1-methylethyl) -amino] propoxy] phenylacetic acid hydrochloride (2.0 mmol) in water (2 ml) was added water / dioxane (2: 1, 15 to a solution of sodium bicarbonate (0.60 g, 7.2 mmol) in ml). A solution of di-tert-butyl dicarbonate (0.48 g, 2.2 mmol) in dioxane (5 ml) was added. The reaction process was monitored by TLC analysis (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5) and a portion of the di-tert-butyl dicarbonate was added until conversion was complete. The reaction mixture was poured into water saturated with potassium hydrogen sulfate and the organics were extracted in ethyl acetate. The organic phase was washed with water and brine, dried (sodium sulfate) and filtered to give 0.6 g of crude material. The product was purified by chromatography (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5). The solution was concentrated and the residue was dissolved in glacial acetic acid and lyophilized. Yield 415 mg (56%), white solid. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[562] b) Synthesis of Lipopeptides Functionalized with Athenol
[563]
[564] The construct was synthesized by the manual bubbler method starting with Fmoc-protected link amide MBHA resin on 0.125 mmol scale using the compound from (a). Coupling was performed using standard TBTU / HOBt / DIEA protocols. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT and 5% water. Crude was precipitated from ether and purified liquid chromatography over 60 minutes using a gradient of 70-100% B at 10 mL / min flow rate (A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile). Purified. 38 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, 20 min, where A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile, flow rate 1 ml / min, detection- UV 214 nm-product residence time 25 minutes). Further characterization was performed using MALDI mass spectroscopy (ACH matrix) to yield M + H 1258, expected 1257.
[565] c) Process for preparing gas-filled microbubbles comprising DSPS and athenol containing lipopeptides
[566] A solution of 1.4% propylene glycol / 2.4% glycerol (1.0 ml) was added to the mixture of DSPS (4.5 mg) and product from (b) (0.5 mg) in a vial. The mixture was sonicated for 5 minutes and heated to 80 ° C. for 5 minutes (shaking the vial while warming) and then cooled. The upper space was flushed with perfluorobutane gas and the vial was shaken for 45 seconds in a cap-mixer and then the components were washed well with deionized water. No compound from (b) was detected in the final wash solution using MALDI mass spectroscopy. Mixing of the athenol-containing lipopeptides into the microbubbles was confirmed by MALDI-MS as follows: About 50 μl of microbubbles were transferred to a clean vial containing about 100 μl of 90% methanol. This mixture was sonicated for 30 seconds and analyzed by MALDI-MS (ACH-matrix) to yield an M + H peak (1259) corresponding to the lipopeptide from (b).
[567] d) in vitro analysis
[568] This microbubble was tested in an in vitro assay as described in Example 21. Gradual accumulation of microbubbles bound to the cells was observed.
[569] Example 53 Gas-Filled Microbubbles Including Heparin Sulfate-Binding Peptides (KRKR) and Fibronectin Peptides (WOPPRARI) for DSPS and Targets and Lipopeptides Containing Athenol for Therapeutic Uses
[570] a) Synthesis of lipopeptides consisting of heparin sulfate-binding peptide (KRKR) and fibronectin peptide (WOPPRARI)
[571]
[572] The lipopeptides were synthesized on an ABI 433A automated peptide synthesizer starting with Fmoc-Ile-Wang resin on a 0.1 mmole scale using a 1 mmole amino acid cartridge. All amino acids and palmitic acid were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT, 5% anisol and 5% H ₂ O to afford 150 mg of crude product. 40 mg of crude material was purified over 40 minutes by preparative HPLC using a gradient of 70-100% B (A = 0.1% TFA / water and B = MeOH) at 9 mL / min flow rate. 16 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, where B = MeOH, A = 0.01% TFA / water: detection-UV 260 and fluorescence, Ex280, Em350-product residence time = 19.44 minute). Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 2198, found 2199.
[573] b) synthesis of protected athenol derivatives suitable for solid phase coupling
[574] i) Synthesis of Methyl 4-[(2,3-epoxy) propoxy] phenyl acetate
[575] A mixture of methyl 4-hydroxyphenylacetate (4.98 g, 0.030 mol), epichlorohydrin (23.5 ml, 0.30 mol) and pyridine (121 μl, 1.5 mmol) was stirred at 85 ° C. for 2 hours. The reaction mixture was cooled down and excess epichlorohydrin was distilled off (rotary evaporation). The residue was dissolved in ethyl acetate, washed with brine and dried (NaSO ₄ ). The solution was filtered and concentrated. The concentrated residue was chromatographed (silica, hexane / ethyl acetate 7: 3) to give 2.25 g (34%) of a colorless oil. The structures are shown in ¹ H (300 MHz) and ¹³ C NMR (75 MHz) spectra.
[576] ii) Synthesis of methyl 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetate
[577] A mixture of methyl 4-[(2,3-epoxy) propoxy] phenylacetate (2.00 g, 9.00 mmol), isopropylamine (23 ml, 0.27 mol) and water (1.35 ml, 74.7 mmol) was stirred overnight at room temperature It was. The reaction mixture was concentrated (rotary evaporation) and the oily residue was dissolved in chloroform and dried (Na ₂ SO ₄ ). Filtration and concentration gave a yellow oil in quantitative yield, which was used in the next step without further purification. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[578] iii) Synthesis of 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid hydrochloride
[579] A solution of methyl 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetate (563 mg, 2.00 mmol) in 6 M hydrochloric acid (15 ml) was heated at 100 ° C. for 4 hours. It was. The reaction mixture was concentrated (rotary evaporation) and the residue was dissolved in water and lyophilized. The structures were confirmed by ¹ H and ¹³ C NMR spectra and the M + H estimate was 268 by MALDI mass spectroscopy.
[580] iv) Synthesis of N-Boc-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid
[581] A solution of 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid hydrochloride (2.0 mmol) in water (2.0 ml) was added water / dioxane (2: 1, 15 ml). ) Solution of sodium bicarbonate (0.60 g, 7.2 mmol). A solution of di-tert-butyl dicarbonate (0.48 g, 2.2 mmol) in dioxane (5 ml) was added. The progress of the reaction was monitored by TLC analysis (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5) and some di-tert-butyl dicarbonate was added until the conversion was complete. The reaction mixture was poured into water saturated with potassium hydrogen sulfate and the organics extracted with ethyl acetate. The organic phase was washed with water and brine, dried (Na ₂ SO ₄ ) and filtered to give 0.6 g of crude material. The product was purified by chromatography (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5). The solution was concentrated and the residue was dissolved in glacial acetic acid and lyophilized. Yield 415 mg (56%), white solid. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[582] c) Synthesis of Lipopeptides Functionalized with Athenol
[583]
[584] The constructs were synthesized by a manual bubbler method starting with Fmoc-protected link amide MBHA resin on 0.125 mmol scale using suitable amino acids, palmitic acid and compounds from (a). Coupling was performed using standard TBTU / HOBt / DIEA protocols. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT and 5% water. Crude was precipitated from ether and purified liquid chromatography over 60 minutes using a gradient of 70-100% B at 10 mL / min flow rate (A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile). Purified. 38 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, 20 min, where A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile, flow rate 1 ml / min, detection- UV 214 nm-product residence time 25 minutes). Further characterization was performed using MALDI mass spectroscopy (ACH matrix) to yield M + H 1258, expected 1257.
[585] d) Process for preparing gas-filled microbubbles comprising DSPS and heparin sulfate-binding peptide (KRKR), fibronectin peptide (WOPPRARI) and athenol containing lipopeptides
[586] A solution of 1.4% propylene glycol / 2.4% glycerol (1.0 ml) was added to the mixture of DSPS (5.0 mg), product from (a) (0.5 mg) and product from (c) in a vial. The mixture was sonicated for 5 minutes and then heated to 80 ° C. for 5 minutes (shaking the vial while warming). This solution was filtered and cooled. The upper space was flushed with perfluorobutane gas and the vial was shaken for 45 seconds in a cap-mixer and then the contents were washed well with deionized water. Mixing of the athenol-containing lipopeptides into the microbubbles was confirmed by MALDI-MS as follows: About 50 μl of microbubbles were transferred to a clean vial containing about 100 μl of 90% methanol. This mixture was sonicated for 30 seconds and analyzed by MALDI-MS (ACH-matrix) to yield M + H peaks (2202 and 1259) corresponding to lipopeptides (a) and lipopeptides (c), respectively.
[587] d) in vitro analysis
[588] This microbubble was tested in an in vitro assay as described in Example 21. Gradual accumulation of microbubbles bound to the cells was observed.
[589] Example 54 Gas-Filled Microbubbles Comprising DSPS and Lipophilic Derivatives of Athenol with Affinity to Adrenergic Receptors for Diagnostic and Therapeutic Uses
[590] a) N-hexadecyl-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetamide
[591] i) Synthesis of Methyl 4-[(2,3-epoxy) propoxy] -phenylacetate
[592] A mixture of methyl 4-hydroxyphenylacetate (4.98 g, 0.030 mol), epichlorohydrin (23.5 ml, 0.30 mol) and pyridine (121 μl, 1.5 mmol) was stirred at 85 ° C. for 2 hours. The reaction mixture was cooled and excess epichlorohydrin was evaporated (rotary evaporation). The residue was dissolved in ethyl acetate, washed with brine and dried (sodium sulfate). This solution was filtered and concentrated. The concentrated residue was chromatographed (silica, hexanes / ethyl acetate 7: 3) to give 2.25 g (34%) of a colorless oil. ¹ H (300 MHz) and ¹³ C NMR (75 MHz) spectra were shown according to the structure.
[593] ii) Synthesis of methyl 4- [2-hydroxy-3-[(1-methylethyl) -amino] propoxy] phenyl acetate
[594] A mixture of methyl 4-[(2,3-epoxy) propoxy] phenylacetate (2.00 g, 9.00 mmol), isopropylamine (23 ml, 0.27 mol) and water (1.35 ml, 74.7 mmol) was stirred overnight at room temperature It was. The reaction mixture was concentrated (rotary evaporation) and the oily residue was dissolved in chloroform and dried (sodium sulfate). Filtration and concentration yielded a quantitative yield of a yellow oil which was used without further purification in the next step. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[595] iii) Synthesis of 4- [2-hydroxy-3-[(1-methylethyl) -amino] propoxy] phenylacetic acid hydrochloride
[596] A solution of methyl 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetate (563 mg, 2.00 mmol) in 6M hydrochloric acid (15 ml) was heated at 100 ° C. for 4 hours. . The reaction mixture was concentrated (rotary evaporation) and the residue was dissolved in water and lyophilized. Depending on the structure, ¹ H and ¹³ C NMR spectra were produced, and MALDI mass spectroscopy yielded M + H at 268 as expected.
[597] iv) Synthesis of N-Boc-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid
[598] A solution of 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid hydrochloride (2.0 mmol) in water (2 ml) was added water / dioxane (2: 1, 15 ml). ) To a solution of sodium bicarbonate (0.60 g, 7.2 mmol). A solution of di-tert-butyl dicarbonate (0.48 g, 2.2 mmol) in dioxane (5 ml) was added. The reaction process was monitored by TLC analysis (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5) and a portion of the di-tert-butyl dicarbonate was added until conversion was complete. The reaction mixture was poured into water saturated with potassium hydrogen sulfate and the organics were extracted in ethyl acetate. The organic phase was washed with water and brine, dried (sodium sulfate) and filtered to give 0.6 g of crude material. The product was purified by chromatography (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5). The solution was concentrated and the residue was dissolved in glacial acetic acid and lyophilized. Yield 415 mg (56%), white solid. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[599] v) Synthesis of N'-Boc, N-hexadecyl-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetamide
[600] N-Boc-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid (92 mg, 0.25 mmol) and hexadecylamine (60 mg, 0.25 in DMF (5 ml) Mmol) was cooled to 0 ° C. HOBt (39 mg, 0.25 mmol) and N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (aqueous carbodiimide) (48 mg, 0.25 mmol) were added. The reaction mixture was stirred at 0 ° C. for 1 hour and at room temperature overnight. The reaction mixture was poured into water (25 ml) containing sodium bicarbonate (2.5 g) and sodium chloride (4.0 g). The precipitated material was filtered off, washed with water and dissolved in chloroform. The chloroform phase was washed with 5% sodium carbonate and water and dried (sodium sulfate). The solution was filtered and concentrated to yield 150 mg of off-white crude. The product was purified by chromatography (silica, chloroform / methanol 95: 5) to give 118 mg (80%) of a white substance. The structure was confirmed by ¹ H (500 MHz) and ¹³ C (125 MHz) NMR. The product was further characterized by MALDI mass spectroscopy to give an M + Na peak at 614.
[601] vi) Synthesis of N-hexadecyl-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetamide
[602] To a solution of N'-Boc-N-hexadecyl-4- [2-hydroxy-3-[(1-methyl-ethyl) amino] propoxy] phenylacetamide (10 mg) in dichloromethane (9 ml) Trifluoroacetic acid (1 ml) was added. The reaction mixture was stirred at rt for 2 h. TLC (silica, chloroform / methanol 95: 5) showed complete conversion of starting material. The solvent was evaporated and the residue was dissolved in water / acetonitrile and lyophilized to give quantitative yield as a solid material. The structure was confirmed by ¹ H (500 MHz) and ¹³ C (125 MHz) NMR analysis and further characterized by MALDI mass spectroscopy to yield M + H (492) and M + Na (514).
[603] b) of gas-filled microbubbles comprising DSPS and N-hexadecyl-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetamide for diagnostic and therapeutic uses Manufacturing method
[604] A solution of 1.4% propylene glycol / 2.4% glycerol (1.0 ml) was added to DSPS (4.5 mg) and N-hexadecyl-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] in a vial. To a mixture of phenylacetamide (0.5 mg). The mixture was sonicated for 5 minutes and heated to 80 ° C. for 5 minutes (shaking the vial while warming). The solution was filtered and cooled. The upper space was flushed with perfluorobutane gas and the vial was shaken for 45 seconds in a cap-mixer and then the contents were washed well with deionized water. Mixing of the compound from (a) into the microbubbles was confirmed by MALDI-MS as follows: About 50 μl of microbubbles were transferred to a clean vial containing about 100 μl of 90% methanol. This mixture was sonicated for 30 seconds and analyzed by MALDI-MS to M + H corresponding to N-hexadecyl-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetamide Peak (492) was obtained.
[605] Example 55 Gas-Filled Microbubbles Encapsulated with DSPS and Folic Acid-Containing Compounds for Diagnostic Uses
[606]
[607] The construct was synthesized by a manual bubbler method starting with Fmoc-protected link amide MBHA resin on 0.125 mmol scale using suitable amino acids, palmitic acid and folic acid. Coupling was performed using standard TBTU / HOBt / DIEA protocols. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT and 5% water. The crude material was precipitated from ether and MALDI mass spectrometry gave an M + H peak corresponding to the structure at 1435 (expected 1430). This material was further characterized by analytical HPLC (gradient of 70 to 100% B, 20 min, A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile, flow rate 1.0 mL / min) retention at UV 368 nm A product peak detected with time 27 minutes was obtained.
[608] b) Process for preparing gas-filled microbubbles comprising DSPS and folic acid-containing lipopeptides
[609] A solution of 1.4% propylene glycol / 2.4% glycerol (1.0 ml) was added to a mixture of DSPS (4.5 mg) and product from (a) (0.5 mg) in a vial. The mixture was sonicated for 5 minutes and then heated to 80 ° C. for 5 minutes (shaking the vial while warming). This solution was filtered and cooled. The upper space was flushed with perfluorobutane gas and the vial was shaken for 45 seconds in a cap-mixer and then the contents were washed well with deionized water. Mixing of the compound from (a) into the microbubbles was confirmed by MALDI-MS as follows: About 50 μl of microbubbles were transferred to a clean vial containing about 100 μl of 90% methanol. This mixture was sonicated for 30 seconds and analyzed by MALDI-MS (ACH-matrix) to yield an M + H peak 1238 corresponding to the structure from (a).
[610] c) in vitro analysis
[611] This microbubble was tested in an in vitro assay as described in Example 21. Gradual accumulation of microbubbles bound to the cells was observed.
[612] Example 56 Gas-Filled Microbubbles Including Cholesteryl Esters of DSPS and Chlorambucil for Diagnostic and Therapeutic Uses
[613] a) Synthesis of Cholesteryl 4- [4- [bis (2-chloroethyl) amino] phenyl] butanoate
[614] DIC (170 μl, 1.10 mmol) was added to a solution of chlorambucil (669 mg, 2.20 mmol) in anhydrous dichloromethane (15 ml). This mixture was stirred at rt for 0.5 h and added to a solution of cholesterol (387 mg, 1.00 mmol) and DMAP (122 mg, 1.00 mmol) in dichloromethane (10 ml). The reaction mixture was stirred overnight and poured onto 5% sodium bicarbonate. The phases were separated and the organic phase was washed with brine and dried (magnesium sulfate). The solution was filtered and concentrated and the product was purified by column chromatography (silica, chloroform) to give 560 mg (83%) of a colorless oil. The product was characterized by MALDI mass spectroscopy to yield M + H at 674 as expected. Further characterizations were performed using ¹ H (500 MHz) and ¹³ C (125 MHz) NMR analysis to obtain spectra according to structure.
[615] b) a process for preparing a gas-filled microbubble comprising a cholesteryl ester of chlorambucil for DSPS and diagnostic and / or therapeutic use
[616] A solution of 1.4% propylene glycol / 2.4% glycerol (1.0 ml) was added to a mixture of DSPS (4.5 mg) and product from (a) (0.5 mg) in a vial. The mixture was sonicated for 5 minutes and then heated to 80 ° C. for 5 minutes (shaking the vial while warming) and cooled. The upper space was flushed with perfluorobutane gas and the vial was shaken for 45 seconds in a cap-mixer and then the contents were washed well with deionized water. MALDI mass spectrometry showed that no compound from (a) was detected in the final wash solution. The mixing of chlorambucil cholesteryl esters into the microbubbles was confirmed by MALDI-MS as follows: About 50 μl of microbubbles were transferred to a clean vial containing about 100 μl of 90% methanol. This mixture was sonicated for 30 seconds and analyzed by MALDI-MS to obtain an M + H peak 668 corresponding to the structure from (a).
[617] Example 57 Gas-Filled Microbubbles Including Lipopeptides Containing DSPS and Athenol and Cholesteryl Derivatives of Chlorambucil for Diagnostic and Therapeutic Uses
[618] a) Synthesis of Protected Athenol Derivatives Suitable for Solid Phase Coupling
[619] i) Synthesis of Methyl 4-[(2,3-epoxy) propoxy] -phenylacetate
[620] A mixture of methyl 4-hydroxyphenylacetate (4.98 g, 0.030 mol), epichlorohydrin (23.5 ml, 0.30 mol) and pyridine (121 μl, 1.5 mmol) was stirred at 85 ° C. for 2 hours. The reaction mixture was cooled and excess epichlorohydrin was evaporated (rotary evaporation). The residue was dissolved in ethyl acetate, washed with brine and dried (sodium sulfate). This solution was filtered and concentrated. The concentrated residue was chromatographed (silica, hexanes / ethyl acetate 7: 3) to give 2.25 g (34%) of a colorless oil. ¹ H (300 MHz) and ¹³ C NMR (75 MHz) spectra were shown according to the structure.
[621] ii) Synthesis of methyl 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetate
[622] A mixture of methyl 4-[(2,3-epoxy) propoxy] phenylacetate (2.00 g, 9.00 mmol), isopropylamine (23 ml, 0.27 mol) and water (1.35 ml, 74.7 mmol) was stirred overnight at room temperature It was. The reaction mixture was concentrated (rotary evaporation) and the oily residue was dissolved in chloroform and dried (sodium sulfate). Filtration and concentration yielded a quantitative yield of a yellow oil which was used without further purification in the next step. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[623] iii) Synthesis of 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid hydrochloride
[624] A solution of methyl 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetate (563 mg, 2.00 mmol) in 6M hydrochloric acid (15 ml) was heated at 100 ° C. for 4 hours. . The reaction mixture was concentrated (rotary evaporation) and the residue was dissolved in water and lyophilized. Depending on the structure, ¹ H and ¹³ C NMR spectra were produced, and MALDI mass spectroscopy yielded M + H at 268 as expected.
[625] iv) Synthesis of N-Boc-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid
[626] A solution of 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid hydrochloride (2.0 mmol) in water (2 ml) was added water / dioxane (2: 1, 15 ml). ) To a solution of sodium bicarbonate (0.60 g, 7.2 mmol). A solution of di-tert-butyl dicarbonate (0.48 g, 2.2 mmol) in dioxane (5 ml) was added. The reaction process was monitored by TLC analysis (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5) and a portion of the di-tert-butyl dicarbonate was added until conversion was complete. The reaction mixture was poured into water saturated with potassium hydrogen sulfate and the organics were extracted in ethyl acetate. The organic phase was washed with water and brine, dried (sodium sulfate) and filtered to give 0.6 g of crude material. The product was purified by chromatography (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5). The solution was concentrated and the residue was dissolved in glacial acetic acid and lyophilized. Yield 415 mg (56%), white solid. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[627] b) Synthesis of Lipopeptides Functionalized with Athenol
[628]
[629] The constructs were synthesized by a manual bubbler method starting with Fmoc-protected link amide MBHA resin on 0.125 mmol scale using suitable amino acids, palmitic acid and compounds from (a). Coupling was performed using standard TBTU / HOBt / DIEA protocols. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT and 5% water. Crude was precipitated from ether and purified liquid chromatography over 60 minutes using a gradient of 70-100% B at 10 mL / min flow rate (A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile). Purified. 38 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, 20 min, where A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile, flow rate 1 ml / min, detection- UV 214 nm-product residence time 25 minutes). Further characterization was performed using MALDI mass spectroscopy (ACH matrix) to yield M + H 1258, expected 1257.
[630] c) Synthesis of cholesteryl 4- [4- [bis (2-chloroethyl) amino] phenyl] butanoate
[631] DIC (170 μl, 1.10 mmol) was added to a solution of chlorambucil (669 mg, 2.20 mmol) in anhydrous dichloromethane (15 ml). This mixture was stirred at rt for 0.5 h and added to a solution of cholesterol (387 mg, 1.00 mmol) and DMAP (122 mg, 1.00 mmol) in dichloromethane (10 ml). The reaction mixture was stirred overnight and poured onto 5% sodium bicarbonate. The phases were separated and the organic phase was washed with brine and dried (magnesium sulfate). The solution was filtered and concentrated and the product was purified by column chromatography (silica, chloroform) to give 560 mg (83%) of a colorless oil. The product was characterized by MALDI mass spectroscopy to yield M + H at 674 as expected. Further characterizations were performed using ¹ H (500 MHz) and ¹³ C (125 MHz) NMR analysis to obtain spectra according to structure.
[632] d) Process for preparing gas-filled microbubbles comprising lipopeptides containing DSPS and cholesteryl esters of athenol and chlorambucil
[633] A solution of 1.4% propylene glycol / 2.4% glycerol (1.0 ml) was added to a mixture of DSPS (5.0 mg), product from (b) (0.5 mg) and product from (c) (0.5 mg) in a vial. The mixture was sonicated for 5 minutes and then warmed to 80 ° C. for 5 minutes (shaking the vial while warming). This solution was filtered and cooled. The upper space was flushed with perfluorobutane gas and the vial was shaken for 45 seconds in a cap-mixer and then the contents were washed well with deionized water. The mixing of compounds (b) and (c) into the microbubbles was confirmed by MALDI-MS as follows: About 50 μl of microbubbles were transferred to a clean vial containing about 100 μl of 90% methanol. This mixture was sonicated for 30 seconds and analyzed by MALDI-MS (ACH-matrix) to yield M + H peaks corresponding to lipopeptides (b) and cholesteryl esters (c).
[634] e) in vitro analysis
[635] This microbubble was tested in an in vitro assay as described in Example 21. Gradual accumulation of microbubbles bound to the cells was observed.
[636] Example 58 Gas-Filled Microbubbles Comprising Lipopeptides Containing Lipophilic Thiol Esters of DSPS and Athenol for Cell Targeting and Caprolyl for Therapeutic Uses
[637] a) Synthesis of Protected Athenol Derivatives Suitable for Solid Phase Coupling
[638] i) Synthesis of Methyl 4-[(2,3-epoxy) propoxy] -phenylacetate
[639] A mixture of methyl 4-hydroxyphenylacetate (4.98 g, 0.030 mol), epichlorohydrin (23.5 ml, 0.30 mol) and pyridine (121 μl, 1.5 mmol) was stirred at 85 ° C. for 2 hours. The reaction mixture was cooled and excess epichlorohydrin was evaporated (rotary evaporation). The residue was dissolved in ethyl acetate, washed with brine and dried (sodium sulfate). This solution was filtered and concentrated. The concentrated residue was chromatographed (silica, hexanes / ethyl acetate 7: 3) to give 2.25 g (34%) of a colorless oil. ¹ H (300 MHz) and ¹³ C NMR (75 MHz) spectra were shown according to the structure.
[640] ii) Synthesis of methyl 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetate
[641] A mixture of methyl 4-[(2,3-epoxy) propoxy] phenylacetate (2.00 g, 9.00 mmol), isopropylamine (23 ml, 0.27 mol) and water (1.35 ml, 74.7 mmol) was stirred overnight at room temperature It was. The reaction mixture was concentrated (rotary evaporation) and the oily residue was dissolved in chloroform and dried (sodium sulfate). Filtration and concentration yielded a quantitative yield of a yellow oil which was used without further purification in the next step. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[642] iii) Synthesis of 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid hydrochloride
[643] A solution of methyl 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetate (563 mg, 2.00 mmol) in 6M hydrochloric acid (15 ml) was heated at 100 ° C. for 4 hours. . The reaction mixture was concentrated (rotary evaporation) and the residue was dissolved in water and lyophilized. Depending on the structure, ¹ H and ¹³ C NMR spectra were produced, and MALDI mass spectroscopy yielded M + H at 268 as expected.
[644] iv) Synthesis of N-Boc-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid
[645] A solution of 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid hydrochloride (2.0 mmol) in water (2 ml) was added water / dioxane (2: 1, 15 ml). ) To a solution of sodium bicarbonate (0.60 g, 7.2 mmol). A solution of di-tert-butyl dicarbonate (0.48 g, 2.2 mmol) in dioxane (5 ml) was added. The reaction process was monitored by TLC analysis (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5) and a portion of the di-tert-butyl dicarbonate was added until conversion was complete. The reaction mixture was poured into water saturated with potassium hydrogen sulfate and the organics were extracted in ethyl acetate. The organic phase was washed with water and brine, dried (sodium sulfate) and filtered to give 0.6 g of crude material. The product was purified by chromatography (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5). The solution was concentrated and the residue was dissolved in glacial acetic acid and lyophilized. Yield 415 mg (56%), white solid. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[646] b) Synthesis of Lipopeptides Functionalized with Athenol
[647]
[648] The constructs were synthesized by a manual bubbler method starting with Fmoc-protected link amide MBHA resin on 0.125 mmol scale using suitable amino acids, palmitic acid and compounds from (a). Coupling was performed using standard TBTU / HOBt / DIEA protocols. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT and 5% water. Crude was precipitated from ether and purified liquid chromatography over 60 minutes using a gradient of 70-100% B at 10 mL / min flow rate (A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile). Purified. 38 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, 20 min, where A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile, flow rate 1 ml / min, detection- UV 214 nm-product residence time 25 minutes). Further characterization was performed using MALDI mass spectroscopy (ACH matrix) to yield M + H 1258, expected 1257.
[649] c) Synthesis of cholanic acid thiol esters of captopril
[650] A mixture of 5-β-cholanic acid (361 mg, 1.00 mmol) and DIC (77 μl, 0.50 mmol) in dichloromethane (5 ml) was stirred for 10 minutes and captopril (130 mg in dichloromethane (10 ml) , 0.600 mmol) and DBU (180 μl, 1.20 mmol). The reaction mixture was stirred overnight and poured into dilute hydrochloric acid. Chloroform (30 ml) was added. The phases were separated and the organic phase was washed with water and brine and dried (sodium sulfate). After lyophilization and concentration the crude material was chromatographed (silica, chloroform / methanol / acetic acid 95: 4: 1). The product was lyophilized from acetonitrile / water / ethanol mixture. Yield 137 mg (49%), off-white solid. The structure was confirmed by ¹ H (500 MHz) and ¹³ C (125 MHz) NMR spectroscopy. Further characterization was performed using MALDI mass spectroscopy to obtain M + Na peak in positive mode at m / z 584.
[651] d) Process for preparing gas-filled microbubbles comprising lipopeptides containing DSPS and lipophilic thiol esters of atenool for cell targeting and captopril for therapeutic use
[652] A solution of 1.4% propylene glycol / 2.4% glycerol (1.0 ml) was added to a mixture of DSPS (5.0 mg), product from (b) (0.5 mg) and product from (c) (0.5 mg) in a vial. The mixture was sonicated for 5 minutes and then heated to 80 ° C. for 5 minutes (shaking the vial while warming) and cooled. The upper space was flushed with perfluorobutane gas and the vial was shaken for 45 seconds in a cap-mixer and then the contents were washed well with deionized water. MALDI mass spectroscopy showed no compound from (b) and (c) in the final wash solution. The mixing of compounds (b) and (c) into the microbubbles was confirmed by MALDI-MS as follows: About 50 μl of microbubbles were transferred to a clean vial containing about 100 μl of 90% methanol. This mixture was sonicated for 30 seconds and analyzed by MALDI-MS (ACH-matrix) to yield peaks corresponding to the structures from (b) and (c), respectively.
[653] e) in vitro analysis
[654] This microbubble was tested in an in vitro assay as described in Example 21. Gradual accumulation of microbubbles bound to the cells was observed.
[655] Example 59 Gas-Filled Microbubbles Containing Phosphatidylserine and Biotinamide-PEG-β-Ala-Cholesterol and Cholesteryl Esters of Chlorambucil for Diagnostic and Therapeutic Uses
[656] a) Synthesis of Cholesteryl N-Boc-β-Alanate
[657] DIC (510 μl) was added to a solution of Boc-β-Ala-OH (1.25 g, 6.60 mmol) in dichloromethane (15 ml) under an inert atmosphere. The reaction mixture was stirred for 30 minutes and transferred to a flask containing a solution of cholesterol (1.16 g, 3.00 mmol) and DMAP (367 mg, 3.00 mmol) in dichloromethane (15 ml). The reaction mixture was stirred for 2 hours and poured into aqueous potassium hydrogen sulfate solution. The phases were separated and the aqueous phase was extracted with chloroform. The combined organic phases were washed with aqueous sodium hydrogen sulfate solution and water and dried (magnesium sulfate). After filtration and concentration, the crude product was chromatographed (silica, chloroform / methanol 99: 1) to give 1.63 g (97%) of a white solid. The structure was identified as ¹ H (500 MHz).
[658] b) Synthesis of Cholesteryl β-alanine Hydrochloride
[659] A solution of compound (279 mg, 0.500 mmol) from (a) in 1M hydrochloric acid (5 ml) in 1,4-dioxane was stirred at room temperature for 4 hours. The reaction mixture was concentrated to yield quantitative yield of cholesteryl β-alanine hydrochloride. This structure was confirmed by 1 H NMR (500 MHz) analysis and MALDI mass spectroscopy to obtain an M + Na peak at 482 (expected 481).
[660] c) Synthesis of Biotin-PEG _3400- β-Ala-Cholesterol
[661] Triethylamine (42 μl, 0.30 mmol) was added to a solution of cholesteryl β-alanine hydrochloride (15 mg, 0.03 mmol) in chloroform / methanol (2.6: 1, 3 ml). The mixture was stirred at room temperature for 10 minutes and a solution of biotin-PEG ₃₄₀₀ -NHS (100 mg, 0.03 mmol) in 1.4-dioxane (1 ml) was added dropwise. After stirring at room temperature for 3 hours, the mixture was evaporated to dryness and the residue was purified by flash chromatography to give 102 mg (89%) of white crystals. The structure was confirmed by MALDI-MS and NMR analysis.
[662] d) Synthesis of cholesteryl 4- [4- [bis (2-chloroethyl) amino] phenyl] butanoate
[663] DIC (170 μl, 1.10 mmol) was added to a solution of chloroambucil (669 mg, 2.20 mmol) in anhydrous dichloromethane (15 ml). The reaction mixture was stirred at rt for 0.5 h and added to a solution of cholesterol (387 mg, 1.00 mmol) and DMAP (122 mg, 1.00 mmol) in dichloromethane (10 ml). The reaction mixture was stirred overnight and poured into 5% sodium bicarbonate. The phases were separated and the organic phase was washed with brine and dried (magnesium sulfate). After the solution was filtered and concentrated, the product was column chromatography (silica, chloroform) to give 560 mg (83%) of a colorless oil. The structure was characterized by MALDI mass spectroscopy to yield M + H at 674 as expected. Further characterization was performed using ¹ H (500 MHz) and ¹³ C (125 MHz) analysis to identify the spectra according to the structure.
[664] e) method of making gas-filled microbubbles
[665] A solution of 1.4% propylene glycol / 2.4% glycerol (1.0 ml) was added to the mixture of DSPS (5.0 mg), product from (c) (0.5 mg) and product from (d) (0.5 mg) in a vial. The mixture was sonicated for 5 minutes and then heated to 80 ° C. for 5 minutes (shaking the vial while warming) and cooled. The upper space was flushed with perfluorobutane gas and the vial was shaken for 45 seconds in a cap-mixer and then the contents were washed well with deionized water. MALDI mass spectroscopy showed no compound from (c) and (d) in the final wash solution. The mixing of compounds (c) and (d) into the microbubbles was confirmed by MALDI-MS as follows: About 50 μl of microbubbles were transferred to a clean vial containing about 100 μl of 90% methanol. This mixture was sonicated for 30 seconds and analyzed by MALDI-MS (ACH-matrix) to yield M + H peaks corresponding to the compounds from (c) and (d).
[666] Example 60 Gas-Filled Microbubbles Including Lipopeptides Containing DSPS and Derivatives of Vestatin for Diagnostic and Target Uses
[667] a) Synthesis of lipopeptides containing derivatives of bestatin
[668]
[669] The construct was synthesized by a manual bubbler method starting with Fmoc-protected link amide MBHA resin on a 0.125 mmol scale using suitable amino acids and palmitic acid. Coupling was performed using standard TBTU / HOBt / DIEA protocols. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT and 5% water. Crude was precipitated from ether and purified liquid chromatography over 60 minutes using a gradient of 70-100% B at 10 mL / min flow rate (A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile). Purified. 12 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, 20 min, where A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile, flow rate 1 ml / min, detection- UV 214 nm-product residence time 25 minutes). Further characterization was performed using MALDI mass spectroscopy (ACH matrix) to yield M + H 1315, expected 1314.
[670] b) Process for preparing gas-filled microbubbles comprising lipopeptides containing DSPS and derivatives of bestatin for diagnostic and / or therapeutic use
[671] A solution of 1.4% propylene glycol / 2.4% glycerol (1.0 ml) was added to a mixture of DSPS (4.5 mg) and product from (a) (0.5 mg) in a vial. The mixture was sonicated for 5 minutes and then heated to 80 ° C. for 5 minutes (shaking the vial while warming) and cooled. The upper space was flushed with perfluorobutane gas and the vial was shaken for 45 seconds in a cap-mixer and then the contents were washed well with deionized water. MALDI mass spectrometry showed that no compound from (b) was detected in the final wash solution. Mixing of the athenol-containing lipopeptides into the microbubbles was confirmed by MALDI-MS as follows: About 50 μl of microbubbles were transferred to a clean vial containing about 100 μl of 90% methanol. This mixture was sonicated for 30 seconds and analyzed by MALDI-MS to give the M + H peak (1320), the expected (1314), corresponding to the lipopeptides from (a).
[672] c) in vitro analysis
[673] This microbubble was tested in an in vitro assay as described in Example 21. Gradual accumulation of microbubbles bound to the cells was observed.
[674] Example 61 Gas-Filled Microbubbles Including DSPS and Chlorambucil-Containing Lipopeptides for Diagnostic and Therapeutic Uses
[675] a) Synthesis of Lipopeptides Containing Chlorambucil
[676]
[677] The construct was synthesized by a manual bubbler method starting with Fmoc-protected link amide MBHA resin on a 0.125 mmol scale using suitable amino acids and palmitic acid. Coupling was performed using standard TBTU / HOBt / DIEA protocols. Chlorambucil was coupled through the side chain of Lys as symmetric anhydride using DIC preactivity. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT, 5% water and 5% ethyl methyl sulfide. 10 mg of crude material was purified over 60 minutes using purified liquid chromatography using a gradient of 70-100% B at 10 mL / min flow rate (A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile). . 30 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, 20 min, where A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile, flow rate 1 ml / min, detection- UV 214 nm-product residence time 26.5 minutes). Further characterization was performed using MALDI mass spectroscopy to yield M + H 1295, expected 1294.
[678] b) Process for preparing gas-filled microbubbles comprising DSPS and lipopeptides containing chloroambucil for diagnostic and therapeutic uses
[679] A solution of 1.4% propylene glycol / 2.4% glycerol (1.0 ml) was added to a mixture of DSPS (4.5 mg) and product from (a) (0.5 mg) in a vial. The mixture was sonicated for 5 minutes and then heated to 80 ° C. for 5 minutes (shaking the vial while warming) and cooled. The upper space was flushed with perfluorobutane gas and the vial was shaken for 45 seconds in a cap-mixer and then the contents were washed well with deionized water. MALDI mass spectrometry showed that no compound from (a) was detected in the final wash solution. The mixing of chloroambucil-containing lipopeptides into the microbubbles was confirmed by MALDI-MS as follows: About 50 μl of microbubbles were transferred to a clean vial containing about 100 μl of 90% methanol. This mixture was sonicated for 30 seconds and analyzed by MALDI-MS (ACH-matrix) to yield M + H peak (1300), expectation (1294) and M + Na peak (1324), expectation (1317).
[680] c) in vitro analysis
[681] This microbubble was tested in an in vitro assay as described in Example 21. Gradual accumulation of microbubbles bound to the cells was observed.
[682] Example 62 Gas-Filled Microbubbles Comprising Lipopeptides Containing DSPS, Athenol and Lipophilic Derivatives of Caprolyl for Diagnostic and Therapeutic Applications
[683] a) Synthesis of Protected Athenol Derivatives Suitable for Solid Phase Coupling
[684] i) Synthesis of Methyl 4-[(2,3-epoxy) propoxy] -phenylacetate
[685] A mixture of methyl 4-hydroxyphenylacetate (4.98 g, 0.030 mol), epichlorohydrin (23.5 ml, 0.30 mol) and pyridine (121 μl, 1.5 mmol) was stirred at 85 ° C. for 2 hours. The reaction mixture was cooled and excess epichlorohydrin was evaporated (rotary evaporation). The residue was dissolved in ethyl acetate, washed with brine and dried (sodium sulfate). This solution was filtered and concentrated. The concentrated residue was chromatographed (silica, hexanes / ethyl acetate 7: 3) to give 2.25 g (34%) of a colorless oil. ¹ H (300 MHz) and ¹³ C NMR (75 MHz) spectra were shown according to the structure.
[686] ii) Synthesis of methyl 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetate
[687] A mixture of methyl 4-[(2,3-epoxy) propoxy] phenylacetate (2.00 g, 9.00 mmol), isopropylamine (23 ml, 0.27 mol) and water (1.35 ml, 74.7 mmol) was stirred overnight at room temperature It was. The reaction mixture was concentrated (rotary evaporation) and the oily residue was dissolved in chloroform and dried (sodium sulfate). Filtration and concentration yielded a quantitative yield of a yellow oil which was used without further purification in the next step. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[688] iii) Synthesis of 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid hydrochloride
[689] A solution of methyl 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetate (563 mg, 2.00 mmol) in 6M hydrochloric acid (15 ml) was heated at 100 ° C. for 4 hours. . The reaction mixture was concentrated (rotary evaporation) and the residue was dissolved in water and lyophilized. Depending on the structure, ¹ H and ¹³ C NMR spectra were produced, and MALDI mass spectroscopy yielded M + H at 268 as expected.
[690] iv) Synthesis of N-Boc-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid
[691] A solution of 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid hydrochloride (2.0 mmol) in water (2 ml) was added water / dioxane (2: 1, 15 ml). ) To a solution of sodium bicarbonate (0.60 g, 7.2 mmol). A solution of di-tert-butyl dicarbonate (0.48 g, 2.2 mmol) in dioxane (5 ml) was added. The reaction process was monitored by TLC analysis (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5) and a portion of the di-tert-butyl dicarbonate was added until conversion was complete. The reaction mixture was poured into water saturated with potassium hydrogen sulfate and the organics were extracted in ethyl acetate. The organic phase was washed with water and brine, dried (sodium sulfate) and filtered to give 0.6 g of crude material. The product was purified by chromatography (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5). The solution was concentrated and the residue was dissolved in glacial acetic acid and lyophilized. Yield 415 mg (56%), white solid. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[692] b) Synthesis of Lipopeptides Functionalized with Athenol
[693]
[694] The constructs were synthesized by a manual bubbler method starting with Fmoc-protected link amide MBHA resin on 0.125 mmol scale using suitable amino acids, palmitic acid and compounds from (a). Coupling was performed using standard TBTU / HOBt / DIEA protocols. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT and 5% water. Crude was precipitated from ether and purified liquid chromatography over 60 minutes using a gradient of 70-100% B at 10 mL / min flow rate (A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile). Purified. 38 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, 20 min, where A = 0.1% TFA / water and B = 0.1% TFA / acetonitrile, flow rate 1 ml / min, detection- UV 214 nm-retention time 25 minutes). Further characterization was performed using MALDI mass spectroscopy (ACH matrix) to yield M + H 1258, expected 1257.
[695] c) Synthesis of N-[(S) -3-hexadecylthio-2-methylpropionyl] proline
[696] DIEA (188 μl, 1.10 mmol) was converted to 1-iodohexadecane (176 mg, 0.500 mmol), captopril (120 mg, 0.550 mmol) and DBU (165 μl, 1.10 mmol) in tetrahydrofuran (5 ml). Was added to the solution. This mixture was heated at 70 ° C. for 2 hours and concentrated. The residue was poured into water saturated with potassium hydrogen sulfate and the organics extracted with chloroform. The organic phase was washed with water and dried (magnesium sulfate). The product was chromatographed (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5) and lyophilized to yield 105 mg (48%) of solid material. The structure was confirmed by ¹ H (500 MHz) and ¹³ C (125 MHz) NMR analysis and further characterization was performed using MALDI mass spectroscopy to obtain MH peak in negative mode as expected at m / z 440.
[697] d) Process for preparing gas-filled microbubbles comprising lipopeptides containing DSPS and atenool and lipophilic derivatives of captopril for diagnostic and therapeutic uses
[698] A solution of 1.4% propylene glycol / 2.4% glycerol (1.0 ml) was added to the mixture of products from DSPS (4.5 mg), (b) (0.5 mg) and (c) in vials. The mixture was sonicated for 5 minutes and then heated to 80 ° C. for 5 minutes (shaking the vial while warming) and cooled. The upper space was flushed with perfluorobutane gas and the vial was shaken for 45 seconds in a cap-mixer and then the contents were washed well with deionized water. MALDI mass spectroscopy showed no compound from (b) or (c) in the final wash solution. The mixing of compounds (b) and (c) into the microbubbles was confirmed by MALDI-MS as follows: About 50 μl of microbubbles were transferred to a clean vial containing about 100 μl of 90% methanol. This mixture was sonicated for 30 seconds and analyzed by MALDI-MS (ACH-matrix) to yield M + H peaks corresponding to the structures from (b) and (c), respectively.
[699] e) in vitro analysis
[700] This microbubble was tested in an in vitro assay as described in Example 21. Gradual accumulation of microbubbles bound to the cells was observed.
[701] Example 63 Gas-Filled Microbubbles Including Lipopeptides Containing DSPS and Cholesterol Derivatives of Athenol for Diagnostic and Therapeutic Uses
[702] a) Synthesis of methyl 4-[(2,3-epoxy) propoxy] -phenylacetate
[703] A mixture of methyl 4-hydroxyphenylacetate (4.98 g, 0.030 mol), epichlorohydrin (23.5 ml, 0.30 mol) and pyridine (121 μl, 1.5 mmol) was stirred at 85 ° C. for 2 hours. The reaction mixture was cooled and excess epichlorohydrin was evaporated (rotary evaporation). The residue was dissolved in ethyl acetate, washed with brine and dried (sodium sulfate). This solution was filtered and concentrated. The concentrated residue was chromatographed (silica, hexanes / ethyl acetate 7: 3) to give 2.25 g (34%) of a colorless oil. ¹ H (300 MHz) and ¹³ C NMR (75 MHz) spectra were shown according to the structure.
[704] b) Synthesis of methyl 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenyl acetate
[705] A mixture of methyl 4-[(2,3-epoxy) propoxy] phenylacetate (2.00 g, 9.00 mmol), isopropylamine (23 ml, 0.27 mol) and water (1.35 ml, 74.7 mmol) was stirred overnight at room temperature It was. The reaction mixture was concentrated (rotary evaporation) and the oily residue was dissolved in chloroform and dried (sodium sulfate). Filtration and concentration yielded a quantitative yield of a yellow oil which was used without further purification in the next step. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[706] c) Synthesis of 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid hydrochloride
[707] A solution of methyl 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetate (563 mg, 2.00 mmol) in 6M hydrochloric acid (15 ml) was heated at 100 ° C. for 4 hours. . The reaction mixture was concentrated (rotary evaporation) and the residue was dissolved in water and lyophilized. Depending on the structure, ¹ H and ¹³ C NMR spectra were produced, and MALDI mass spectroscopy yielded M + H at 268 as expected.
[708] d) Synthesis of N-Boc-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid
[709] A solution of 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid hydrochloride (2.0 mmol) in water (2 ml) was added water / dioxane (2: 1, 15 ml). ) To a solution of sodium bicarbonate (0.60 g, 7.2 mmol). A solution of di-tert-butyl dicarbonate (0.48 g, 2.2 mmol) in dioxane (5 ml) was added. The reaction process was monitored by TLC analysis (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5) and a portion of the di-tert-butyl dicarbonate was added until conversion was complete. The reaction mixture was poured into water saturated with potassium hydrogen sulfate and the organics were extracted in ethyl acetate. The organic phase was washed with water and brine, dried (sodium sulfate) and filtered to give 0.6 g of crude material. The product was purified by chromatography (silica, CHCl ₃ / MeOH / AcOH 85: 10: 5). The solution was concentrated and the residue was dissolved in glacial acetic acid and lyophilized. Yield 415 mg (56%), white solid. The structure was confirmed by ¹ H and ¹³ C NMR analysis.
[710] e) Synthesis of Cholesteryl N-Boc-β-alanineate
[711] DIC (510 μl) was added to a solution of Boc-β-Ala-OH (1.25 g, 6.60 mmol) in dichloromethane (15 ml) under an inert atmosphere. The reaction mixture was stirred for 30 minutes and transferred to a flask containing a solution of cholesterol (1.16 g, 3.00 mmol) and DMAP (367 mg, 3.00 mmol) in dichloromethane (15 ml). The reaction mixture was stirred for 2 hours and poured into aqueous potassium hydrogen sulfate solution. The phases were separated and the aqueous phase was extracted with chloroform. The combined organic phases were washed with aqueous sodium hydrogen sulfate solution and water and dried (magnesium sulfate). After filtration and concentration, the crude product was chromatographed (silica, chloroform / methanol 99: 1) to give 1.63 g (97%) of a white solid. The structure was identified as ¹ H (500 MHz).
[712] f) Synthesis of cholesteryl β-alanine hydrochloride
[713] A solution of compound (279 mg, 0.500 mmol) from (a) in 1M hydrochloric acid (5 ml) in 1,4-dioxane was stirred at room temperature for 4 hours. The reaction mixture was concentrated to yield quantitative yield of cholesteryl β-alanine hydrochloride. This structure was confirmed by 1 H NMR (500 MHz) analysis and MALDI mass spectroscopy to obtain an M + Na peak at 482 (expected 481).
[714] g) Synthesis of N-Boc-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetyl-β-alanineate
[715] N-Boc-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetic acid (55 mg, 0.15 mmol) and cholesteryl β-alanine in DMF (5 ml) To a solution of hydrochloride (74 mg, 0.15 mmol) DIEA (26 ml, 0.15 mmol) was added. HOBt (23 mg, 0.15 mmol) and water soluble carbodiimide (WSC) (29 mg, 0.15 mmol) were added. The reaction mixture was stirred at rt overnight and poured into water (25 ml) containing sodium carbonate (2.5 g) and sodium chloride (4.0 g). The precipitated material was extracted with chloroform. The organic phase was washed with water and dried (magnesium sulfate). After filtration and concentration the crude material (132 mg) was purified by column chromatography (silica, chloroform / methanol / acetic acid, 95: 4: 1). The pooled fractions were concentrated, dissolved in glacial acetic acid and lyophilized. Yield 83 mg (69%), off-white solid. The structure was confirmed by ¹ H NMR analysis.
[716] h) Synthesis of cholesteryl 4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetyl-β-alanine trifluoroacetate
[717] Of N-Boc-4- [2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenylacetyl-β-alanineate (40 mg, 0.05 mmol) in anhydrous dichloromethane (4 ml) Trifluoroacetic acid (2 ml) was added to the solution. The reaction mixture was stirred for 2 hours and concentrated. The product was lyophilized from an acetonitrile / water mixture to give an off white material in quantitative yield. The product was characterized by MALDI mass spectroscopy to yield M + H at 708 as expected.
[718] i) a process for preparing a gas-filled microbubble comprising DSPS and a cholesterol derivative of athenol for diagnostic and therapeutic use
[719] A solution of 1.4% propylene glycol / 2.4% glycerol (1.0 ml) was added to the mixture of DSPS (4.5 mg) and product from (h) (0.5 mg) in a vial. The mixture was sonicated for 5 minutes and then heated to 80 ° C. for 5 minutes (shaking the vial while warming) and cooled. The upper space was flushed with perfluorobutane gas and the vial was shaken for 45 seconds in a cap-mixer and then the contents were washed well with deionized water. MALDI mass spectrometry showed that no compound from (b) was detected in the final wash solution. Mixing of the compound from (h) into the microbubbles was confirmed by MALDI mass spectroscopy.
[720] j) in vitro analysis
[721] This microbubble was tested in an in vitro assay as described in Example 21. Gradual accumulation of microbubbles bound to the cells was observed.
[722] Example 64 Preparation of Multi-Specific Transferrin / Avidin-Coated Gas-Filled Microbubbles for Target Ultrasound Imaging
[723] This embodiment relates to the preparation of microbubbles containing target ultrasound / therapeutic vectors.
[724] a) Synthesis of thiol-functionalized lipid molecules: dipalmitoyl-Lys-Lys-Lys-Aca-Cys.OH
[725]
[726] The lipid structure was synthesized on an ABI 433A automated peptide synthesizer starting with Fmoc-Cys (Trt) -Wang resin on a 0.25 mmol scale using a 1 mmol amino acid cartridge. All amino acids and palmitic acid were preactivated using HBTU prior to coupling. Simultaneous removal of peptides from the resin and side chain protecting groups was performed for 2 hours in TFA containing 5% EDT and 5% H ₂ O to afford 250 mg of crude product. 40 mg of crude material was purified over 50 minutes by purified HPLC using a gradient of 90-100% B (A = 0.1% TFA / water and B = MeOH) at 9 mL / min flow rate. 24 mg of pure material was obtained after lyophilization (analytical HPLC, gradient 70-100% B, where B = 0.1% TFA / acetonitrile, A = 0.01% TFA / water: detection-UV 214 nm-product residence time = 23 minute). Further characterization of the product was performed using MALDI mass spectroscopy; M + H expected 1096, found 1099.
[727] b) Process for preparing gas-filled microbubbles comprising DSPS 'doped' with thiol-containing lipid constructs
[728] Lipid constructs from DSPS (4.5 mg) and (a) (0.5 mg) were weighed into clean vials and 0.8 ml of a 1.4% propylene glycol / 2.4% glycerol containing solution in water was added. The mixture was warmed to 80 ° C. for 5 minutes (shaking the vial while warming) and filtered through a 40 mm filter while still hot. The sample was cooled to room temperature and the top space was flushed with perfluorobutane gas. The vial was shaken for 45 seconds in a cap-mixer and then placed on a roller table overnight. The resulting microbubbles were washed several times with deionized water and analyzed for thiol group mixing using Elman reagent.
[729] c) modification of transferrin and avidin to fluorescein-NHS and sulfo-SMPB
[730] To a mixture of 2 mg transferrin (Holo, human) and 2 mg avidin in PBS (1 ml) was added 0.5 ml of a DMSO solution containing 1 mg of sulfo-SMPB and 0.5 mg of fluorescein-NHS. The mixture was stirred at room temperature for 45 minutes and passed through a Sephadex 200 column using PBS as eluent. Protein fractions were collected and stored at 4 ° C. before use.
[731] d) microbubbles in combination with modified transferrin / avidin
[732] To the thiol-containing microbubble from (b) was added 1 ml of the modified transferrin / avidin protein solution from (c). After adjusting the pH of the solution to 9, the binding reaction was carried out at room temperature for 2 hours. Microbubbles were washed well with deionized water and analyzed by Coulter counter (81% between 1 and 7 microns) and fluorescence microscopy (highly fluorescent microbubbles were observed).
[733] Example 65 Gene Transfer by Gas-Filled Microbubbles
[734] This example relates to the preparation of targeted microbubbles for gene transfer.
[735] a) Process for preparing gas-filled microbubbles comprising DSPS and lipopeptides coated with poly-L-lysine
[736] DSPS (4.5 mg) and lipopeptides from Example 41 (0.5 mg) were weighed in two 2 ml vials. To each vial was added 0.8 ml of propylene glycol / glycerol (4%) in water. Each solution was heated at 80 ° C. for 5 minutes, shaken and cooled to ambient temperature, and the top space was flushed with perfluorobutane. The vial was shaken in the cap-mixer for 45 seconds at 4450 vibrations / min and left on the roller table for 5 minutes. The contents of the vial were mixed and the resulting sample was washed by centrifugation at 2000 rpm for 5 minutes. The lower layer liquid was removed and the same volume of distilled water was added. The wash process was repeated once. Poly-L-lysine HBr (20.6 mg) was dissolved in 2 mL of water and an aliquot (0.4 mL) was used to give 2 mL of water. To 1.2 ml of diluted poly-L-lysine solution was added 0.12 ml of DSPS-lipopeptide microbubble suspension. After incubation, excess polylysine was removed by thorough washing with water.
[737] b) cell infection
[738] Endothelial cells (ECV 304) were incubated in a uniform lower confluent layer in 6 well plates. An infection mixture containing 5 μg of DNA [enhanced green fluorescence protein vector from CLONTECH] and 50 μl of microbubble suspension from (a) in RPMI medium was prepared in a final volume of 250 μl. The mixture was left at room temperature for 15 minutes before 1 ml of complete RPMI medium was added. The medium was removed from the cell culture dish and the DNA-microbubble mixture was added to the cells. Cells were incubated in a cell culture incubator (37 ° C.).
[739] c) ultrasonic treatment
[740] After incubation for 15 minutes, the selected wells were exposed to continuous wavelength ultrasound at 1 MHz, 0.5 W / cm 2 for 30 seconds.
[741] d) incubation and evaluation
[742] The cells were further incubated for approximately 4.5 hours in a cell culture incubator (37 ° C.). The medium containing DNA-microbubbles was removed by suction and 2 ml of complete RPMI medium was added. Cells were incubated for 40 to 70 hours before evaluation. Most of the medium was removed and cells were evaluated by fluorescence microscopy. The results were compared with the results from control experiments in which DNA or DNA-polylysine was added to the cells.
[743] Example 66 Suspension of Endothelial Cells by Microbubbles with Vectors Specific to Endothelial Cells
[744] This experiment was performed to show whether the present invention can be used to isolate cells targeted by microbubbles. (ATCC CRL-1998) human endothelial cell line ECV 304 derived from normal umbilical cord was cultured in an Nuk culture flask (Chutney 153732) in RPMI 1640 medium, where L-glutamine (200 mM), penicillin / streptomycin (10,000 U / Ml and 10,00 μg / ml), and 10% fetal bovine serum. Cells were secondary cultured and then trypsinized at a split ratio of 1: 5 to 1: 7 when confluence was reached. Two million cells from the trypsinized confluent culture were added to each set of five centrifuge tubes. Subsequently, microbubbles that bind to control microbubbles or endothelial cells prepared as described in Examples 21 and 38 were added at 2, 4, 6, 8, or 10 million per tube. After centrifugation at 400 g for 5 minutes, the cells at the bottom of the tube were counted with a Coulter counter. It has been found that four or more microbubbles that bind to cells move cells up the fluid in centrifuge tubes. All cells are suspended by the microbubbles from Example 38, while about 50% are suspended by the microbubbles from Example 21.
[745] Example 67 Gas-Filled Microbubbles of Distearoylphosphatidylserine Containing Lipopeptides Containing Vectors Having Affinity to Endothelial Receptors for Desired Ultrasound Imaging
[746] a) Synthesis of 4 '-[(3,4-dimethyl-5-isoxazolyl) -sulfamoyl] succinianiline acid
[747] To a solution of sulfisoxazole (267 mg, 1.00 mmol) in DMF (10 mL) was added succinic anhydride (1.00 g, 10.0 mmol) and 4-dimethylaminopyridine (122 mg, 1.00 mmol). The reaction mixture was stirred at 80 ° C for 2 h and then concentrated. The residue was dissolved in 5% aqueous sodium bicarbonate solution and extracted with ethyl acetate. The aqueous solution was acidified with dilute hydrochloric acid and the organic material was extracted with ethyl acetate. The organic phase was washed with dilute hydrochloric acid, water and brine, treated with activated charcoal and dried (MgSO ₄ ). The solution was filtered and concentrated to give 280 mg (76%) of a white solid. ^The structure was confirmed by ¹ H (300 MHz) and ¹³ C (75 MHz) NMR spectroscopy. Further characterization was performed using MALDI mass spectroscopy (ACH matrix) to obtain M + Na peaks at m / z 390 and M + K peaks at m / z 406 as expected.
[748] b) Synthesis of Lipopeptides Functionalized with Sulfisoxazoles
[749]
[750] The construct was synthesized using a suitable amino acid, palmitic acid and a compound from (a) on a passive nitrogen bubbler device starting from a Fmoc-protected link amide BMHA resin with a size of 0.125 mmol. Coupling was performed using standard TBTU / HOBt / DIEA methods. Simultaneous removal of peptides from the resin and deprotection of the side chain protecting groups were performed for 2 hours in TFA containing 5% EDT and 5% water. The crude material was precipitated with ether. The product was analyzed by analytical HPLC (gradient: 70-100% B over 20 minutes, A = 0.1% TFA / water and B = 0.1% THF / acetonitrile, flow rate 1 ml / min, detection UV 214 nm, residual Time 27 minutes). Further characterization was performed using MALDI mass spectroscopy to obtain an M + H peak at m / z 1359 (expected 1356).
[751] c) a process for preparing a gas-filled microbubble comprising the compound from (b)
[752] A solution of 1.4% propylene glycol / 2.4% glycerol (1.0 mL) was added to a mixture of DSPS (4.5 mg) and product from (b) (0.5 mg) in a vial. The mixture was sonicated for 5 minutes, then heated at 80 ° C. for 5 minutes (shaking the vial while heating) and cooled. The upper space was flushed with fluorobutane gas and the vial was shaken in a cap-mixer for 45 seconds and then thoroughly washed with deionized water. The results of MALDI mass spectrometry showed that the compound from (b) was not detected in the final wash solution. The incorporation of isoxazole containing lipopeptides into microbubbles confirmed by MALDI-MS that about 50 μl of microbubbles were transferred to clean vials containing about 100 μl of 90% methanol. The mixture was sonicated for 30 seconds and analyzed by MALDI-NS (ACH-matrix) to obtain m + H peak at m / z 1359 corresponding to lipopeptides (b).

权利要求:
Claims (37)
[1" claim-type="Currently amended] A target traceable diagnosis and / or comprising a suspension of a reporter consisting of a gas filled microbubble stabilized by a monolayer of film-forming surfactant in an aqueous carrier solution, further comprising one or more vectors. Therapeutically active agent.
[2" claim-type="Currently amended] The process of claim 1 wherein the gas comprises air, nitrogen, oxygen, carbon dioxide, hydrogen, inert gas, sulfur fluoride, hexafluoride, low molecular weight hydrocarbons, ketones, esters, halogenated low molecular weight hydrocarbons or any mixture thereof. Diagnostic and / or therapeutically active agent.
[3" claim-type="Currently amended] 3. The diagnostic and / or therapeutically active agent of claim 2, wherein the gas comprises a perfluorinated ketone, a perfluorinated ether or a perfluorocarbon.
[4" claim-type="Currently amended] The diagnostic and / or therapeutically active agent of claim 2, wherein the gas comprises sulfur hexafluoride or perfluoropropane, perfluorobutane or perfluoropentane.
[5" claim-type="Currently amended] 5. The diagnostic method according to claim 1, wherein the film-forming surfactant material comprises a non-polymeric and non-polymeric wall-forming surfactant material, a polymeric surfactant material or a phospholipid. Or) therapeutically active agent.
[6" claim-type="Currently amended] 6. The diagnostic and / or therapeutically active agent of claim 5, wherein at least 75% of the film-forming surfactant material comprises phospholipid molecules individually carrying a total net charge.
[7" claim-type="Currently amended] The diagnostic and / or method according to claim 6, wherein at least 75% of the film-forming surfactant substance comprises at least one phospholipid selected from phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, phosphatidic acid and cardiolipin. Therapeutically active agent.
[8" claim-type="Currently amended] 8. The diagnostic and / or therapeutically active agent of claim 7, wherein at least 80% of the phospholipids comprise phosphatidylserine.
[9" claim-type="Currently amended] The diagnostic and / or therapeutically active agent according to any one of claims 1 to 8, wherein the film-forming surfactant substance comprises lipopeptides.
[10" claim-type="Currently amended] The method of claim 1, wherein the vector is an antibody; Cell adhesion molecules; Cell adhesion molecule receptors; Cytokines; Growth factor; Peptide hormones and fragments thereof; Non-peptide agonists / antagonists and non-living binders of receptors for cell adhesion molecules, cytokines, growth factors and peptide hormones; Oligonucleotides and modified oligonucleotides; DNA-binding drugs; Protease substrate / inhibitors; Molecules generated from combinatorial libraries; And bioactive small molecules.
[11" claim-type="Currently amended] The diagnostic and / or a method according to any one of claims 1 to 10, wherein the vector (s) have affinity for the target at a concentration at which the diagnostic / therapeutic agent interacts but does not bind statically to the target. Therapeutically active agent.
[12" claim-type="Currently amended] The diagnostic and / or therapeutically active agent of claim 11, wherein the vector (s) is selected from a ligand for cell adhesion protein and a cell adhesion protein having a corresponding ligand on the endothelial cell surface.
[13" claim-type="Currently amended] 13. The diagnostic and / or therapeutically active agent of any one of claims 1 to 12, wherein the vector (s) are positioned such that they are not easily exposed to the target.
[14" claim-type="Currently amended] The diagnostic and / or therapeutically active agent of claim 1, wherein the vector is covalently coupled or linked to the reporter.
[15" claim-type="Currently amended] The diagnostic and / or therapeutically active agent of claim 1, wherein the vector is coupled or linked to the reporter via electrostatic interaction.
[16" claim-type="Currently amended] The diagnostic and / or therapeutic according to any one of claims 1 to 13, wherein the vector is coupled or linked to the reporter by avidin-biotin and / or streptavidin-biotin interactions. Active agent.
[17" claim-type="Currently amended] The diagnostic and / or therapeutically active agent of claim 1, further comprising a moiety that is radioactive or effective as an X-ray contrast agent, optical imaging probe, or spin label.
[18" claim-type="Currently amended] 18. The diagnostic and / or therapeutically active agent according to any one of claims 1 to 17, further comprising a therapeutic compound.
[19" claim-type="Currently amended] The method of claim 18, wherein the therapeutic compound is an anti-neoplastic agent, blood product, biological response modifier, antifungal agent, hormone or hormonal homologue, vitamin, enzyme, antiallergic agent, tissue factor inhibitor, platelet inhibitor, aggregate protein target inhibitor: fibrin formation Inhibitors, fibrin breakdown accelerators, anti-angiogenic agents, circulatory drugs, metabolic enhancers, anti-nodal agents, antiviral agents, vasodilators, antibiotics, anti-inflammatory agents, antiprotozoal agents, antirheumatic agents, anesthetics, opiates, cardiac glycosides, neuromuscular A diagnostic and / or therapeutically active agent characterized in that it is a growth blocker, a sedative, a local anesthetic, a general anesthetic or a genetic material.
[20" claim-type="Currently amended] 20. The diagnostic and / or therapeutically active agent of claim 18 or 19, wherein the therapeutic compound is covalently coupled or linked to the reporter via a disulfide group.
[21" claim-type="Currently amended] 20. The diagnostic and / or method of claim 18 or 19, wherein the lipophilic or lipophilic induction therapeutic compound is linked to a surfactant monolayer that stabilizes the gas filled microbubbles of the reporter through hydrophobic interactions. Therapeutically active agent.
[22" claim-type="Currently amended] i) a first dosage composition comprising a pretargeting vector having affinity for the selected target; And
ii) a combination comprising a second dosage composition comprising a diagnostic and / or therapeutically active agent as claimed in claim 1 comprising a vector having affinity for said pretargeting vector. Formulation.
[23" claim-type="Currently amended] The combination formulation of claim 22, wherein the pretargeting vector is a monoclonal antibody.
[24" claim-type="Currently amended] i) a first dosage composition comprising a diagnostic and / or therapeutically active agent as claimed in any one of claims 1-21; And
ii) A combination formulation comprising a second dosage composition comprising a substance capable of replacing or leaving said diagnostic and / or therapeutically active agent from its target.
[25" claim-type="Currently amended] i) a first dosage composition comprising a diagnostic and / or therapeutically active agent as claimed in claim 20; And
ii) a combination formulation comprising a second dosage composition comprising a reducing agent capable of reductively cleaving a disulfide group coupling or linking a therapeutic compound and a reporter in the diagnostic and / or therapeutically active agent of the first dosage composition .
[26" claim-type="Currently amended] Coupling or linking one or more vectors to a reporter consisting of gas filled microbubbles stabilized with a single layer of film-forming surfactant, or using a film-forming surfactant with one or more vectors attached, gas filled receptor microbubbles A method of making a target traceable diagnostic and / or therapeutically active agent as defined in claim 1 comprising generating a.
[27" claim-type="Currently amended] 27. The method of claim 26, wherein the therapeutic compound is also combined with a reporter.
[28" claim-type="Currently amended] 28. The method of claim 27, wherein the disulfide group is formed by reacting a therapeutic compound containing a thiol group under oxidizing conditions to a thiol group containing surfactant monolayer that stabilizes the gas filled microbubbles of the reporter.
[29" claim-type="Currently amended] Use of a diagnostic and / or therapeutically active agent as claimed in claim 1 as a target traceable ultrasound contrast agent.
[30" claim-type="Currently amended] 22. A diagnostic and / or therapeutically active agent as claimed in any one of claims 1 to 21 is administered to a human or non-human animal and ultrasound, magnetic resonance, X-ray, radiation in at least a portion of the human or animal body. A method for generating an augmented image of a human or non-human animal, comprising generating a photographic or optical image.
[31" claim-type="Currently amended] The method of claim 30,
i) administering to the human or non-human animal a pretarget vector having affinity for the selected target; And
ii) administering the diagnostic and / or therapeutically active agent of any one of claims 1-21, comprising a vector having affinity for said pretargeting vector.
[32" claim-type="Currently amended] 32. The method of claim 31, wherein the pretarget vector is a monoclonal antibody.
[33" claim-type="Currently amended] The method of claim 30,
i) administering the diagnostic and / or therapeutically active agent of any one of claims 1 to 21 to said human or non-human animal; And
ii) administering a substance capable of replacing or leaving said diagnostic and / or therapeutically active agent from its target.
[34" claim-type="Currently amended] 34. The method of any one of claims 30-33, wherein said diagnostic and / or therapeutically active agent further comprises a therapeutic compound.
[35" claim-type="Currently amended] 35. The composition of claim 34, wherein the therapeutic compound is covalently coupled or linked to the reporter via a disulfide group, and subsequently the composition is administered comprising a reducing agent capable of reductively cleaving the disulfide group. Way.
[36" claim-type="Currently amended] The cell representing the target is fixedly placed in a flow chamber, and a suspension of the diagnostic and / or therapeutically active agent as defined in any one of claims 1 to 21 in a carrier solution is passed through the chamber, and Test for binding of said diagnostic and / or therapeutically active agent to said in vitro target traceability by said diagnostic and / or therapeutically active agent.
[37" claim-type="Currently amended] 37. The method of claim 36, wherein the flow rate of the carrier liquid is adjusted to indicate the shear rate occurring in vivo.

类似技术:

---

公开号 | 公开日 | 专利标题

---

Elsabahy et al.2015|Polymeric nanostructures for imaging and therapy

---

Qhattal et al.2014|Hyaluronan polymer length, grafting density, and surface poly | coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes

---

Soni et al.2016|Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation

---

Peng et al.2015|Polymeric multifunctional nanomaterials for theranostics

---

Morshed et al.2016|Cell-penetrating peptide-modified gold nanoparticles for the delivery of doxorubicin to brain metastatic breast cancer

---

Wang et al.2014|Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates

---

US9056138B2|2015-06-16|Multivalent constructs for therapeutic and diagnostic applications

---

Min et al.2015|pH-controlled gas-generating mineralized nanoparticles: a theranostic agent for ultrasound imaging and therapy of cancers

---

Paefgen et al.2015|Evolution of contrast agents for ultrasound imaging and ultrasound-mediated drug delivery

---

Chen et al.2014|In vivo tumor vasculature targeted PET/NIRF imaging with TRC105 |-conjugated, dual-labeled mesoporous silica nanoparticles

---

Hak et al.2012|The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging

---

Longmire et al.2011|Biologically optimized nanosized molecules and particles: more than just size

---

Unnikrishnan et al.2012|Microbubbles as ultrasound contrast agents for molecular imaging: preparation and application

---

Mailander et al.2009|Interaction of nanoparticles with cells

---

Kievit et al.2011|Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers

---

Tartis et al.2006|Therapeutic effects of paclitaxel-containing ultrasound contrast agents

---

Li et al.2012|Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor

---

Leamon et al.2003|Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo

---

Yang et al.2014|Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation

---

Hallahan et al.2003|Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels

---

Lanza et al.2001|Targeted ultrasonic contrast agents for molecular imaging and therapy

---

JP2013209388A|2013-10-10|Nanoparticle for targeted delivery of active agent

---

Xiao et al.2012|Gold nanorods conjugated with doxorubicin and cRGD for combined anticancer drug delivery and PET imaging

---

ES2287599T3|2007-12-16|Diagnostic image formation technique.

---

Thomas et al.2004|In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles

同族专利:

---

公开号 | 公开日

---

CA2270120A1|1998-05-07|

---

JP2001503407A|2001-03-13|

---

CN1234742A|1999-11-10|

---

DE69735354T2|2006-11-30|

---

IL129444D0|2000-02-29|

---

BG103438A|2000-01-31|

---

CN1440816A|2003-09-10|

---

AU4786697A|1998-05-22|

---

NO991889D0|1999-04-21|

---

DE69735354D1|2006-04-27|

---

BR9712683A|1999-10-19|

---

NZ335596A|2000-10-27|

---

NO991889L|1999-06-28|

---

AU733495B2|2001-05-17|

---

CZ149499A3|1999-09-15|

---

US6264917B1|2001-07-24|

---

AT318618T|2006-03-15|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1996-10-28|Priority to GBGB9622368.0A

---

1996-10-28|Priority to GBGB9622367.2A

---

1996-10-28|Priority to GB9622367.2

---

1996-10-28|Priority to GB9622366.4

---

1996-10-28|Priority to GB9622368.0

---

1996-10-28|Priority to GBGB9622366.4A

---

1997-01-15|Priority to GB9700699.3

---

1997-01-15|Priority to GBGB9700699.3A

---

1997-04-24|Priority to GB9708265.5

---

1997-04-24|Priority to GBGB9708265.5A

---

1997-06-06|Priority to GBGB9711842.6A

---

1997-06-06|Priority to GB9711842.6

---

1997-06-06|Priority to GB9711846.7

---

1997-06-06|Priority to GBGB9711846.7A

---

1997-10-28|Application filed by 조오지 디빈센조, 토브 아스 헬지, 에바 요한손, 니코메드 이메이징 에이에스

---

2000-08-25|Publication of KR20000052829A

优先权:

---

申请号 | 申请日 | 专利标题

---

GBGB9622367.2A|GB9622367D0|1996-10-28|1996-10-28|Improvements in or relating to diagnostic/therapeutic agents|

---

GB9622367.2|1996-10-28|

---

GB9622366.4|1996-10-28|

---

GB9622368.0|1996-10-28|

---

GBGB9622366.4A|GB9622366D0|1996-10-28|1996-10-28|Improvements in or relating to diagnostic/therapeutic agents|

---

GBGB9622368.0A|GB9622368D0|1996-10-28|1996-10-28|Improvements in or relating to diagnostic/therapeutic agents|

---

GB9700699.3|1997-01-15|

---

GBGB9700699.3A|GB9700699D0|1997-01-15|1997-01-15|Improvements in or relating to diagnostic/therapeutic agents|

---

GBGB9708265.5A|GB9708265D0|1997-04-24|1997-04-24|Contrast agents|

---

GB9708265.5|1997-04-24|

---

GB9711842.6|1997-06-06|

---

GB9711846.7|1997-06-06|

---

GBGB9711846.7A|GB9711846D0|1997-06-06|1997-06-06|Improvements in or relating to diagnostic/therapeutic agents|

---

GBGB9711842.6A|GB9711842D0|1997-06-06|1997-06-06|Improvements in or relating to diagnostic/therapeutic agents|